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ABSTRACT
The liver expressed chemokine CCL16/LEC exerts chemotactic activity on human 
monocytes and lymphocytes and is also active on murine cells. An adenovirus encoding 
the chemokine CCL16 was used to test whether this chemokine might inhibit pre-existing 
tumors in mice. AdCCL16, but not control empty vector, when injected in established TSA 
mammary carcinoma, significantly delayed tumor growth. Immunohistochemistry revealed 
accumulation at tumor site of CD4+ and CD8+ T cells, macrophages, and dendritic cells 
(DC) the latter being also enriched in draining lymph nodes. Despite the robust and rapid 
immune response triggered by intratumoral injection of AdCCL16, the lesions were not 
completely rejected. However the same treatment given before surgical excision of 
primary lesions prevented metastatic spread and cured 63% of mice bearing the 4T1 
mammary adenocarcinoma. The finding of an hostile tumor microenvironment preventing 
innate immunity explains the weak effect on the primary tumor. As CCL16 promotes 
accumulation of macrophages and DC at the site of pre-established tumor nodules this 
treatment was combined with the TLR9 ligand CpG and with anti-interleukin 10-receptor 
(IL10R) antibody to contrast the local tumor-induced immunosuppression. CpG plus anti- 
IL10R promptly switched M2 infiltrating macrophages to Ml that, triggering a strong 
innate response, debulked large tumors within 16 hrs. Tumor infiltrating DC matured and 
migrated in parallel with the onset of the innate response, allowing the initiation of 
adaptive immunity before the diffuse hemorrhagic necrosis halted the communication 
between tumor and draining lymph node. Treatment of B6>CXB6 chimeras implanted 
with BALB/c tumors induced an efficient innate response but not CTL-mediated tumor 
lysis; in these mice tumor rejection did not exceed 25%. The requirement of CD4 help for 
an effective CTL induction was shown in CD40KO, as well as in mice depleted for CD4 T 
cells during the priming rather than the effector phase. Together the data describe the 
critical requirements for the immunological rejection of large tumors: a hemorrhagic 
necrosis initiated by activated Ml macrophages and a concomitant DC-migration to DLN 
for subsequent CTL priming and clearing of any tumor remnants.
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CHAPTER 1 INTRODUCTION
1.1 Immunotherapy of cancer
The immune system has evolved strategies to efficiently localize and destroy disease- 
inducing agents. The idea that the same defence mechanisms might be directed against 
cancer started the age of tumor immunology.
The dramatic advances in understanding the basic aspect of the immune system as well as 
the progress in genetic engineering techniques highlighted the possibility that the immune 
system could be manipulated to destroy cancer, starting the era of immunotherapy. The 
following sections of this introduction describe the newest approaches in cancer 
immunotherapy. Evidence for tumor-induced suppression of the patient’s immune system 
has always existed; a section of this introduction will be devoted to immune escape 
mechanisms and how these mechanisms can be manipulated for therapy of established 
malignancies.
1.1.1 Differences between therapy and prevention of cancer
Immunotherapy approaches can be divided in two main categories: i) those targeting 
healthy individuals with a high risk of developing cancer or individuals with preneoplastic 
lesions, ii) those that aim at curing established tumors.
Immunoprevention of cancer has many theoretical advantages. Individuals in which the 
immune system has not been yet negatively instructed by tumor are expected to mount a 
more efficient immune response.
In this setting two treatments can be foreseen: enhancement of non-specific immunity and 
specific vaccination with tumor associated antigens (TAAs) [reviewed in ref. (Fomi et al., 
2000; Lollini and Fomi, 1999)].
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Numerous data obtained in cancer patients as well in mouse models of cancer have shown 
that proinflammatory cytokines such as IL-2, IL-12 and interferons elicit modulation of 
natural immune reactivity that can results in antitumor response.
In particular, non-specific stimulation using IL-12 has been extensively tested in animal 
cancer models. BALB/c female expressing the MMTV-driven rat oncogene HER2/neu, 
develop hyperplasia starting at 5 weeks of age, which then progresses to in situ carcinoma 
and at 33 weeks of age all mammary glands display large tumors.
Chronic administration of low doses of IL-12, starting at 1 weeks of age till the 15th week, 
markedly delays the progression of mammary carcinogenesis by interfering with the 
passage from atypical hyperplasia to invasive carcinoma, suggesting an indirect inhibition 
of the angiogenic switch. The same treatment, started at the stage of invasive carcinoma, 
looses its effectiveness posing major concern on the use of non-specific therapy to treat 
already established lesions (Boggio et al., 1998).
Similarly, IL-12 triggered mechanisms inhibited chemical induced carcinogenesis. 
BALB/c mice injected subcutaneously with 3-methylcholantrene showed reduced tumor 
appearance and reduced tumor incidence when treated chronically with IL-12 (Noguchi et 
al., 1996).
Specific vaccination of persons at risk or with preneoplastic lesions represents a 
completely different scenario. In this setting the identification of altered gene products 
predictably destined to become a TAA is the first step towards the engineering of effective 
vaccines (Fomi et al., 2000). The protection provided by vaccination of BALB/NeuT mice, 
with a plasmid containing the extracellular domain of the neu oncogene, suggests that 
prophylactic vaccination may be effective (Rovero et al., 2000) (Spadaro et al., 2004).
The preventive effect of early vaccination is markedly increased by combination with IL- 
12 treatment. In addition to improving the protection rate of the DNA vaccine, IL-12
15
significantly delayed the initiation of antigen-specific anti-tumor vaccination (Spadaro et 
al., 2004).
Numerous studies on animal models suggest that immunoprevention is effective in 
inhibiting tumor onset, but many issues limit the translation of this approach to the clinic. 
First there are very few situations in which genetic screening can select a population with a 
specific risk of cancer where prevention could be contemplated. Second, one should be 
absolutely certain that preventive vaccination would not elicit any autoimmune effect 
considering that many TAA are inappropriately expressed self-antigens.
A more realistic approach that follows true clinical need considers the treatment at early 
diagnosis or post-surgery. This approach is centered on manipulation of the immune 
system to reject rather than prevent tumors.
The final goal of therapy of established tumors is development of T cell and/or Ab- 
responses against TAA that are able to destroy tumor and generate long lasting immunity 
that will protect against minimal residual disease and relapse.
The most recent therapeutic attempts use DC that have been ex-vivo manipulated or 
stimulated in vivo, to present tumor antigens. Other attempts aim at stimulating the innate 
response as a preliminary step towards adaptive response and subsequent memory 
activation (see next sections for further details).
1.2 DC in cancer immunotherapy
1.2.1 Dendritic cell as antigen presenting cells
Dendritic cells belong to a family of antigen presenting cells that orchestrate signals 
derived from different component of the immune system. At the immature state, DC reside 
in peripheral tissues and act as sentinel sensing antigenic environment for the presence of 
pathogens and any danger signals.
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The encounter with pathogens or with a highly inflamed tissue initiates a series of events 
that culminates with antigen presentation to T cells residing in lymphoid tissues [reviewed 
in ref. (Banchereau and Steinman, 1998)].
The kind of immune response that is produced by DC depends on how antigens are 
presented to T cells.
Antigenic stimulation needs to be coupled with an inflammatory or danger signal to fully 
activate DC maturation, transforming a cell equipped to capture antigens into a cell 
equipped to process and present them to T cells. DC are indeed provided with receptors 
belonging to the toll-like receptor (TLR) family that recognize pathogens and whose 
triggering initiate the process of maturation. Other cell types such as macrophages also 
express TLR that upon triggering induce the production of inflammatory cytokines (TNF- 
a , ILl-p, IL-12, IFN-y) that are instrumental for proper phagocytosis and activation of DC 
(Banchereau and Steinman, 1998).
Antigens from pathogens infecting directly APC (called endogenous antigens) are 
transported to the endoplasmatic reticulum (ER) by a specialized protein complex named 
TAP (transported associated with antigen presentation) and here loaded into the groove of 
MHC class I molecules. The peptide-MHC-I complexes are finally conveyed to the cell 
surface via the secretory pathway. Once DC reach lymphoid tissues the processed antigens 
are presented to CD8 T cells that are able to kill directly the infected cells. Extracellular 
pathogens, on the contrary, are engulfed by DC and degraded in phagosomes (membrane- 
bound cellular compartments); here the produced peptide fragments are loaded onto MHC 
class II molecules that once translocated to the cell surface stimulates CD4 T helper cells. 
Helper T cells are not able to kill directly the pathogens instead they trigger the production 
of antigen specific antibodies and produce inflammatory stimuli that contribute to 
eliminate pathogens (Banchereau and Steinman, 1998).
17
The rules governing antigen presentation are even more complex, in fact DC can present 
exogenous antigens also via the MHC class I pathway to CD8 T cells, a process named 
cross-presentation. This pathway is important to generate specific CTL immunity against 
pathogens that do not infect DC. If direct presentation was the only way to elicit CTL 
response, pathogens would escape immune response by avoiding DC infection. Instead DC 
can capture and cross-present pathogen antigens from other infected cells avoiding such 
escape.
Several types of antigens have been reported to be cross-presented. Among them soluble 
proteins, intracellular bacteria, parasite and cellular antigens.
In particular cross-presentation of cellular antigens is thought to be important to generate 
CTL response against tumor cells or self-tolerance against tissue-derived antigens 
[reviewed in ref. (Heath et al., 2004; Melief, 2003)]. Indication that cellular antigens can 
be captured and indirectly presented by APCs can be found in early experiments 
investigating the MHC-restriction of responses to minor histocompatibility antigens. 
Bevan et al, primed (BALB/c XBALB/B) FI hybrids mice (H-2d XH-2b) with cells from 
C57BL/10 (BIO) mice that share the H-2b MHC molecules but diverge in their expression 
of BIO minors. These authors found that not only the H-2b-restricted CTLs specific for 
BIO minors were induced after immunization, but H-2d-restricted CTLs were found as 
well. To induce the H-2d-restricted response, minor antigens must have been transferred to 
APCs of host origin, Bevan named this process “cross-priming” referring specifically to 
CTL associated with presentation of cellular antigens captured and presented by APC of 
the host-BM compartment (Bevan, 1976).
In the past years many studies have investigated the processes governing cross­
presentation. The clarification of such process is essential especially if considering that 
cell-associated antigens has been shown to promote a superior CD8 T cell response in vivo 
than soluble antigens raising the possibility that immunotherapeutic strategies
implementing cross presentation of tumor associate antigens would results in a more 
vigorous CTL response (Li et al., 2001).
The existence of a fusion process between the phagosomes and the ER has been reported, 
by three different groups, as essential for extracellular antigens to escape the phagosomes 
and to be loaded onto MHC class I molecules (Ackerman et al., 2003; Houde et al., 2003) 
(Guermonprez et al., 2003). The phagocytated antigens are then transported to the cytosol 
by a protein complex named Sec 61. Once the exogenous proteins have reached the cytosol 
they are degraded by the proteasome and resulting peptides are translocated by TAP into 
the lumen of the same phagosomes, before loading on phagosomal MHC class I molecules. 
Therefore, cross-presentation in dendritic cells occurs in a specialized, self-sufficient, ER- 
phagosome mixed compartments demonstrating that the phagosome is a fully competent 
antigen processing compartments for the MHC class I pathway.
Norbury et al. demonstrated that cells expressing stable proteins were capable of cross­
priming, whereas those expressing minimal peptide were not, indicating that cross priming 
occurs when intact proteins are transferred from donor cells to DC (Norbury et al., 2004). 
Moreover, the location of the antigenic peptide within the protein is an important factor 
limiting the efficiency of cross-presentation. Indeed, Wolkers et al. constructed a chimeric 
secretable GFP protein in which the antigenic epitope was placed at the N terminus within 
a signal sequence or near the C terminus. Only the protein in which the epitope was at the 
C-terminus could be cross-presented revealing the importance of location and an 
unexpected bias of epitopes located within functional signal sequences. These and other 
studies indicated that cellular proteins rather than peptides are the source materials for 
cross presentation, suggesting that strategies aimed at maximazing steady state expression 
of the target antigen and its stability within the donor cells would be predicted to generate 
a better CTL response (Heath et al., 2004; Melief, 2003).
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Figure 1.1 DC process intracellular or extracellular antigens differently
It has been argued that cross priming of TAA by DC is an inefficient and rare process and 
therefore not able to elicit protective anti-tumor immunity [reviewed in ref. (Ochsenbein et 
al., 2001; Zinkernagel, 2002)]. The idea here is that tumor cells need to migrate to 
draining lymph nodes to directly present their own antigens in secondary lymphoid organs. 
In the cases where tumor cells metastasize to draining lymph nodes authors found immune 
activation based on a direct presentation of TAA to CD8 T cell. Therefore, it has been 
proposed that T cell tolerance to tumors is simply the consequence of an immunological 
ignorance due to the fact that most tumors never reach secondary lymphoid organs. 
However, virtually, all the studies investigating this phenomenon, report that the 
predominant pathway of presentation of TAA to CD8 T cells is the cross-presentation 
pathway by host APC.
The reason for the inefficiency of this process resides on the findings that tumor infiltrating 
DC are insufficiently activated and therefore incapable of efficiently cross-priming TAA
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(Melief, 2003). Indeed, if tumor bearing mice were treated with anti-CD40 agonist Ab, a 
DC activation signal, a strong expansion of CD8 tumor-specific T cells was obtained in 
peripheral lymphoid tissues (van Mierlo et al., 2002). The same study demonstrated that 
CD llc+ DC in DLN, rather than directly tumor cells, present TAA to CD8 T cells. Such 
phenomenon was strictly dependent on the TAP pathway reinforcing the idea of an indirect 
DC-mediated cross-presentation of TAA (Melief, 2003).
Pardoll’s group has demonstrated that cross-presentation is implicated in the induction of 
CTL against tumors. Indeed, CTL against a tumor cell line transfected with the gene of the 
influenza nucleoprotein (NP) were restricted to the haplotype of the host BM compartment 
(Huang et al., 1994a).
Tumor antigens are thought to enter into the cross-presentation pathway after undergoing 
cell death (Heath et al., 2004; Melief, 2003). Two types of cell death have been described: 
apoptosis and necrosis. The main difference between (programmed) apoptosis and 
accidental/ toxic (necrotic) death is that apoptosis results in the ordered fragmentation of 
the cells and leads to a rapid phagocytosis by neighbour cells and APC without inducing 
cell activation or inflammation. Apoptotic cells accumulation in patients affected by SLE 
or other autoimmune syndromes develop into the late phase of apoptosis, also called 
secondary necrosis, function as danger signals and activate the immune system.
It was demonstrated that although DC can engulf both necrotic and apoptotic bodies, only 
phagocytosis of necrotic bodies results in up regulation of co-stimulatory molecules and 
the capacity to prime T cells. Therefore it was proposed that phagocytosis of apoptotic 
cells by DC leads to tolerance to self or tumor antigens while necrosis leads to full 
activation of T cell immunity (Sauter et al., 2000).
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1.2.2 Dendritic cell migration and priming of T cells
After antigen exposure in the context of an inflamed site, DC undergo a process of 
maturation that includes up-regulation of costimulatory molecules, of MHC-class I and II 
complex and secretion of cytokines such as IL-12, TNF-a, IL-6. Maturation is 
accompanied by the acquisition of migratory capacity that allows DC to reach the 
appropriate lymphoid compartment for priming of T cells (Banchereau and Steinman,
1998). Exogenous mediators of DC maturation are the already mentioned Toll-like 
receptor ligands such as LPS, CpG motifs, double strand RNA and bacterial toxins, all 
components of pathogenic bacteria and viruses. Endogenous mediators of maturation are 
cytokines such as TNF-a, IFN-y, IL-ip which are released locally in inflamed tissue.
In a very recent work, Sporri and Reis e Sousa (Sporri and Reis e Sousa, 2005), 
demonstrated the existence of two distinct mature states for DC in vivo. These authors 
generated mixed bone marrow chimeras containing a DC subset able to respond directly to 
pathogens signalling but expressing the wrong haplotype for presenting an antigen to a test 
CD4 T cell population; the second subsets of DC have the right haplotype for presentation 
but are unable to respond directly to the TLR triggering. Inoculation of TLR ligands in 
these mice (LPS or CpG) elicited similar maturation phenotype by both DC subsets, with 
the first subsets maturing directly via TLR triggering and the second one via inflammatory 
cytokines produced as secondary mediators following TLR ligands inoculation. Although 
CD4 T cells proliferate upon antigen encounter in these chimeras they were not able to 
develop in effector cells able to produce IFN-y or IL-4. These experiments demonstrate 
that DC that did not directly receive TLR signals are unable to develop immunity despite 
their ability to show a mature phenotype.
Acquisition of migratory capacity is concomitant with the upregulation of adhesion
molecules such as CD44, a 6px integrins and chemokine receptors switching [reviewed in
ref. (Cavanagh and Von Andrian, 2002)]. Immature DC express receptors for
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inflammatory chemokines such as CCR1, 2, 3, 5 and 6. Upon maturation these are down- 
regulated while CCR7 becomes readily upregulated. CCR7 has two ligands CCL21 and 
CCL19; CCL21 is expressed by the endothelium of the lymphatic vessels by the high 
endothelia venules (HEV) and by the stromal cells of the T cell area, while CCL19 is 
released by mature DC and stromal cells in the T cell area of lymph nodes and spleens 
(Cavanagh and Von Andrian, 2002). CCL21 is upregulated on lymphatic endothelial cells 
after administration of inflammatory stimuli as TNF-a and its up regulation is one of the 
mechanisms by which inflammation promotes DC entering into the lymphatic vessels 
(Martln-Fontecha et al., 2003).
Mature DC entering the draining LN are driven into the paracortical area in response to 
CCL21 and CCL19 expressed by cells spread over the T cell zone (Cavanagh and Von 
Andrian, 2002).
Lack of CCR7 or its ligand has profound effects on lymph nodes structure and lymphocyte 
trafficking. Indeed, both Langherans cells and dermal DC were found unable to migrate to 
draining lymph nodes in the absence of CCR7 or in presence of blocking antibody to 
CCL21 (Forster et al., 1999) (Gunn et al., 1999).
In mice that have a spontaneous mutation of CCL19, DC fail to enter in the T cell zone of 
the lymph nodes (Nakano and Gunn, 2001).
Figure 1.2 describes some of the events following antigen exposure in an inflamed tissue 
environment.
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Figure 1.2 Schematic representation of dendritic cell migration from peripheral 
tissues to draining lymph nodes.
Dendritic cells capture antigens in peripheral tissue and as a consequence of the inflamed 
environment mature and migrate to peripheral lymphoid tissues. Homing to the LN and 
localization in the T cell area is orchestrated by chemokines.
Once in the lymph nodes, DC form an immunological synapse with T cells and activate 
them. Activation occurs when DC display the appropriate ligands to the responding T cells 
together with the proper engagement of TCR (T cell receptor) on T cells. The strength of 
the signal depends on different factors: 1) the amount of MHC-peptide molecules that bind 
to TCR, 2) the level of costimulatory molecules on DC and 3) the duration of the synapse.
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Once entered in the first cell division T cells proliferate and become able to respond to IL- 
2, which is produced by the same proliferating T cells.
The strength of the signal together with the polarizing cytokines present in the environment 
determines the class of the immune response. CD4 T cells polarize towards T helper 1 
(Thl) secreting IFN-y or Th2 producing IL-4, IL-5 and IL-13. Thl are adept at 
macrophage activation and immunoglobulin (Ig) selection for isotypes that mediate Ab- 
dependent cellular cytotoxicity and complement activation against intracellular pathogens, 
including viruses, bacteria yeast and protozoa. Th2 cells are involved in the development 
of humoral immunity protecting against extracellular pathogens. Polarization towards Thl 
and Th2 is promoted by IL-12 and IL-4 respectively [reviewed in ref. (Lanzavecchia and 
Sallusto, 2000; Lanzavecchia and Sallusto, 2001)].
For tumor cell and defined antigen-based therapeutic approaches T cell depletion 
experiments have demonstrated that both CD4 and CD8 T cell are needed for an optimal 
response. Because the majority of non-haematological tumors express MHC class I but not 
MHC class II molecule, it has been proposed that CD4 are necessary for the generation of 
tumor specific CTL (Hung et al., 1998).
It was proposed that DC have a rather passive relationship with the killer CD8 T cells 
mainly functioning in stimulating CD4 T helper cells to produce the appropriate cytokines, 
such as IL-2, that favours the CTL differentiation (Fearon et al., 1990).
However, recent studies suggest a much more dynamic model in which CD4 T cell 
licences DC to correctly activate CD8 T cells. Indeed, during DC-CD4 T cell cross-talk 
both cells become reciprocally stimulated [reviewed in ref. (Behrens et al., 2004)].
In 1998, three groups reported independently that CD40 on DC and CD40L on CD4 T 
cells were the prime means of helper-dependent DC licensing for CTL induction (Ridge et 
al., 1998) (Bennett et al., 1998) (Schoenberger et al., 1998). Bennet et al, demonstrated 
that induction of OVA specific CTL response was dependent on both CD40 and CD40L
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molecules and that in absence of CD4 T cells CD40 agonist Ab could substitute for the 
help. Schoenberger et al, demonstrated that CTL priming to TAA is dependent on CD40 
expressed by DC and again CD40 agonist Ab could substitute for the lack of T helper cells. 
Similarly Ridge et al, demonstrated that DC stimulated in vitro with agonist Ab to CD40 
can prime CTL in vitro even in the absence of CD4 T cells.
Information accumulated in the past years suggest that activated CD4 T cells trigger DC 
through CD40L, enhancing their capacity to produce IL-12, extending their survival and 
certifying their ability to activate CD8 effector T cells (Celia et al., 1996; Miga et al., 
2001). It remains to be elucidated whether all the signals downstream to CD40 triggering 
are essential for CTL induction or whether one, maybe undiscovered CTL priming signal, 
is generated through CD40 triggering.
Lu et al, demonstrated the existence of CD40-independent pathways of T cell help. They 
hypothesized two alternative pathways, one consisting of cytokine-mediated direct cross­
talk between CD4 and CD8 T cells, possibly through IL-2, and the other through a signal 
mediated by direct contact of CD4 T cells with the DC. The nature of this contact- 
mediated signal, however, was not identified (Lu et al., 2000).
Helper-independent CTL responses were also found. In most cases such responses were 
directed against pathogens. However even if, for the generation of CD8 primary effector T 
cells against virus, CD4 T cell help was found to be dispensable, such “unhelped” CD8 T 
cells responded poorly to subsequent antigenic challenge indicating that CD4 help is 
necessary for a qualitative and durable CD8 memory response (Shedlock and Shen, 2003; 
Sun and Bevan, 2003).
In antitumor responses, CD4 T cells are important not only in CTL generation but also in 
maintaining the CTL pools. Indeed, a greater number of MHC class I-restricted, HA 
peptide reactive CD8 T cells can be recovered from animals that have been transferred 
with both antigen specific CD8 and CD4 T cells. The authors proposed that CD4 T cells
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“help”, in maintaining the CD8 T cells activity, is particularly important when the immune 
system is responding to replicating target such as tumors and viruses (Marzo et al., 2000). 
In addition to activating T cell responses, mature DC can induce NK activation and B cell 
differentiation into antibody producing cells.
1.2.3 Dendritic cells and tolerance induction
Although most studies focus on the role of DC in activation of T cells, DC can also have 
an apparently opposite effect, the induction of tolerance [reviewed in ref. (Steinman et al., 
2003)]. Before T cells encounter foreign antigens, the T cell repertoire must be shaped to 
delete those cells self-reactive against self-antigens. This event occurs in the thymus, and is 
called central tolerance
In the thymus, DC are located exclusively in the medulla and induce deletion of positively 
selected thymocytes. Thymic medullary epithelium also expresses high levels of MHC- 
class II and plays a significant role in central tolerance to self-antigens expressed by 
epithelial cells.
Central tolerance however is not complete. Self-reactive T cell clones with low affinity for 
TCR escape negative selection. Moreover, the abundant proteins present in the periphery 
for which tolerance is needed may not be presented in the thymus. Peripheral tolerance is 
consequently necessary to complement and complete thymic induced tolerance. DC have a 
role in the induction and maintenance of both central and peripheral tolerance (Steinman et 
al., 2003).
DC present self-antigens in the steady state and induce deletion or anergy of naive T cells 
in the periphery. Indeed when antigens of the pancreatic islet (3 cells are presented in the 
draining LN in the steady state, clone specific CD8 T cells are deleted suggesting that the
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state of DC during antigen presentation conveys immunity or tolerance (Morgan et al.,
1999).
In immature DC, the secretion of cytokines such as TGF-P and IL-10 induces CD4 T 
regulatory cells (Trl) that in turn suppress the immune response (Jonuleit and Schmitt, 
2003). Tolerance is an obstacle to cancer immunotherapy because several TAA are 
inappropriately expressed self-antigens. Data from mouse studies and human clinical trials 
demonstrate that it is possible to elicit a CD8 T cell response to tumor antigens, suggesting 
that tolerance to these tumor antigens is not complete. Strategies based on recruiting DC to 
the tumor site and aiming at eliciting CD8 T cell response should consider the possibility 
that DC, biased by the tumor microenvironment, will present tumor antigens in an 
inappropriate costimulatory context, leading to tolerance instead of immunity (see section
1.5 for further discussion).
Figure 1.3 schematizes the discussed functions of dendritic cells in the immune system.
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Figure 1.3 Overview of DC functions in immune responses 
1.2.4 Dendritic cells-based immunotherapy
Given their central role in triggering the immune response, DC are most commonly used to 
stimulate T cell response against malignancies.
There is a large body of evidence showing that in animal models, DC loaded ex-vivo with 
tumor antigens and re-infused in the animal, lead to protection against subsequent 
challenges with live tumor cells and in some case rejection of pre-existing tumors (Celluzzi 
et al., 1996; Fields et al., 1998; Gong et al., 1997; Paglia et al., 1996; Zitvogel et al., 1996). 
A number of different strategies have been used to deliver tumor antigens to DC, including 
electroporation with naked plasmid DNA, liposome DNA complexes, peptides, tumor cell 
lysate and fusion with tumor cells.
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These studies created the translational basis to test this approach in clinical trials. The most 
common approach consists in preparing large quantity of autologous DC from peripheral 
blood monocytes differentiated with GM-CSF and IL-4. Such DC are then loaded with 
tumor antigens and often matured with TNF-a before injection into patients [reviewed in 
ref. (Fong and Engleman, 2000; O'Neill et al., 2004; Schuler et al., 2003)].
The choice of the right tumor antigen remains the critical issue determining the success of 
such strategy. Tumors may resist to CD8 T cell lysis by selecting antigen-loss variants, 
therefore antigenic molecules necessary for the tumor growth are avidly searched. 
MHC-restricted peptides modified to enhance binding to MHC-class I molecule have been 
used; however the most encouraging data from clinical trials come from the use of whole 
protein, killed tumor cells or tumor cell lysate. The advantage of these approaches is that 
the entire antigenic repertoire is delivered to DC for cross-presentation.
The availability of sensitive techniques to monitors the induction of T-cell responses has 
proved that DC-based vaccines can induce primary response to TAA. Unfortunately in the 
majority of these trials the presence of specific T cells response did not correlate with 
tumor regression [reviewed in ref. (Rosenberg et al., 2004)]. A number of reasons may 
explain this incongruence: 1) is not yet clear what magnitude of T cell response correlates 
with protective immunity; therefore the number of the induced CD8 T cells may have been 
too small; 2) the induced CTL may have been ineffective in tumor killing because biased 
by the tumor microenvironment; 3) patients that were enrolled in many of these studies 
may had a tumor load such to render the sole adaptive response insufficient for its 
elimination.
Strategies based on ex vivo manipulation of DC are extremely expensive and time 
consuming; moreover, by altering the physiology of antigen processing and presentation, 
such method may loose the desired efficacy. To avoid this problem, alternative approaches 
are available that foresee the possibility of loading DC with tumor antigen directly in vivo.
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This obviates the need for DC purification and in vitro manipulation, and ensures the 
continuous availability of DC precursors, which upon antigen uptake, undergo migration 
and encounter with T cells in a more physiological manner.
An extremely efficient way to recruit DC locally is the in situ delivery of chemokines (see 
section 1.3 for further discussion).
DC have also been loaded directly in vivo by targeting the DEC 205 receptor expressed on 
their surface (Bonifaz et al., 2004) (Hawiger et al., 2001). In these studies the authors 
demonstrated that small amounts of DEC205-conjugated OVA antigen were capable of 
inducing CD4 and CD8 combined immunity, in the presence of a DC maturation stimulus 
(anti-CD40 triggering Ab). Interestingly, targeting the antigen via DEC 205 without 
maturation stimuli induced tolerance rather than immunity, strongly suggesting that 
effective in situ targeting strategies must be coupled with maturation stimuli to trigger 
immunity.
1.3 Chemokines
1.3.1 Chemokines and the trafficking of cells of the immune system
Chemokines are small molecules (9kDa) that orchestrate the circulation of leukocytes by 
mediating their adhesion to endothelial cells, initiation of transendothelial migration and 
tissue-invasion. Chemokines have also a role in angiogenesis, hematopoiesis and 
organogenesis [reviewed in ref. (Baggiolini, 1998; Mackay, 2001; Moser and Loetscher, 
2001; Zlotnik and Yoshie, 2000)].
Members of the family have in common a repetition of four cysteins in their protein 
sequences. Depending on the position of the first two cysteins residues chemokines have 
been divided in 4 subgroups, the C-C, CXC, C and CX3C.
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A high redundancy is present among the chemokines family in terms of function and 
receptor sharing. The chemokines that are located on the same chromosome within gene 
clusters have the highest redundancy in terms of function, while those mapping unclustered 
have mostly unique receptors and function. Such redundancy may reflect their ability to 
orchestrate the movement of different leukocyte subsets in complicated situations such as 
acute or chronic inflammation where a variety of leukocytes are abundantly present.
The biological effects of chemokines are mediated by G-protein coupled transmembrane 
receptors (GPCR), which are also located into clusters within chromosomes.
A recent classification has divided chemokines on the basis of their function and 
distinguishes them between “inflammatory” and “homeostatic” (Moser and Loetscher, 
2001).
Inflammatory chemokines are produced by tissue or infiltrating leukocytes after the 
encounter with pathogens or in situations of inflammation. Such chemokines recruit 
monocytes, granulocytes and effector T cells at the site where they are released.
On the contrary, homeostatic chemokines are endowed of more “housekeeping” functions 
such as trafficking and homing of lymphocytes, assuring their homeostatic recirculation 
(Moser and Loetscher, 2001).
Monocytes and DC when immature use receptors for inflammatory chemokines such as 
CCR1, 2, 5, 6 and 9 to enter peripheral tissue.
Upon entering in peripheral tissues and exposure to maturation stimuli, such as pathogens 
or other stimuli delivered by innate effectors cells, DC down regulate inflammatory 
receptors and upregulate the “lymphoid” receptor CCR7 that allows DC to respond to 
CCL19 and CCL21 (Mackay, 2001; Zlotnik and Yoshie, 2000).
CCR7 is important in the circulation of T cells and its expression discriminates between 
homing to the secondary lymphoid organs and peripheral tissues.
32
Naive T cells express CCR7 that assure the retention in lymphoid organs where the 
immune response is mounted. Once activated, antigen specific T cells lose CCR7 
expression and use other chemokines to reach the site of inflammation. Indeed, CCR7 
deficient mice not only show strong defect in DC homing to LN but have significantly 
reduced number of naive T cells in lymphoid organs. As a consequence of both DC and T 
cells homing defects, CCR7-deficient mice have impaired immune responses such as 
delayed-type hypersensitivity reaction (DTH) and antibodies production (Forster et al., 
1999; Randolph et al., 1999). A number of new evidences have demonstrated that 
chemokines not only orchestrate leukocytes circulation but act on the target cells to modify 
their effector functions. For example, the human CC chemokine CCL5 is able to co- 
stimulate cell proliferation in response to anti-CD3 triggering. Such effect depends on the 
presence of IL-2. Indeed IL-2 up regulates CCR5 expression on T lymphocytes, providing 
an additive effect. Interestingly other human CC chemokines that use CCR5 receptor have 
similar activity (Taub et al., 1996). SDF-la can also co-stimulate human CD4 positive T 
cells in response to anti-CD3 triggering, by augmenting production of IL-2, IL-4 and IFN-y 
(Nanki and Lipsky, 2000; Suzuki et al., 2001).
1.3.2 Chemokines in cancer immunotherapy
Engineering tumor cells to express immunostimolatory molecules is one of the most 
popular approaches to study the role of such molecules in tumor rejection and to generate 
cell-based vaccines.
A large number of studies (the most important ones are summarized in Table 1.1) use 
chemokine genes, given the ability of the corresponding proteins to recruit leukocytes and 
to enhance certain functions [reviewed in ref. (Homey et al., 2002)].
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Beside their role in anticancer strategies this method also addresses the biological function 
of chemokines in vivo.
The different approaches have been used: transduction of tumor cells with chemokines 
genes in vitro and their transplantation in vivo, delivery of chemokines directly in vivo in 
pre-established tumors and combination of chemokines with other immunomodulatory 
molecules. The following paragraphs will summarize such studies.
In many cases chemokine gene transduction reduced or completely abrogated 
tumorigenicity of tumor cell lines by a T cell dependent mechanism, as demonstrated by 
experiments performed in T cells depleted mice (Homey et al., 2002).
Antitumor response chemokine-induced is not only mediated by T cells, but cells of the 
innate response are often involved and angiostatic effects are important as well. For 
example antitumor mechanisms mediated by hCCL16 were found to be dependent on the 
presence of polymorphonucleated cells (PMN) within the tumor (Giovarelli et al., 2000). 
Neutrophil accumulation mediated tumor destruction of SPO/2 myeloma cell transfected 
with XCL1 although complete regression required a T cell response, indicating that this 
chemokine exert antitumor activity by both innate and effector mechanisms (Cairns et al.,
2001).
CXCL10 and CXCL9 share the same receptor (CXCR3) and are chemotactic in vitro for T 
lymphocytes and NK cells (Loetscher et al., 1996). Both chemokines have a strong 
inhibitory effect on angiogenesis (Angiolillo et al., 1995). Indeed, CXCL10- and CXCL9- 
gene transduction into tumor cell lines resulted in tumor rejection, an effect thought to 
result from their action on lymphocytes as well as their anti-angiogenic properties 
(Arenberg et al., 1996) (Sgadari et al., 1996) (Sgadari et al., 1997).
Results obtained with this approach are not always consistent. For instance CCL2-gene 
transfer resulted in macrophage recruitment and, as a consequence, had no effects on 
(Hirose et al., 1995), tumor destruction, (Huang et al., 1994b), partial inhibition of tumor
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(Laning et al., 1994) (Bottazzi et al., 1992) or augmentation of tumor growth and of 
metastatic spreading (Bottazzi et al., 1992) (Nesbit et al., 2001) (Nakashima et al., 1995). 
Nesbit et al, have elegantly investigated these contradictory results by transducing tumor 
cell line with an adenoviral vector at different MOI such to obtain different level of CCL2 
expression. They demonstrated that the effect of CCL2 on tumor growth is dose dependent 
and related to the degree of leukocyte infiltration. Indeed, low level of CCL2 increased 
tumor growth, while higher-level provoked tumor destruction throughout massive 
macrophages infiltration. Macrophages recruited by low CCL2 promoted tumor growth 
because of macrophages effect on angiogenesis and as supporter of tumor stroma. 
Interestingly, tumors producing low CCL2 level had the macrophages located at the edge 
of the tumor area suggesting that their peritumoral localization is beneficial for the tumor 
(Nesbit et al., 2001).
As mentioned in section 1.2, strategies that aim at enriching DC at the tumor site have 
shown some promising results. This approach is based on the concept that DC 
chemoattration directly at the tumor site can favour uptake of tumor derived antigens.
In this context interesting results came from the use of CCL20 and CCL21, both effective 
in attracting DC in vitro. Vicari et al, showed that mouse CCL21 delayed tumorigenicity of 
transfected C26 colon carcinoma cell through angiostatic and CD8 T cell mediated 
mechanisms (Vicari et al., 2000). Although tumors were infiltrated by a large number of 
granulocytes, their depletion did not abrogate tumor rejection, while NK cells were found 
necessary. Because of the ability of CCL21 to recruit both naive T cells and DC, the 
authors suggested that T cell priming could took place within the CCL21-expressing tumor 
rather than in its DLN. This hypothesis is supported by the notion that CCL21 can promote 
the development of an ectopic lymphoid tissue (Fan et al., 2000). Formal proof of this 
hypothesis came from a more recent study from Kirk et al (Kirk et al., 2001a). These 
authors used BM derived DC infected with an adenoviral vector expressing CCL21 and
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injected them intratumorally in the attempt to mount a specific T cell response. 
Interestingly such modified DC were unable to reach the DLN, but promoted an 
accumulation of CD4 and CD8 T cells at the tumor site. By using mice lacking secondary 
lymphoid organs (Lta the authors demonstrated that the priming of T cells by DC 
took place inside the tumor that became the site of T cell triggering and, as well, T cells 
target. Indeed, in Lta-/- mice, activated T cells were recruited at the tumor site and 
antitumor activity, manifested as delayed tumor growth, was comparable to that of wt mice 
(Kirk etal., 2001a).
CCL21 was found to be effective as an antitumor agent when injected into prestablished 
tumors as recombinant protein. In two studies multiple intratumoral injection of 
recombinant protein induced 40% complete tumor regression (Sharma et al., 2000) and 
significantly delayed tumor growth (Kirk et al., 2001b).
In the same vein, Fushimi and co-authors injected adenovirus-encoding CCL20 into 
prestablished tumors and reported a cure rate between 70 and 50%, depending on the 
tumor model used. Inflammation and enlargement of DLN, was accompanied by 
accumulation of DC; however authors did not investigated whether such DC-infiltration 
was the consequences of a general inflammation or whether they migrated from the tumor. 
Tumor rejection was reported to involve exclusively T cell response, but the presence/role 
of innate immunity was not investigated (Fushimi et al., 2000).
Chemokines seem to have limited therapeutic potential when used as single agent against 
well-established tumors. Therefore, many approaches have combined the chemoattratant 
proprieties of chemokines with other immunomodulatory molecules such as cytokines, or 
TLR ligand CpG (Homey et al., 2002).
For example an adenoviral vector expressing XCL1 was ineffective when used alone 
against pre-established mammary carcinomas, but when co-expressed with IL-2 or IL-12, 
induced tumor regression in 40 to 60% of treated mice (Emtage et al., 1999).
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In a separate study, an adenoviral vector delivering XCL1 was combined with adoptive T- 
cell therapy (Huang et al., 2002a) to treat pre-established SP2/0 myloma. The authors 
prepared SP2/0 tumor-specific T lymphocytes by isolating T cells from mice that rejected 
SP2/0 cells transfected in vitro with XCL1. T cells were then expanded in vitro and re­
injected in vivo in combination with intratumoral administration of the adenovector 
expressing XCL1. Neither adenovirus-mediated XCL1 gene transfer alone nor adoptive T- 
cell transfers cured tumor-bearing mice. In contrast, by combining the two treatments, six 
of eight mice were cured indicating the synergistic therapeutic effects of locally expressed 
XCL1 with adoptive T-cell therapy. The study shows that tumor-specific activated T 
lymphocytes expressed XCR-1 mRNA and migrated in response to XCL1 in vitro. 
Moreover the authors demonstrated an enhanced tumor infiltration of adoptively 
transferred tumor-specific T cells in XCL1 treated tumors, supporting the hypothesis that 
the observed antitumor activity is derived from the combined chemotactic and stimulatory 
effects of XCL1 on adoptively transferred activated T cells (Cairns et al., 2001).
Narvaiza et al, combined an adenovirus expressing CXL10 with one expressing IL-12 a 
strategy that allowed lowering the dose of effective IL-12, preventing its toxicity, while 
improving the therapeutic efficacy of the T cell response. The antitumor response was 
observed only when the two agents were delivered together in the same tumor nodules, 
supporting the so called “attraction and activation hypothesis” which predicts the need of 
activating the chemokine-recruited leukocytes to obtain an optimal antitumor response 
(Narvaiza et al., 2000).
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Table 1.1
CHEMOKINE MODEL INFILTRATING
LEUKOCYTES
IMMUNE RESPONSE 
/OUTCOME
REF
m/h CCL2 Gene transfer into 
CHO cell line. 
Comparison with 
other h/m CCL
Neutrophils No tumor rejection or 
reduce growth
(Hiros 
e et 
al., 
1995)
hCCL2 Gene transfer into 
B16 melanoma 
model.
Macrophages Slower growth rate when 
cells are injected s.c.
(Botta 
zzi et 
al., 
1992)
mCCL2 Gene transfer into 
CT26 co lon  
carcinoma model.
N.D. Reduce number of 
metastases following i.v. 
injection of modified 
cells.
(Huan 
g et 
al.,
1994b)
hCCL2 Gene transfer into 
C26 c o lo n  
carcinoma.
N.D. Increase number of 
metastases upon i.v. 
injection. The authors 
conclude that CCL2 
augment angiogenesis
(Nakas 
hima 
et al., 
1995)
hCCL2 Gene transfer into 
SBcl2 melanoma 
cell line via 
adenoviral vector 
to obtain different 
a m o u n t o f 
production of 
CCL2.
Macrophages Low level of CCL2 at 
the time of tumor take 
led  to in c re a se  
tumorigenesis whereas 
an higher production to a 
massive infiltration of 
macrophages and tumor 
destruction.
(Nesbi 
t et al., 
2001)
mCCLl Gene transfer into 
IgG and IgA 
myeloma.
Macrophages 
and neutrophils
Reduce tumorigenesis 
local necrosis
(Lanin 
g et 
al., 
1994)
hCXCL8
mCCL3
hCCL3
Gene transfer into 
C 26 c o lo n  
carcinoma.
Macrophages 
and neutrophils
Reduced tumorigenesis 
of cells transfected with 
h/m CCL3 but not with 
hCXCL8.
(Nakas 
hima 
et al., 
1996)
hCCL5 Gene transfer into
murine
fibrosarcoma.
Macrophages Complete rejection. 
Complete abrogation of 
rejection  in mice 
depleted for CD8 T cells. 
Only partial need of CD4 
T cells.
(Mule 
et al., 
1996)
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Table 1.1
CHEMOKINE MODEL INFILTRATING
LEUKOCYTES
IMMUNE
RESPONSE
/OUTCOME
REF
hCCL16 Gene transfer 
into murine TSA 
adenocarcinoma.
DC, CD8, CD4 
and macrophages
Complete rejection 
dependent on CD8 T 
cells andPMN.
(Giovarel 
li et al., 
2000)
hCCL19 Retrovirus 
in fection  of 
C3L5 breast 
carcinoma cell 
line.
N.D. Tumor rejection of 
CCL19 transfected 
cells. NK and CD8 
mediated. Same cells 
used as vaccine 
s h o w e d  lo w  
therapeutic activity.
(Braun et 
al., 2000)
XCL1 Gene transfer 
in to  SP2/0 
myloma model.
Mainly
Neutrophils
T cells are needed for 
total rejection but in 
their absence the only 
p r e s e n c e  o f  
neu trophils was 
s u f f i c i e n t  to  
significantly delay 
tumor growth
(Cairns et 
al., 2001)
XCL1 In jection  of 
adenovirus 
expressing 
X C L1 in  
prestablished 
SP/20 myloma 
tumor combined 
or not with 
adoptive T cell 
transfer.
Activated T cells Strong synergy of 
XCL1 expression at 
tumor site with 
adoptive T cell 
therapy. XCL1 attract 
effector T cells at 
tumor site.
(Huang et 
al.,
2002a)
MCP-3 Gene transfer 
in to  P815 
mastocytoma 
cell line.
Macrophages, 
neutrophils 
accumulate 
within the tumor 
w h ile  DC 
peritumorally
Tumor rejection of 
modified cells. T cell 
depletion and IFN-y 
blocking abrogated 
rejection.
(Fioretti 
et a l., 
1998)
CCL3 Gene transfer 
in to  B 16 
melanoma 
model.
N.D. CCL3 expression had 
no effect on s.c. 
injection of modified 
tumor cells while 
significantly inhibited 
the ab ility  of 
modified cells to 
form metastases in a 
CD8 dependen t 
fashion.
(van
Deventer 
et a l., 
2002)
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Table 1.1
CHEMOKINE MODEL INFILTRATING
LEUKOCYTES
IMMUNE
RESPONSE
/OUTCOME
REF
CCL5 Gene transfer 
into EL4 
tymoma cell line 
and intratumoral 
injection of 
plasmid
encoding CCL5- 
Ig fusion protein 
for therapy
T cells and NK Decreased
tumorigenicity of 
modified cell lines 
and decreased tumor 
growth when used in 
a therapeutic setting. 
T cell mediated.
(Lavergn 
e et al., 
2004)
CCL21 Gene transfer 
into C26 colon 
carcinoma 
model.
DC, monocytes, 
granulocyte
Reduced
tumorigenesis by 
angiostatic and CD8 
mediated T cell 
response.
(Vicari et 
al., 2000)
CCL21 M ultiple i.t. 
in jec tion  of 
recombinant 
CCL21 in 3LL 
and LIC2 lung 
carcinoma.
DC, CD4 and 
CD8T
R educed tum or 
growth and 40% of 
complete regression.
(Sharma 
et a l., 
2000)
CCL21 M ultiple i.t. 
in jec tion  of 
recombinant 
CCL21 in B16 
tum or p lus 
vaccine
consisting of DC 
expressing SLC.
DC, CD4 and 
CD8T
Decreased tumor 
growth after direct 
injection of rCCL21
{Kirk, 
2001 #26
CCL21 DC genetically 
m odified via 
adenoviral 
vector
inoculated into 
prestablished 
B16 melanoma 
tumor model.
CD4 and CD8 Inhibition of growth 
of p restab lished  
tumors. Rapid influx 
of T cells secreting 
IFN-y into treated 
tumors. Priming of T 
cells is independent 
from DLN.
(Kirk et 
al.,
2001a)
XCL10 Combination of 
adenovirus 
expressing 
XCL10 with one 
expressing IL- 
12.
Lymphocytes
infiltration
S trong synergy 
observed only when 
the two molecules 
were delivered at the 
same tumor site. CD4 
and CD8 were 
needed.
(Narvaiza 
et a l., 
2000)
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Table 1.1
CHEMOKINE MODEL INFILTRATING
LEUKOCYTES
IMMUNE
RESPONSE
/OUTCOME
REF
CCL20 Intratumoral 
in jec tion  of 
adenovirus 
expressing 
CCL20. Three 
tumor model 
used: CT26 
(colon
carcinoma), B16 
(melanoma) and 
LLC (lung  
carcinoma)
DC infiltrates 
treated tumor 
and their DLN
40-60% of rejection 
rate.
T cells are needed.
(Fushimi 
et a l., 
2000)
Table 1.1 Some models of chemokine treated tumors. Abbreviation used i.t., intratumoral;
PMN, polymorphonuclear leukocyte; ND, not determined; h/m human and mouse.
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1.3.3 The biology of CCL16
Liver-expressed chemokine CCL16, also known as LEC, novel chemokine 4, human CC 
chemokine 4, human CC chemokine 1, was originally found as expressed sequence in a tag 
library, and its gene was then mapped in the CC chemokine cluster on chromosome 17 
(Fukuda et al., 1999; Naruse et al., 1996).
CCL16 was found to be chemotactic for human lymphocytes, monocytes and DC. It was 
reported to bind to CCR1 with the highest affinity but also to CCR2, CCR5 (Nomiyama et 
al., 2001) and CCR8 (Howard et al., 2000).
Two CCL16 transcripts of 1,5 kb and 0.5 kb have been described to be expressed at the 
same level in the normal human liver (Shoudai et al., 1998). Both messages encode a 
protein of 120 aa. Few reports have investigated its biological role.
Hedrick at al, demonstrated that the CCL16 shorter message is expressed at weak level by 
human lymphocytes, including NK cells and yb T cells. The highest level was detected in 
human monocytes activated by LPS and IFN-y. Interestingly when monocytes were 
activated by these agents in the presence of IL-10, the longest message was found to be 
upregulated. The biological significance of this upregulation remains unclear but the 
authors proposed that CCL16 act as an anti-inflammatory chemokine (Hedrick et al.,
1998). However, recent data suggest that it acts as inflammatory chemokine. Indeed, 
CCL16 enhances the ability of murine macrophages to phagocyte and their antigen 
presenting cell function. Small amount of recombinant protein (10-100 ng) triggers the 
killing activity of macrophages against a mammary carcinoma cell line, TSA, via increased 
expression of TNF-a and FasL. Moreover CCL16 induced macrophages to release 
downstream mediators such as CCL2 and CCL5 and inflammatory cytokines such as TNF- 
a, IL-1|3 and IL-12 (Cappello et al., 2004).
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It has been proposed that IL-10 secretion can increase inflammation as a results of 
upregulated CCL16 expression that in turn leads to a massive enhancement of CCL2 
release (Cappello et al., 2004). CCL2 is an inflammatory chemokine that is upregulated in 
various types of hepatic injury, and in this environment IL-10 synergizes with CCL16 to 
upregulate its expression. A recent study analyzes CCL16 expression in human biopsy of 
Ulcerative Colitis (UC), an inflammatory disease associated with high level of IL-10 
expression. Abundant inflammatory infiltrate can be detected within the lesions where 
macrophages were found to express high level of CCL16. The immunohistochemical and 
ultra structural characteristics of the lamina propria in UC suggest that IL-10 mediated up 
regulation of CCL16 is responsible for the inflammatory reaction associated with these 
lesions (Pannellini et al., 2004). Therefore it seems likely that the peculiar pro- 
inflammatory activity of IL-10 in certain pathological conditions can be explained by the 
upregulation of CCL16 that leads to leukocyte recruitment and induction of a further 
inflammatory cytokines and chemokines cascade.
Finally, in human, CCL16 was found to promote angiogenesis in 3 different ways 1) by 
inducing endothelial cell motility, 2) by inducing the release of proinflammatory and 
proangiogenic chemokines, such as CCL2 and CXCL18 and 3) by sensitizing endothelial 
cells to otherwise ineffective concentration of VEGF (Strasly et al., 2004).
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1.4 TLR9 triggering via CpG ODN in cancer immunotherapy
1.4.1 Mechanisms of action
The innate immune system is activated by exposure to pathogen-associated molecular 
patterns (PAMP) expressed by infectious microrganism.
The triggering of the innate response contrasts with the early proliferation of the infectious 
agent and stimulates the induction of the adaptive response that not only clears the 
pathogens but retains the memory of their encounter. The recognition of PAPM is 
mediated by the already mentioned TLR.
Unmethylated DNA in a particular sequence context (CpG motifs) constitutes one of the 
most potent PAMP. Because bacteria cannot methylate cystein residues and most of the 
mammalian genome is methylated, CpG motifs in bacterial DNA are recognized as 
diverse, such to alert the immune system about the pathogen presence.
Cells of the innate response recognize the CpG motifs using TLR9 receptor. Upon binding 
to CpG the TLR9 TIR domain recruits the adapter protein MyD88 that in turn recruits the 
IL-1 receptor-associated kinase (IRAK) and TNF receptor-associated factor 6 (TRAF6) to 
the TLR9 complex, leading to the activation of transcription factors such as NF-kB, API, 
CEBP and CREB. These factors activate the transcription of a number of inflammatory 
cytokines and chemokines genes that are the final mediators of CpG effect on the innate 
system. To the activation of the innate system follows a strong activation of the adaptive 
response; indeed CpG motifs, among the various PAMP, appears to induce the strongest 
Th-1 type immune response [reviewed in ref. (Klinman, 2004; Verthelyi and Zeuner, 
2003)].
Mice and humans differ for the type of cells, that expressing TLR9, are able to respond to 
CpG motifs. In mice, TLR9 is expressed by murine plasmacytoid and non-plasmacytoid 
DC regardless their spleen, thymus or bone marrow origin. In mice also
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monocytes/macrophages respond to CpG. On the contrary, in human CpG response is 
restricted to plasmacytoid DC (pDC) and B cells.
In mice, optimal immune activation requires a CpG motif in which an unmethylated CpG 
dinucleotide is flanked by two 5' purines and two 3' pyrimidines. The cascade of events 
activated by TLR9 leads to increase antigen presenting functions of DC and secretion of 
inflammatory chemokines/cytokines by DC, macrophages and NK cells (Verthelyi and 
Zeuner, 2003).
Interestingly, among a number of different TLR ligands, CpG ODN seems the only able of 
increasing the ability of murine BM derived DC to cross-present exogenous antigens, 
demonstrating a peculiarity of CpG in affecting the antigen-processing machinery (Datta et 
al., 2003).
In humans, two types of immunostimolatory sequences, the K and the D, have been 
described to have different effects. The major differences among the two are on pDC. K 
ODN act on pDC to promote TNF-a synthesis, to increase survival and up regulation of 
maturation markers (CD40, CD80, CD86) but induces low level of IFNa/p. On the 
contrary, the D type promotes large amount of IFNa/p secretion that in turn promotes 
secondary effects on other immune cell types (Verthelyi and Zeuner, 2003). For example 
pDC release of type I IFN promotes secretion of CXCL10 by human monocytes 
(Blackwell and Krieg, 2003), mediates monocytes differentiation into DC (Hartmann et al.,
1999) and induces monocytes to secretes TNF-related-inducing ligand (TRAIL) enabling 
them to kill tumor cells (Kemp et al., 2003). Recently a new class of CpG ODN (class C) 
was shown to elicit both human B cells and pDC activation associated with release of high 
amount of types I IFN (Marshall et al., 2003).
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1.4.2 Antitumor applications of CpG oligodeoxynucleotide.
The described ability of CpG to activate the immune system has found important 
therapeutic applications in the fields of vaccine development, protection by infectious 
organisms and treatment of cancer.
Figure 1.3 schematizes the field in which synthetic CpG have been shown to have potential 
therapeutic effects.
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Figure 1.4 CpG alone have been shown to induce protective immunity against 
pathogens.
Because of its effect on antigen presenting cell functions and B cell activation, CpG ODN 
creates a cytokine/chemokine milieu that enhances the effectiveness of co-administered 
vaccines. The cascade of events associated with intratumoral administration of CpG has 
been shown to induce tumor rejection to a certain degree.
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Several applications of CpG in cancer immunotherapy have been described either in 
settings of prevention, as adjuvant of tumor vaccines or of therapy to treat already 
established tumors [reviewed in ref. (Klinman, 2004)].
In prevention settings, when incorporated into DNA or peptide based antigen-specific 
vaccines, CpG were shown to protect against subsequent tumor challenge (Huang et al., 
1997) (Miconnet et al., 2002; Stem et al., 2002).
The efficacy of CpG monotherapy to cure pre-established tumors appears to vary 
dramatically depending on the tumor model used and the number of administrations 
(Krieg, 2004) (see table 1.2).
In a highly immunogenic tumor model of cervical cancer, complete regression was 
observed if repeated systemic administrations were started two days after injection, while 
lower (50%) regression was obtained when treatment began ten days after tumor 
inoculation. Interestingly, CD8 but not CD4 T cells were needed for the observed 
therapeutic effect. In this tumor model CD4 appeared to function as immunosuppressive 
cells, as CD4 KO mice showed increase antitumor effect of CpG in comparison with wt 
mice (Baines and Celis, 2003).
Systemic administration of CpG was shown to delay carcinogenesis in a model of 
spontaneous mammary carcinogenesis (FVB-NeuN). Transgenic female were treated 
weekly from the 10th week of age with CpG. Tumor incidence and number of 
tumors/mouse were significantly lower in treated mice compared with the control group, 
indicating that by only maintaining the immune system on alert, carcinogenesis can be 
impaired. However, no complete regression or memory response against tumor challenges 
was obtained, consistent with the notion of a predominant or exclusive role for the innate 
immunity in the observed inhibitory effect.
Peritumoral or intratumoral administration of CpG was found to be more effective than its 
systemic administration (Heikenwalder et al., 2004; Kawarada et al., 2001). Sfondrini et al,
Al
studied the effectiveness of CpG given locally in relation to the immunogenicity of the 
treated tumor. Repeated intratumoral injections of CpG into B16 tumor leads to reduced 
tumor growth and expansion of IFN-y-producing specific CD8 T cells. However NK rather 
than CD8 T cells were found to be responsible for the antitumor activity. The authors 
suggested that because B16 melanoma is a highly aggressive tumor and expresses low 
level of MHC class I molecule, the CTL response mounted after CpG treatment is 
insufficient to block tumor growth and to completely reject growing tumors (Sfondrini et 
al., 2002).
Of great interest are studies that combined TLR9 stimulation with other therapeutic agents 
such as other immunostimolatory molecules, adoptive T cell transfer or chemotherapy. 
Furomoto et al, found that multiple intratumoral administrations of CpG into B16 tumor 
are not able to halt tumor growth while its combination with rCCL21 induces a potent 
systemic antitumor response. The authors demonstrate that both the number of DC 
infiltrating the tumor and their activation state were important for an optimal induction of 
T cell response especially when poorly immunogenic tumors were treated. Indeed, CCL20 
alone was able to reject CT26 tumor that contrary to B16 tumor has functional infiltrating 
DC that therefore do not need further stimuli like CpG to become activated (Furumoto et 
al., 2004).
In another study TLR9 triggering was combined with Ag-specific immunization to cure 
spontaneous tumors in RIP-Tag transgenic mice. Vaccination with antigen-encoding 
plasmid DNA elicited specific CTL that however were unable to infiltrate the tumors. The 
number of elicited CTL was not the limiting factor since transfer of high number of pre­
activated specific CD8 T cells gave similar results. Combination of pre-activated CD8 and 
CD4 T cells with CpG proved to be highly effective, because CpG rendered the tumor 
permissive for massive leukocytes infiltration and destruction (Garbi et al., 2004).
Weigel et al, demonstrated that CpG or chemotherapeutic agents, cyclophosphamide or 
topotecan, given as single treatments, could not induce rejection of well-established 
rabdomyosarcoma tumors. On the contrary when chemotherapy was combined with 
systemic or local administration of CpG, 15 to 40% of mice rejected the tumor, suggesting 
that chemotherapy releases tumor antigens that are better presented by TLR9 stimulated 
DC. Antitumor activity required T cells but not NK cells suggesting a role for T cells in 
controlling the residual tumor remnants left by the chemotherapy (Weigel et al., 2003). 
These studies, together with many others in the literature, strongly suggest that the 
outcome of TLR9 stimulation varies depending on the type of tumor, its size, the level of 
MHC molecules expression, the susceptibly to the immune effector cells as well as the 
status of responsiveness of the infiltrates to the triggering, and clearly indicate that TLR9 
may strongly synergize with other immunomodulatory therapies towards tumor rejection. 
(Table 1.2 represents a summary of murine tumor models treated with CpG ODN).
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Table 1.2
Tumor Model Schedule of 
treatment
Outcome Ref
C3 cervical cancer 
model
Systemic injection of 
CpG starting day 2 
or day 10 post tumor 
challenge.
Complete tumor rejection if 
treatment started at day 2 and 
50% if started at day 10. 
CD8 T cells are needed but 
not CD4.
(Baines and 
Celis, 2003)
FV B N eu N  
transgenic mice
Weekly injection of 
20 py of CpG 
starting at the 10th 
week of age.
Delayed tumor onset. 
A c c u m u la t io n  o f  
macrophages infiltrate at the 
site of mammary gland. No 
complete rejection or 
memory response was 
elicited.
(Sfondrini et 
al., 2002)
A G 104A , IE7 
fibrosarcoma , B16 
melanoma and 3LL 
lung carcinom a 
models
C o m p are  th e  
effectiveness of 
system ic versus 
peritumoral 
administrations of 
CpG. Schedule: 8 
injection of 20 py 
given twice a week 
for four weeks.
Systemic administration had 
only minor effects whereas 
intratumoral injection led to 
co m p le te  re je c t io n . 
In troduction  of the 
immunogenic antigen, OVA, 
ameliorated rejection rate 
and induced a stronger 
memory response. CD8 and 
NK cells were needed.
(Kawarada et 
al., 2001)
C26 colon and 
RENCA carcinoma 
models
Correlation between 
injection site and 
effectiveness of CpG 
treatment. CpG were 
given intratumoral or 
on opposite flanks 
starting 5 days after 
tumor inoculation 
(100 py weekly for 4 
weeks).
CpG given alone or with 
irradiate tumor cells on the 
opposite flank of tumor 
challenge reduced tumor 
growth while intratumoral 
adm inistration led to 
complete tumor rejection in 
70% of treated mice. 
Long-term memory. Major 
contribution of CD8 T cells. 
Innate effector were needed 
although have not been 
investigated in details
(Heckelsmiller 
et al., 2002)
RM lym phom a 
model
3 injection of 20 py 
on day 5 ,8 ,11 .
Tumor rejection. CD8 and 
NK mediated.
(Lonsdorf et 
al., 2003)
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Table 1.2
Tumor Model Schedule of 
treatment
Outcome Ref
B16 melanoma 5 daily injection 
starting 5 days after 
tumor inoculation.
Reduced tumor growth with 
10-20% of com plete 
rejection. No memory 
response detected. NK rather 
than CD8 T cells were 
involved in the antitumor 
activity.
(Sfondrini et 
al., 2004)
B16 and CT26 rCCL20 (lOOng 
daily injection for 
three weeks) was 
combined with 5 
injection of CpG (80 
pyeach) starting 12 
days after tumor 
inoculation.
In B16 tumor model 
combination treatment led to 
50 % tumor rejection. CpG 
activate TIDC recruited by 
CCL20. CD8 T cells but not 
NK or CD4 are needed for 
antitumor activity.
(Furumoto et 
al., 2004)
RIPl-Tag5 
transgenic mice 
spontaneous model 
o f p a n c re a tic  
carcinoma
50 py of purified 
Tag protein in CFA 
starting at 6 weeks 
of ages and repeated 
every two weeks.
50 p y CpG-ODN 
combined with 2.5 x 
106 Tag specific 
activated CD8 or 
CD4 T.
Between 50-60% long-term 
survival when CpG was 
given together with Tag 
antigen in a preventive 
setting. Uptake of CpG by 
tumor resident macrophages 
changes the tis su e  
microenvironment to support 
effectors cell extravasion.
(Garbi et al., 
2004)
76-9
Rhabdomyosarcoma
100 pg of CpG ODN 
were given on day 9, 
12, 16, 19. 22. 26 
after tumor injection 
either systemically 
or intratumorally, 
chemotherapeutic 
agent
cyclophosphamide 
or to p o te c a m  
(200mg/kg) on day 9 
and 19.
CpG or chemotherapy alone 
were not able to induce 
tumor rejection while 
combination resulted to 50% 
tumor rejection.
T cell dependent mechanism.
(Weigel et al., 
2003)
Table 1.2. Some models of CpG-treated tumors. Abbreviation used: CpG ODN (CpG 
oligoneucleotide), TIDC (tumor associated dendritic cells)
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1.5 Tumor escape mechanisms
1.5.1 The cancer immunosurveillance hypothesis
Paul Ehrlich, in 1909, was one of the first to formulate the hypothesis that the immune 
system can repress tumors that otherwise would occur at a greater frequency.
Fifty years later the demonstration that mice could be immunized against syngenic 
implants of tumors induced by carcinogens, virus or spontaneously arisen, proved the 
existence of tumor associated antigens and provided the foundation for the “cancer 
immunosurveillance” hypothesis formulated by Macfarlane Burnet and Lewis Thomas in 
1957. Burnet defined the immunosurveillance concept as follows: “In large, long lived 
animals, like most of the warm-blooded vertebrates, inheritable genetics changes must be 
common in somatic cells and a proportion o f these changes will represent a step toward 
malignancy. It is an evolutionary necessity that there should be some mechanism for 
eliminating or inactivating such potentially dangerous mutant cells and it is postulated 
that this mechanism is of immunological character ” (Burnet, 1970).
The fundamental of such hypothesis is that lymphocytes act as sentinels in recognising and 
eliminating developing transformed cells that arise to a frequency similar to infection with 
pathogens [reviewed in ref. (Dunn et al., 2002; Pardoll, 2003)].
A prediction of this hypothesis is that immunodeficient individuals would develop cancer 
at a much higher frequency. However, epidemiological studies performed in 1970s-1980s 
on individuals affected by immunodeficiencies, found that although cancers such as 
lymphoma (Epstein-Barr origin) and Kaposi sarcoma (Herpesvirus 8 origin), developed in 
these individuals to a much higher frequencies, epithelial cancers such as colon, lung and 
prostate cancer, were not increased. This suggested that only cancers induced by viral 
infection are controlled by the immune system. However it should be taken into account 
that the majority of immunosuppressed patients tend to die in theirs forties raising the
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possibility that not-pathogens associated cancers may have not been detected (Pardoll,
2003). Indeed, a number of recent experimental studies performed in animals suggest that 
the immune system is able to control tumor outgrowth. One of the most informative studies 
was performed using RAG2-/- mice, which lack T, B and NKT cells. As a consequences of 
subcutaneous injections of the chemical carcinogen 3’methylcholantrene (MCA), RAG 
deficient mice developed sarcomas at the injection site with greater frequency than wt 
mice, suggesting that cells of the immune system controlled tumor development. 
Moreover, tumors developed in immunosufficent mice were less immunogenic and more 
aggressive then those in immunodeficient hosts, suggesting that the immune system 
favours the outgrowth of tumors that are more capable of escaping its control (Shankaran 
et al., 2001). This implies that the immune system not only plays a protective role against 
cancer in the first stages of transformation, but at later stages takes active part in its 
progression. Therefore the “cancer immunosurveillance” hypothesis was reformulated by 
the same authors under the name of “cancer immunoediting” hypothesis (Dunn et al.,
2002).
Cancer immunoediting consist of three phases. 1) elimination, that is the phase in which 
cells of the immunosurveillance network, innate and adaptive, destroy the tumor; 2) the 
equilibrium phase in which tumor cells are in a state of chronic maintenance and in which 
tumor variants are selected to survive the immune attack; 3) the escape phase in which 
tumors evade the immune system control and grow in an uncontrolled manner (Fig. 5.1).
A number of tumor escape mechanisms have been described including down regulation of 
tumor-associated antigens, induction of immune un-responsiveness, via anergy or clonal 
deletion of effector T cells, expansion of CD5+CD25+ regulatory T cells and paralysis of 
the tumor infiltrating leukocytes.
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ELIMINATION EQUILIBRIUM ESCAPE
(Cancer Immunosurveillance)
Protection
Modified from Dunn et al, 2004
Innate and adaptive immunity
I
Genetic instability 
immune selection
Figure 1.5 Schematic representation of three phases of the cancer immunoediting 
process.
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The next sections are focused on the mechanisms by which infiltrating leukocytes, in 
particular macrophages and DC, are biased by the tumor to favour its own growth.
1.5.2 Alternative activated tumor-associated macrophages
The immunological function of macrophages has been well documented. They are released 
by the bone marrow as immature monocytes and circulate in the undifferentiated state 
before extravasion into tissue, where they differentiate into macrophages. Macrophages are 
abundantly present at the site of inflammation and infections, where they orchestrate the 
recruitment of other immune cells, contribute to destroy pathogens, and promote tissue 
repair. Macrophages represent a major part of the leukocytes infiltrating human tumors and 
in some cases up to a 1:1 ratio between tumor cells and infiltrating macrophages was 
observed. These cells are often referred as tumor infiltrating macrophages (TAM). TAM 
are thought to originate from blood monocytes recruited in the tumor, rather then from 
resident macrophages present in the tissue before tumor development.
TAM infiltrate a number of different human tumors such as breast, prostate, ovarian and 
cervical cancer, where their number correlates with poor prognosis. In only 10% of the 
analyzed biopsies the presence of TAM correlate with tumor destruction and good 
prognosis.
A number of factors produced directly by the tumor or by infiltrating leukocytes and 
stromal cells, such as chemokines CCL2, CCL8, CCL3 and colony CSF-1 recruit 
circulating monocytes and stimulate their differentiation into macrophages [reviewed in 
ref. (Murdoch et al., 2004; Pollard, 2004)]. Of note, in humans, tumor expression of CSF- 
1, which promotes differentiation from monocytes to macrophage and their proliferation, 
correlates with poor prognosis. Therefore tumors are able to co-opt some of the normal 
functions of macrophages promoting their own growth and spread of metastases.
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Experiments performed in murine models of spontaneous carcinogenesis confirm this 
interpretation. Lin et al, used mice that develop spontaneous mammary tumors due to the 
expression in the mammary gland of the polyoma-middle T oncoprotein (PyMT mice) and 
crossed them with CSF-1 null mice. The resultant mice had strong defects in macrophages 
accumulation at the tumor site. While the initial tumor growth was similar to that of CFS-1 
sufficient mice, tumor progression and metastatic ability was greatly reduced, suggesting a 
role of infiltrating macrophages in supporting tumor progression rather than its early 
formation (Lin et al., 2001).
Mantovani and collaborators divided macrophages into two major subclass, named Ml and 
M2, and referring to the two opposite functional activities of macrophages [reviewed in 
ref. (Mantovani et al., 2002)]. Different patterns of cytokines expression identify the two 
classes of macrophages. Ml macrophages express IL-12, TNF-a, IFN-y and have potent 
tumoricidal activity while M2, also called alternative activated macrophages, typically 
express IL-10 and IL-lrcx antagonist (Mantovani et al., 2002) (Mantovani et al., 2004).
The arginine metabolism in Ml macrophages is characterized by high level of inducible 
nitric oxide syntase (iNOS) that promotes its conversion to molecules with cytostatic 
activities, while in M2 macrophages generates polyamines that sustain cell growth.
TAM accumulating in human and murine tumors show an IL10high IL12low phenotype and 
have very low tumoricidal activity consistent with an M2 biased phenotype. Sica et al, 
demonstrated that the defective IL-12 expression was due to autocrine production of IL-10 
and was paralleled by the lack of NFkB activation, suggesting that the macrophage- 
production of immunosuppressive cytokines is part of the tumor strategies to escape 
immune surveillance (Sica et al., 2000).
M2 macrophages produce a variety of factors that promote growth and invasiveness of 
tumor cells, including fibroblast growth factor (FGF), hepatocyte growth factor (HGF) and 
epidermal growth factor (EGF). EGF for example, promotes tumor cell proliferation and
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macrophages expressing EGF are often localized near blood vessels within the tumor 
suggesting that it may promotes blood extravasion of tumor cells (Pollard, 2004).
Ml macrophages are capable of tumoricidal activity through different molecules among 
which nitric oxide and TNF-a are the most important.
NO is produced from L-ariginine by iNOS, an enzyme inducible upon exposure to 
inflammatory cytokines or bacterial products, NO mediates tumor suppression by inducing 
cell death via necrosis and/or apoptosis, therefore disrupting membranes and organelles 
such as mitochondria or inducing DNA fragmentation and cell shrinkage (Klimp et al., 
2002). TNF-a was the first cytokine described to mediate the killing activity of 
macrophages (Carswell et al., 1975). Among the effects reported, there is the generation of 
reactive oxygen intermediates in mitochondria that results in cell membrane 
permeabilization (Goossens et al., 1995), and the induction of DNA-strands breaks (Baloch 
et al., 1990). Other members of the TNF family such as TRAIL and FasL provoke cell 
death but their role in macrophage-mediated tumor cell killing has not been elucidated 
(Klimp et al., 2002). Interestingly, TNF-a production by human cancer correlates with 
poor prognosis. The ability of TNF-a to promote angiogenesis, to induce chemokines and 
to stimulate fibroblast growth and functions, has been proposed to be involved in its pro- 
tumoral function (Balkwill, 2002). Thus TNF-a, has contrasting activities depending on 
many factors, among them its concentration.
Although macrophages seem capable of destroying tumor cells, tumor microenvironment 
potently halts such ability. For example phosphatidylserine, which is a natural component 
of tumor cell membrane, inhibits macrophage tumor cytotoxicity likely through inhibition 
of NO synthesis (Calderon et al., 1994). IL-4 and IL-10, alone or in combination, affect 
tumoricidal activity in part by the suppression of IL-1, TNF-a and IFN-y synthesis 
(Nabioullin et al., 1994) (Oswald et al., 1992).
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Because TAM can promote tumor growth but still maintain the intrinsic capacity to kill 
tumor cells, they could be a target of antitumor therapy. Possible strategies could aim at 
reducing their number and/or increasing their tumoricidal activity by switching their 
phenotype to M l. Factors that reduce the number of TAM or affect their functionality were 
tested for their ability to halt tumor growth. For example, Linomide was shown in mice to 
have the ability to reduce TAM number and to decrease tumor growth likely through 
impairing angiogenesis (Joseph and Isaacs, 1998).
Differently, Paclitaxel and Prolactin enhanced IL-12 production by mouse TAM and 
contributed to restore a Thl response in tumour bearers (Majumder et al., 2002) (Mullins 
etal., 1999).
Chemokine inhibitors too, were shown to affect tumor growth by reducing macrophage 
infiltration (Robinson et al., 2003).
A number of studies demonstrated that IL-10 pushes macrophages towards a pro-tumoral 
phenotype, suggesting that IL-10 inhibition could restore the killing capacity of 
macrophages and activates type I antitumor immune responses (Sica et al., 2000). This 
latest approach has been investigated in this thesis.
Adoptive macrophage immunotherapy has been studied in a clinical setting [reviewed in 
ref. (Klimp et al., 2002)]. Macrophages were differentiated and activated from peripheral 
blood monocytes and reinfused into patient systemically. Although no clinical responses 
have been reported, biological response such as increase blood level of inflammatory 
cytokines IL-1, IL-6 and TNF-a were found in treated patients. The problem with this 
approach may be the poor recruitment of autologous activated macrophages at the tumour 
site, suggesting that additional studies are needed to assure a correct localization and 
activation of reinfused macrophages (Klimp et al., 2002).
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1.5.3 Defective function of DC in cancer
In cancer patients, defective DC may result from abnormal myeloid-cell differentiation 
which has at least three main consequences: decreased number of circulating DC, 
accumulation within tumor of DC that are unable to upregulate costimulatory molecules or 
to produce cytokines necessary for T cell priming, and the increased production of 
immature myeloid cells with immune suppressive functions [reviewed in ref. (Gabrilovich,
2004)]. Early studies in animal models demonstrated a lower number of DC in LN, spleen 
and skin of tumor-bearing mice compared with controls animals (Gabrilovich et al., 1996). 
These studies were extended to human where a two/four fold decrease in the number of 
circulating DC was found in patients affected by head and neck cancer. Moreover clinical 
studies demonstrated that patients that had the primary tumor surgically removed showed 
restored number of circulating DC.
Because of decreased DC number, cancer patients are poorly responsive to immune 
stimulation (Gabrilovich, 2004).
Even more dramatic are the effects exerted by the tumor on TIDC (tumor infiltrating DC). 
A large number of studies demonstrated that DC infiltrating human tumors have an 
immature phenotype associated with poor activity, an observation that has been confirmed 
in several mouse tumor models [reviewed in ref. (Vicari et al., 2002)].
The first tumor-derived factor shown to inhibit DC function was VEGF. VEGF is 
produced by most tumors and has a crucial role in the recruitment and organization of 
tumor neovasculature. VEGF acts directly on the haematopoietic progenitors and inhibits 
DC maturation in vitro. Infusion of VEGF in mice resulted in inhibition of DC 
development thus confirming the in vitro results. The use of blocking Ab to VEGF 
abrogated the negative effect of tumor-cell-conditioned medium on DC differentiation in 
vitro (Gabrilovich et al., 1998; Ishida et al., 1998).
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Another well-known immunosuppressive factor is IL-10, which is produced by the tumor 
itself or by its infiltrating leukocytes (Vicari et al., 2002). IL-10 suppresses the 
proinflammatory functions of DC by antagonizing expression of costimulatory molecules, 
the release of proinflammatory cytokines and DC maturation (Marincola et al., 2003). In 
mouse, addition of recombinant IL-10 to splenic DC halted their ability to secrete IL-12 
and to prime T cells in vivo (De Smedt et al., 1997). Interestingly, Faulkner et al, 
demonstrated that IL-10 does not block phagocytic activity of DC but their maturation and 
consequently T cell activation (Faulkner et al., 2000).
Tumor-induced IL-10 was found to be specifically responsible for DC dysfunctions in 
response to antigenic driven maturation. Splenic DC from tumor bearing mice were found 
to be defective in stimulating allogenic proliferation and tumor-antigen specific T cell 
responses. Authors showed that in absence of IL-10, DC from tumor bearing mice were 
equally effective in stimulating type-1 immune response to non-tumor bearing mice and 
that the lack of IL-10 resulted in tumor rejection (Yang and Lattime, 2003).
Another negative effect of IL-10 in the tumor milieu is to prevent DC accumulation at 
tumor site. Qin et al, analyzed the effect of spontaneous IL-10 expression by the J558L 
mouse plasmacytoma. J558L cells engineered to express GM-CSF were ineffective as 
vaccine when used to prevent growth of the parental cell line. In the presence of the IL-10, 
DC accumulation promoted by GM-CSF was completely inhibited rendering the vaccine 
ineffective. Reversion of this phenotype was observed upon block of IL-10 (Qin et al., 
1997).
Similarly to IL-10, TGF-J3 has been shown to have a wide range of immunosuppressive 
effects on DC, including down-regulation of cell surface MHC, costimulatory molecules 
and chemokine receptors. In particular Kobie et al, demonstrated that TGF-(3 halts the 
capacity of TIDC to reach DLN and prime T cells. Combinatory use of antisense TGF-B
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gene transfer plus TGF-fi-neutralizing antibody, increased the efficacy of DC vaccines in 
treating established TGF-B-secreting 4T1 mammary carcinoma (Kobie et al., 2003).
The above observations suggest that the tumor microenvironment not only does not 
provide activatory stimuli to TIDC, but inhibits their differentiation and/or functions. DC 
inactivation occurs also systemically (Vicari et al., 2002). In particular the systemic effects 
have to be taken into account when planning immunotherapeutic approaches that use ex- 
vivo loaded DC to be reinfused into cancer patients to generate T cell response. Enk et al, 
demonstrated that TIDC derived from progressive melanoma tumors have decreased 
ability to stimulate T cell proliferation in an allogenic setting and moreover induced tumor 
specific T cell tolerance. Thus tumor-derived factors can convert DC antigen presenting 
function to induction of tolerance against tumor TAA rendering tumor DC active 
"silencers" of anti-tumoral immune responses (Enk et al., 1997).
These observations should be taken into account in all the approaches that foresee DC 
injection into the tumor or the use chemokines to attract DC at the source of tumor 
antigens. In addition to fail, these approaches are likely to worsen the host immune 
response generating tolerance to TAA.
A model of the possible alternative functions of tumor infiltrating macrophages and 
dendritic cells is given in Figure 1.6.
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Figure 1.6 Pro- and anti-tumorigenic properties of macrophages and DC infiltrating 
tumor.
62
1.6 Aims of the thesis
Many protocols of cancer immunotherapy have been designed to induce tumor-specific 
CTL that are thought to be the most efficient effector cells to destroy existing tumors. 
Based on the critical role of DC in inducing T-cell dependent immunity, significant effort 
has been placed in studies based on the use of TAA-loaded DC to be used as vaccine or in 
strategies that, by enriching DC at tumor site, are expected to promote a tumor specific 
CTL response. However, when translated in clinical trials many of these approaches were 
found to induce a weak response that inversely correlates with tumor size.
Likely, the presence of systemic and local induced-immune suppression halts the 
effectiveness of such approaches. Combinatory treatments able to simultaneously break 
tumor induce immunosuppression and to load DC with TAA may then result in a more 
effective therapy for established tumors.
The aims of this thesis were:
• To characterize the antitumor activity of the human chemokine CCL16 in murine 
models of prestablished tumors;
• To study whether CCL16 can block the metastatic spreading of 4T1 mammary 
carcinoma, a model of spontaneous metastases from primary tumor;
• To determine the effect of the tumor microenvironment on leukocytes recruited by 
CCL16 at the tumor site;
• To study whether block of the IL10R and stimulation with microbial stimuli, CpG, 
could break the infiltrate paralysis;
• To characterize the synergy between a strong innate response, triggered at tumor 
site, and the resulting systemic adaptive response, in the rejection of large tumors.
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CHAPTER 2. MATERIALS AND METHODS
2.1 Tumor cells and mice
The murine colon adenocarcinoma cell line C26 was derived from BALB/c mice treated 
with N-nitroso-N-methylurethane (Griswold and Corbett, 1975). TSA tumor is a murine 
mammary adenocarcinoma that arose spontaneously in a multiparous BALB/c mouse 
(Nanni et al., 1983). 4T1 tumor is a 6-thioguanine-resistant cell line derived from a 
spontaneous mammary carcinoma (American Tissue Culture Collection, ATCC-LGC 
Promochen, United Kingdom) (Aslakson and Miller, 1992). MCA38 (H2b) is a colon 
carcinoma cell line established from primary cultures (Goldrosen et al., 1976). 293 are 
human embryo kidney cells transformed by shared Adenovirus type 5 DNA, used to 
complement the growth of El defective Adenoviral vectors (Harrison et al., 1977). Murine 
tumor cells were cultured in DMEM supplemented with 10% FCS, 200U/ml penicillin, 
200 pg/ml of streptomycin and 600 pg/ml of L-glutamine (Biowhittaker, Walkersville, 
MD). 293 were cultured in EMEM (Biowhittaker) supplemented as above described.
Eight-10 wk old female BALB/c mice, BALB/c nu/nu mice and C57/BL6 mice were 
purchased from Charles River (Calco, Italy).
IL-12p35-KO and IFN-y KO mice (GKO) mice on BALB/c background, TNF-KO mice on 
C57/BL6 background and B6.SJL/J (CD45.1) were purchased from The Jackson 
Laboratory (Bar Harbor, ME, USA).
CD40-KO mice, backcrossed for 10 generation to BALB/c, were kindly provided by L. 
Adorini (Roche, Milan, Italy) (Castigli et al., 1994). CCR7-KO mice were kindly provided 
by M. Lipp (Max-Delbruck-Center, Berlin). All mice were maintained at the Istituto 
Nazionale Tumori under standard conditions according to institutional guidelines.
64
2.2 Construction of recombinant adenoviral vector.
Recombinant adenovirus carrying the human CCL16 gene under the control of mouse 
CMV promoter was constructed using the Cre-lox recombination system (Microbix, 
Toronto Canada) (Ng P, 2000). The 500 bp fragment containing the cDNA of CCL16, 
derived from PCDNA3/CCL16 (a kind gift of Prof. Mirella Giovarelli, University of Turin, 
Turin, Italy) was excised with Eco RI and cloned into Eco RI site of pDC316 adenoviral 
shuttle plasmid, which is designed for the insertion of coding sequences for rescue into 
vectors by Cre-mediated recombination (see chapter 3.1.1 for maps of the plasmids). 
PDC316/CCL16 plasmid was sequenced before use to verify the correct sequence of the 
inserted CCL16cDNA.
Recombinant adenovirus were isolated from a single plaque amplified on 293 cell 
monolayers and purified by double cesium chloride gradient centrifugation as below 
described according to Hitt et al. (Hitt, 1998). Experiments were carried out with at least 5 
independently prepared adenovirus stocks. The empty adenoviral vector Addl70-3 was 
kindly provided by Dr. Frank Graham (Me Master University, Hamilton, Canada) (see 
figure 2.1 for scheme of the steps involved in rescue of Ad vectors).
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Co-trasfection of 293 cells with 
PDC316/CCL16 and PBGHIoxAEl,3Cre 
(section 2.3.1)
I
Analysis of recombinant Ad vectors (section 2.3.2)
I
Preparation of high titer virus stocks (section 2.3.3)
I
Purif ication of high titer viral stocks (section 2.3.3)
1
Titration of viral stocks (section 2.3.4)
Figure 2.1: Overview of the steps involved in rescue, propagation, purification of 
AdCCL16.
2.2.1 Cotransfection of 293 cell line
PDC316 shuttle plasmid containing CCL16 cDNA was cotrasfected together with 
PBHGloxAEl,3Cre genomic plasmid, in 293 cells. The cotrasfection was performed in 
60mm dishes containing 70-80% confluent, low passage 293 cells (passage 27-38) using 
calcium phosphate method. For each 60mm dish 10[xg of salmon sperm DNA was added to 
0.5 ml sterile lx HeBS (21mM HEPES, 137 mM NaCl, 5mM KC1, 0.5 mM Na^PC^, 5.6 
mM glucose, adjusted to PH 7.1) and the DNA was sheared by vortexing 1 min. Five 
micrograms of the shuttle plasmid PDC316/CCL16 and of the genome plasmid
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PBHGloxAEl,3 Cre was added to the mix and mixed gently. Following this, 25 pi of 2.5 
M CaCl2 was added for 0.5 ml of DNA solution and after incubation at RT for 30 min the 
precipitate was added to 293 cells. Dishes were incubated with the DNA precipitate for 4-5 
h at 37°C. After incubation the medium was removed and cells were overlayed with 1:5 
mixture of overlay medium (EMEM supplemented with 5% inactivated horse serum, 
200U/ml penicillin, 200 pg/ml of streptomycin and 600 pg/ml of L-glutamine) to 1 % 
agarose. Dishes were incubated at 37°C until plaques developed (5-10 days).
2.2.2 Screening of recombinant viral plaques
An agar plug containing the viral plaque was removed from the dish the stored at -80°C in 
0.5 ml of sterile PBS (137 mM NaCl, 3 mM KC1, 4 mM Na2HP04) containing 10% 
glycerol. In order to screen plaques, 0.2 ml of the plaque isolate was used to infect a 60mm 
dish of 293 cells. Following incubation for 45 min at 37°C, 5 ml of complete medium was 
replaced and when the complete cytopatic effect (CPE) was observed (90% of the cells no 
longer attached to the dish) the cells were allowed to settle for 30 min at RT and the 
supernatant removed. One ml of the viral supernatant was stored at -20°C and used to 
detect the presence of secreted CCL16 by ELISA and part was added to glycerol (10% 
final concentration) and stored at -80°C. The remaining cells on the dish were lysed in 0.5 
ml pronase-SDS (500 pg of pronase in lOmM Tris pH 7.4, 10 mM EDTA, 0.5% SDS). 
The DNA was then extracted by addition of 1/10 of 3M sodium acetate and 2 volume of 
cold ethanol. After centrifugation at 16000 rpm the DNA pellets were washed twice with 
70% ethanol dried at RT and resuspended in water. The structure of the viral DNA was 
analysed by restriction enzyme digestion.
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2.2.3 Propagation and cesium chloride banding of the virus
293 cells were seeded in 150mm cell culture dishes and when confluent used to prepare 
high titer-stocks. Four ml of viral screening supernatant was diluted to 36 ml of medium 
and used to infect a total of eighteen dishes (2 ml for dish). Infection was carried out for 45 
min at 37 °C after which 25 ml of complete medium was added. After complete CPE the 
infected cells were collected by centrifugation and resuspended in 5 ml of PBS containing 
10% glycerol and stored at -80°C. Virus was titrated prior to further use (see the following 
section). 293NS cells were used for the preparation of cesium chloride gradient purified 
viral stocks. 293NS are a variant of 293 cells able growing in suspension in Pro-293-CDM 
medium (Biowhittaker) supplemented with 5% of foetal calf serum. Three litres of 293NS 
spinner culture (at a density of 4xl05/ml) was centrifuged at 2000 rpm for 15 min, half of 
the conditioned medium was saved and the cell pellet was resuspended in 100 ml of fresh 
medium containing 5 PFU of crude viral stock. Cells were incubated at 37°C, with stirring, 
for 2 hr, at which time the infected cells were transferred back to the spinner flask along 
with the reserved conditioned medium and an equal volume of fresh medium. After 3 days, 
cells were harvested by centrifugation and pellet resuspended in 30 ml of lOmM Tris HC1 
and stored at -80°C until cesium chloride gradient banding.
The frozen infected cells suspension was thawed and 1/10 volume of 5% sodium
deoxycholate was added. The solution was incubated at RT for 30 min after which DNase I
(bovine pancreatic deoxyribonuclease I, Sigma-Aldrich) was added at a final concentration
of lmg/ml. The solution was incubated at 37°C for 30min, centrifuged at 3000 rpm for 20
minutes and 5 ml of it applied on the top of a CsCl gradient prepared as followed: at 13 ml
ultraclear tube was added 0.5 ml of 1.5 g/ml solution, followed by 3 ml of 1.35 g/ml and
by 2.5 ml of 1.25 g/ml. Gradients were centrifuged at 35000 rpm for 1 hr in a Beckman
SW 41T1 rotor. The virus band, visible as a whitish band in the upper 1/3 of the tube, was
collected by puncturing the tube, and transferred into a 5 ml ultraclear tube, topped with
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1.35 g/ml CsCl solution, mixed and centrifuged for 16 hr at 35000 rpm in a Beckman SW 
55T1 rotor. The viral band was collected again by puncturing and then dialyzed twice 
against 1 litre of lOmM TrisHCl pH 8, for at least 4 hr per dialysis medium change.
2.2.4 Titration of viral stocks
Virus titer was determined by plaque assay in 293 cells and given as Plaques Forming 
Units (PFUs). Briefly virus stocks were serially diluted in PBS and 0.25 ml of each 
dilution was used to infect 60 mm dishes of 293 cells. Following infection the cells were 
overlayed with agarose containing medium as previously described. Plaques were counted 
7 days post-infection and the titer was calculated as follows: number of plaque x 4 
(dilution factor) = pfu/ml.
2.3 Adenovirus infection of tumor cell lines in vitro
In vitro infections were carried out as follows: 5xl05 TSA or C26 cells were plated in 60 
mm cell culture dishes. After 10 h cells were infected with various MOI of AdCCL16 or 
Addl70-3 virus. Supernatants were collected 24 and 48 h later and the amount of CCL16 
secreted was quantified by ELISA.
2.4 In vitro differentiation of DC from bone marrow
DC were differentiated from bone marrow as follows: bone marrow cells from femurs and 
tibias were plated at 5X105/ml in RPMI 5% FCS supplemented with 20% of a murine 
fibroblast cell line engineered to express mGM-CSF (corresponding to 20 ng/ml of GM- 
CSF). On day 2, one-half of supplemented medium was replaced with fresh medium. On 
day 4, floating cells were centrifuged and plated in fresh medium at 5xl05/ml. On day 5 
non-adherent cells were harvested. DC collected on day 5 were 90% CD 11c positive and
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displayed the following characteristic phenotype: MHC classll mtermediate, CD80Iow, CD40low, 
CD86 low. In some experiments BM-DC were matured by seeding them at a concentration 
of 2xl06/ml in the presences of 1 pg/ml of LPS (Sigma-Aldrich) for lOh.
2.5 Chemotaxis assay
CD4 and CD8 lymphocytes were obtained from naive mouse spleens; the two populations 
were enriched more than 95% by positive selection using MiniMacs™ separation columns 
(Miltenyi Biotec, Germany). Immature and mature DC were obtained as above described. 
Recombinant human CCL16 and mouse CCL20 were purchased by PeproTech (Rocky 
Hill, NJ). Chemotactic activity was tested using the Boyden chamber method as described 
(Zigmond and Hirsch, 1973). Briefly, triplicate assay were carried out in 96-well 
microchemotaxis chambers (Neuro Probe, Cabin John, MA) with an 5-/<m pore 
polycarbonate membrane (Costar, Cambridge, MA) separating cells from the medium 
containing the chemoattractant. T cells (4xl06/ml) or DC (2xl06/ml) were allowed to 
migrate for 3 or 2 hr respectively, in DMEM medium containing 0.1% of BSA. When 
necessary cells, were preincubated with 200 ng/ml pertussin toxin (Sigma Chemical Co., 
St. Louis, MO) for 1 hr at 37 C°. The membrane was removed and stained with Diff Quick 
kit. Migrated cells were counted with a Nikon microscope (40X objective).
In some experiments, viral supernatants were used as the source of CCL16. To obtain these 
supernatants TSA cells were plated at a concentration of 2xl05/ml, 1 day later infected 
with 100 MOI of AdCCL16 or Addl70-3, and supernatants harvested 48 hr later. CCL16 in 
the medium was quantified by ELISA.
Migration index was calculated as: number of cells migrated in the presence of 
recombinant or viral CCL 16/number of cells migrating in medium alone or in supernatant 
of Addl70-3-infected TSA cells, respectively.
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2.6 Tumors injection and in vivo treatments
BALB/c mice were inoculated s.c. into the right flank, equidistant from the inguinal and 
axillary lymph nodes, with 5xl04 C26 or lxlO5 TSA or 7xl03 4T1 cells. After 7-10 days, 
when tumors reach 3-4 mm in diameter (depending on the experiment), nodules were 
inoculated with lxlO9 pfu of AdCCL16 or control virus Addl70-3 and the treatment was 
repeated four days later or not as indicated.
For the part of the project in which the synergy between AdCCL16 and CpG plus 
antilLlOR treatment was studied, 2xl05 TSA or lxlO5 MCA38 or lxlO4 4T1 cells was 
inoculated s.c. into the right flank of the mice. After 10-14 days, when tumors reach 5 mm 
in diameter, nodules were inoculated with lxlO9 pfu of AdCCL16 or control virus Addl70- 
3 and 36 h later with 5 pg of CpG 1668 (5'-TCCATGAGGTTCCTGATGCT-3') (MWG, 
Germany) while 200 pg anti-ILlOR antibody (IB 1.3a; IgGl) or matching control rat IgG 1 
antibody (clone GL113) (Vicari et al., 2002) were given intraperitoneally. Purified anti- 
IL10R and control antibodies were provided by our collaborator Dr. Alain Vicari 
(Schering-Plough, Dardilly, France).
In some experiments, mice were depleted of CD4 and CD8 cells by i.p. injection of 250 
pg/mice of anti-CD4 (GK1.5 hybridoma, Lyt2; ATCC) or anti-CD8 (clone 2.43; ATCC) 
mAb. Depletion was started one week before tumor challenge by injecting mice twice per 
week thereafter until the end of the experiment. In some experiments, depletion was started 
five days after tumor treatments. FACS analysis of peripheral blood confirmed that 
depletion was never inferior to 95%.
For surgical excision of primary 4T1 tumors, mice were anesthetized before surgery and 
tumors resected with sterilized instruments. Wounds were closed with metallic clips. All 
mice survived surgery. Mice in which primary tumors recurred at the site of the surgical 
excision (4 out of 60) were eliminated from the experiment.
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Tumor growth and size were recorded twice each week and tumor growth was expressed 
as % of tumor free mice over total injected mice, while tumor size was measured with 
calipers, and volume was calculated by the formula: Vol = (longest diameter) X (shortest 
diameter)2 and expressed in mm3.
2.6.1 Quantification of 4T1 distant metastases
Because 4T1 are 6-thioguanine-resistant 4T1 metastatic cells can be detected and 
quantified by explanting organs, plating dissociated cells in medium supplemented with 
the drug (Pulaski and Ostrand-Rosenberg, 1998; Pulaski, 2000). Briefly lungs were 
collected and dissociated in a HBSS solution containing lmg/ml collagenase type 4 and 6 
units/ml elastase for 1 h at 4 °C; organs were then plated either neat or serially diluted in 10 
cm cell culture dishes in a medium supplemented with 6-thioguanine (lOng/ml). Individual 
colonies representing micrometastasis were counted after 10-15 days. Colonies were 
counted as follows: medium was discarded and 5 ml of methanol was added to each plate 
and incubated for 5 min at RT, washed with PBS and stained with GIEMSA staining 
solution (Sigma-Aldrich, St. Louis, MO) according to manufacture instructions.
2.7 Morphological analysis and immunocytochemistry
Tumor fragments and tumor-draining lymph nodes were embedded in OCT compound
(Miles Laboratories, Inc., Elkhart, Nederland), snap-frozen in liquid nitrogen, and stored at
-80°C. For histological evaluation, tissue samples were fixed in 10% neutral buffered
formalin, embedded in paraffin, sectioned at 4 pim and stained with hematoxylin and eosin
or Masson’s trichrome according to manufacture instructions (Sigma-Aldrich).
For immunohistochemistry, acetone-fixed 5 pm cryostat sections were incubated 5 min in
3% Me0H/H20 2 to block endogenous peroxidase. After washing for 10 min in PBS,
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sections were incubated lh with the following antibodies: anti-CD 11c (clone N418, 
Chemicon International, Temecula CA), anti-CD 1 lb/CD 18 (clone Ml/70.5), anti-CD8 
(Ly/T2, clone YT5 169.4) and anti-CD4 (LT34, clone YT5.191.1.2) (all from Sera-lab, 
Crawley Down, Sussex, UK), or anti-GRl (clone RB6-8C5, ATCC), anti-NK (asialo 
GMl)(Wako Chemicals GM&H, Dusseldorf, Germany), anti-F480 (clone C1:A31, Caltag) 
anti-IFN-y (clone XMG1.2, provided by Dr. S. Landolfo, University of Turin, Turin, Italy). 
After washing, sections were overlaid with biotinylated goat anti-rat, anti-hamster and anti­
rabbit, and horse anti-goat Ig (all from Vector Laboratories, Burlingame, CA) for 30 min. 
Unbound Ig was removed by washing and slides were incubated with Avidin-peroxidase 
complex (Dako, Glostrup, Denmark). Sections were then incubated with 0.03% H20 2 and 
0.06% 3,3’-diaminobenzidine (Sigma-Aldrich) for 2-5 min, washed in tap water and 
counterstained with with Mayer’s hematoxylin (Sigma-Aldrich), dehydrated in graded 
alcohol (70, 95 and 100% ethanol) and mounted in BDH medium (Merck Eurolabs) 
according to the manufacturer’s instructions. Tetramethyl rhodamine isothiocyanate 
(TRITC)-conjugated goat anti-rat IgG (Jackson ImmunoResearch Laboratories, Inc., West 
Grove, PA) was used as secondary antibody for CD8+ cell immunofluorescence and 
fluorescein (FITC)-conjugated chicken anti-goat IgG (Rockland Inc., Gilbertsville, PA) 
used as secondary antibody for IFN-y immunofluorescence.
For the intracellular staining of IL-10, IL-12 and TNF-a cytokines, 5 pm-cryostat sections 
were fixed with 2% PFA for 20 min and washed. Sections were sequentially incubated for 
30 min with the following solutions made in PBS: 1) 1% BSA 2) 0.1% saponine /1% FCS. 
After washing, sections were incubated with avidin-biotin blocking solution (Vector) for 
15 min. After washing, sections were incubated with the following monoclonal antibodies: 
a) rat anti-mouse IL-10 (clone JES5-2A5, eBioscience), rat anti-mouse TNF-a (clone 
XT22, BD Bioscience), and rat anti-mouse IL-12p70 (clone 9A5, Endogene). One-hour
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later, sections were washed and then incubated with secondary antibodies and revealed as 
above described.
Cell counts were obtained in 10 randomly chosen fields on a 1mm2 grid and is given as 
cell/mm2 (mean ± SD). Image were acquired with a light microscope (Nikon) equipped 
with a digital camera (DXM 1200, Nikon) and analyzed using ACT1 software (Nikon). 
Confocal microscopy was performed with Zeiss LSM 510 META.
Immunoistochemistry analysis was performed with the collaboration of Dr. Emma di Carlo 
(Department of Oncology and Neuroscience, University of Chieti, Chieti, Italy) and Dr. 
Sabina Sangaletti (Immunotherapy and Gene Therapy Unit, Istituto Nazionale Tumori, 
Milan, Italy).
2.8 Lymph node analysis
At the indicated time points, inguinal and axillary lymph nodes draining the treated tumors 
were harvested, mechanically disrupted and digested for 45 min at 37 °C with a solution of 
1 mg/ml collagenase D (La Roche, Nutley, NJ) in HBSS (Biowhittaker). Lymph nodes 
were passed over a 70-pm nylon filter and cells were counted and used for FACS analysis. 
All antibodies used were purchased from (BD Bioscience, San Diego, CA). For analysis of 
T cell subsets and DC populations, cells were stained with PE-conjugated anti-CD 11c, 
anti-CD4 and anti-CD8. Analyses were performed on a FACScan (BD Bioscience). When 
indicated, lymph node cells were suspended at lxlO6 cells/ml and stimulated for 10 h with 
antiCD3 antibody (1 pg/ml; PharMingen). Supernatants were tested for IFN-y production 
by ELISA using specific antibodies (see below for details). Cells were analyzed for IFN-y 
production in the CD4 and CD8 subsets using mouse IFN-y secretion assay kit according 
to manufacture instructions (Miltenyi Biotec, Germany). Stained cells were analyzed by 
FACS analysis.
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2.9 Analysis of tumor cell infiltrate by FACS analysis
For analysis of T cell infiltration, treated tumors were measured, harvested, removed of 
extraneous tissue, and digested for 1 h at 37°C in 1 mg/ml collagenase D (La Roche) in 
HBSS (BioWhittaker/Cambrex). Digested tumors were passed over a 70 pm nylon filter 
and washed once with RPMI complete medium. Each smashed tumors were resuspended 
in 3 ml of RPMI complete medium and let to adhere on 35 mm diameter dishes for 4 hr 
after which the floating leukocyte infiltrate was collected and counted. For analysis of T 
cell subsets and DC populations, cells were stained with PE-conjugated anti-CD 11c, anti- 
CD4 and anti-CD8. All antibodies used were purchased from (BD Bioscience, San Diego, 
CA). Analyses were performed on a FACScan (BD Bioscience) with counting of 50000 
events. The number of infiltrating CD4 or CD8 or DC were expressed as number of 
cells/mm3 and calculated as follows: percentage of positive cells x total number of 
infiltrating leukocytes x 100/tumor volume. The data were normalized to the tumor volume, 
because the tumors were of different sizes.
2.10 IFN-y production by env-specific CTL clones
Six mice bearing TSA tumors were treated with AdCCL16 on days 0 and 4. Two days after
the last treatment, mice were divided into two groups. DLNs from each group were pooled
and treated independently. DC were enriched from the lymph node populations using anti-
CD 11c magnetic beads (Miltenyi Biotec, Germany) and used to stimulate a specific CTL
clone. The negative fraction of DC purification containing lymphocytes was used to test
CTL activity (see below). The generation and maintenance of the CTL line E-88 specific
for murine leukemia virus (MuLV) env-derived peptide 423-431 SPSYVYHQF (AH1) has
been described (Rodolfo et al., 1991). E-88 cells (105 well of 96 well plates) were
incubated with stimulating cells (2xl05 DC or 105 TSA cells) for 18 hr at 37 C° in 200 pi
of complete medium (RPMI, supplemented with 10% FCS). Supernatants were tested for
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IFN-y content by specific ELISA (as described below). Lymphocytes from the CD 11c- 
negative fraction were restimulated in vitro in a mixed lymphocyte tumor culture and 
tested for CTL activity as above described. TSA and C26 (sharing the env antigen with 
TSA) were the specific targets and blast cells, pulsed or not with AH1 peptide, were the 
control for TSA tumor-specific lysis.
2.11 Mixed lymphocyte tumor culture and cell-mediated cytotoxicity assay
Splenocytes (5 x 105 cells/ml) from treated mice were restimulated in vitro with the H2-Ld 
peptide AH1 (SPSYVYHQF) or H2-Kb KSP (lpg/ml) or with irradiated parental tumor 
cells (1 to 10 ratio tumor cells/splenocytes) in RPMI 1640 medium supplemented with 
10% FCS and lOU/ml of hIL-2. The env gene of the endogenous ecotropic MuLV, 
containing the Ld-restricted peptide AH1 or the Lb-restricted peptide KSP, is expressed by 
TSA and MCA38 tumor as an immunodominant antigen (Huang et al., 1996). After 5 days, 
cytotoxic activity was tested in a standard 4-h 51Cr release assay. Cells were washed three 
times and resuspended in complete RPMI-10 medium at 2 X 104/ml. 100 pi of effector 
activated-splenocytes (2 X 106/ml) were plated in U-bottom 96-well plates (Costar) with 
100 pi of 51Cr-labelled target cells at different E:T ratios starting from 100:1 (100 pi of 2 X 
104/ml target cells). After a brief centrifugation at 500 rpm, the plates were incubated for 4 
h at 37°C. The plates were then centrifuged for 5 min at 500 rpm, 80 pi of supernatants 
were harvested into 96 well LumaPlates (Packard, Groningen, Netherlands) and the 
radioactivity of the supernatants samples was determined using a y- irradiation counter 
(Top count microplate scintillation counter, Packard). The percent of lysis was calculated 
using the following equation:
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experimental cpm -  spontaneous cpm
% lysis = ------------------------------------------------  X 100
maximum cpm -  spontaneous cpm
where experimental cpm = cpm of supernatants from wells containing effectors plus 
targets, spontaneous cpm = cpm of supernatants from wells containing targets plus 
medium, and maximum cpm = supernatants of wells containing target plus TritonX-100. 
Blast cells, pulsed or not with the env peptides, as well as tumor cells were used as specific 
targets.
2.12 In vitro and in vivo assay with tumor infiltrating DC (TIDC)
TIDC were purified from treated tumors as previously described (Chiodoni et al., 1999). In 
brief, tumor masses were perfused with collagenase D solution (1 mg/ml) and incubated for 
1 h at 37°C. After gentle pipeting, the suspension was allowed to adhere for 4 h at 37°C in 
complete RPMI medium after which non-adherent cells were collected and purified using 
CD llc+ microbeads (Miltenyi Biotech). Flow cytometry showed that the cells were more 
than 80% pure. Phenotypic characterization of TIDC was performed by FACS analysis 
using FITC-conjugated monoclonal antibodies: anti-CD40-FITC clone 3/23; anti-CD80 
clone IG10; anti-CD86 clone GL1; anti-MHC-II clone B21.2 and isotype-matched 
monoclonal antibodies of unrelated specificity (BD Bioscience). TIDC were seeded in 
round-bottom non-coated 96-well plates at a concentration of lx l06/ml in RPMI complete 
medium containing 5 ng/ml of GM-CSF (Peprotech). Supernatants were collected 48 hr 
later and assayed by ELISA for IL-12 using specific antibodies (as below described). 
Experiments in which TIDC were used as T cell lymphocyte stimulators were performed 
as follows: CD4+ T lymphocytes were purified from spleen of C57/BL6 mice using CD4 
microbeads (Miltenyi Biotech). Triplicate of 2xl05 CD4 T cells were seeded in round-
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bottom non-coated 96-well plates with various ratios of irradiated (3000 rad) TIDC for 5 
days. [3H] thymidine (ICi/well; Amersham) was added for the last 10 h of culture.
For in vivo DC-migration experiments, mice bearing TSA tumors were intratumorally 
injected with the indicated treatment plus 2xl07 FITC-conjugated latex particles of 1 mm 
of diameter (Polysciences, Warrington, PA). At the indicated time points, mice were 
sacrificed and DLN were collected, teased and incubated for 1 h in collagenase D solution 
(lmg/ml). Cells were stained for C D llc expression and 5x10s events per LN were 
acquired by cytofluorimetry. The total number of double positive CDllc-PE/beads-FITC 
events was calculated for each LN.
2.13 Nitric Oxide evaluation
Total NO in tumor samples was determined as function of nitrate and nitrite concentrations 
using a specific kit (nitrate and nitrite colorimetric assay kit, Cayman Ann Arbor, MI). In 
brief, 5 mm tumors were treated with the various combinations, collected 4 h later, 
perfused and minced in 300 pi of PBS. The homogenate was centrifuged at 10000 rpm for 
20 min and then ultra filtered using a 30 KDa molecular weight cut-off (Millipore). Forty 
pi of each filtrate was assayed for nitrate and nitrite concentration according to the 
manufacturer's instructions.
2.14 Bone marrow chimera
CB6F1 mice were lethally irradiated with 900 cGy (given as a split dose 450+450 cGy at a 
3 h interval). Two hour later, mice were injected i.v. with 2xl07 bone marrow (BM) 
nucleated cells obtained from BALB/c or C57L/B6 mice. BM cells were obtained by 
flushing the cavity of freshly dissected femurs with complete RPMI medium. To verify 
engraftment, PBMCs withdrawn from the retro-orbital sinus at 8 weeks after BM
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transplantation were stained with FITC-conjugated anti-mouse H2Kb and PE-conjugated 
anti mouse H2Kd as well as matching isotype controls.
B6.SJL mice were reconstituted with BM from TNF-KO mice to obtain mice lacking TNF- 
a  in the BM compartment. Engraftment was verified using CD45.2 Ab (BD Bioscience). 
We used mice showing at least 95% of donor phenotype.
2.15 Enzyme-linked immunosorbent assay (ELISA): CCL16, CCL2, IFN-y, IL-12 
and TNF-a measurement
To perform the ELISA, BD Bioscience IL-12 (clone 9A5 as capture Ab and C l7-8 as 
detection antibody), TNF-a ( clone XT22 as capture Ab and XT3 as detection antibody), 
IFN-y (clone R4-6A2 as capture Ab and XMG1.2 as detection Ab) or Peprotech Abs 
detecting CCL16 or CCL2 were used following the standard procedure. Briefly, anti­
cytokines capture Abs were diluted to 2 pg/ml in coating solution (0.1 M NaHC03, pH 
8.2). 50 pi of diluted Ab was added to wells of an enhanced protein-binding ELISA plate 
(Nunc Maxisorb, Life technologies, Naperville, IL) and incubated overnight at 4°C. 
Capture Ab solution was removed and non-specific binding was prevented by adding 200 
pl/well of blocking buffer (IX PBS/10% fetal calf serum). The plate was incubated 1 h at 
37°C and washed 3 times with PBS/Tween (0.05% Tween-20 in PBS). 50 pl/well of 
samples and a serial dilution of a standard cytokine protein solution of known 
concentration was added and left for 2-4 h at 37°C. The plate was washed 4 times with 
PBS/Tween, 50 pi per well of diluted biotinylated anti-cytokine detection Ab (1 pg/ml) 
was added and incubated 1 h at RT. After washing 4 times with PBS/Tween, 50 pl/well of 
diluted Avidin-Horseradish Peroxidase (e.g. Sigma-Aldrich 1:400 of 1 mg/ml solution) 
was added and plates were incubated for 30 min at RT. After washing 8 times with 
PBS/Tween. 100 pl/well of 2,2’-Azino-bis 3-ethylbenzthiazoline-6-sulfonic acid (ABTS)
substrate solution (150 mg ABTS to 500 ml of 0.1 M anhydrous citric acid in dH20 , pH
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4.35; 10 ml/11ml of 30%H2O2 added prior to use) were used for color development and the 
optical density (O.D.) for each well was read with a microplate reader (MRX microplate 
reader, DYNEX) set to 405 nm.
2.16 Statistical analysis
Data were analyzed using a two-sided Student’s t-test, except for metastasis formation 
data, which were analyzed using the Mann-Whitney test. All analysis were performed 
using Prism software (GraphPad Software). Differences were considered significant at 
p<0,05.
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CHAPTER 3: GENERATION OF ADENOVIRAL VECTOR EXPRESSING 
CCL16 AND CHARACTERIZATION OF VIRAL AND RECOMBINANT 
CHEMOKINE.
3.1 Introduction
Vectors based on adenovirus have been widely used in cancer gene therapy because of 
their capacity to infect efficiently a wide variety of cell types. This virus has been well 
characterized throughout the last 30 years and has been chosen as vector backbone because 
it is relatively non-pathogenic producing symptoms, at worse similar to influenza. Unlike 
retroviruses, adenoviruses can infect both quiescent and proliferating cells and do not 
integrate into the host genome, a characteristic that confers important safety feature for in 
vivo gene transfer [reviewed in ref. (Hitt and Graham, 2000; Mizuguchi et al., 2001)]. 
Although adenoviruses have been shown to induce oncogenic transformation of rodent 
cells, no serotypes have ever been related to human cancer or any naturally occurring 
malignancy in other species.
Currently, adenovirus vectors are derived mainly from serotypes 2 and 5 - the most 
common serotypes to which humans have been exposed. After virus entry, the vector borne 
transgene, is expressed at very high level but only transiently, vanishing after about two 
weeks.
To accommodate large amounts of DNA a number of manipulations have been performed 
leading to the development of three types of adenovirus vectors, namely first, second and 
third generation vectors.
First generation vectors were obtained by deleting the El and/or E3 regions of the genome. 
This deletion abolishes the transforming potential of the virus, renders the virus replication 
defective and allows insertion of a larger amount of foreign DNA (up to 8 kb). Propagation
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of these vectors requires complementing cell lines that provide in trans the products of the 
El region necessary for the initiation of viral replication.
Many techniques have been developed to construct first generation adenovectors. In earlier 
methods, foreign DNA was inserted into a plasmid containing the left end of the Ad 
genome, the inverted terminal repeat (ITR), the gene of interest, and this was joined with a 
plasmid with all the viral genome modified to be non infectious. The ligation was done 
either in vitro with restriction enzymes or in vivo by homologous recombination between 
two overlapping sequences in 293 cells (Mizuguchi et al., 2001).
Ng and coworkers substituted homologous recombination with Cre-mediated 
recombination, further improving the efficiency and the accuracy of the process (Ng P, 
2000). The major problem with first generation adenovectors is their tendency to induce 
immune response against capside proteins. This is a major disadvantage when, as in the 
case of gene therapy of hereditary disease, long-term expression of the transgene is needed, 
but may be advantageous in cancer treatment where often there is no need for long-term 
expression and where the virus immunogenicity may enhance the clearing of infected 
tumor cells. Subsequent manipulations of the viral genome were designed to decrease 
vector immunogenicity throughout deletions of additional early genes. Recently, a third 
generation of adenovectors, the helper-dependent or gutless vectors, were generated. In 
this system, deletion of all viral sequences, except for the packaging signal, increases the 
cloning capacity up to 37 kb and significantly decreases the virus immunogenicity. This 
renders the vectors more attractive for gene therapy of somatic disorders. However, their 
isolation and purification are time consuming and need to be simplified for a scale up 
compatible with pharmaceutical distribution (Mizuguchi et al., 2001).
First generation adenoviral vector have been widely used in cancer immunotherapy. The 
major advantages of these vectors are: 1) a broad host range in terms of target tissue; 2)
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easy preparation of highly purified viral stocks for in vivo treatments; 3) an high cloning 
capacity; 4) a transient expression that may limits the toxicity of the active molecule.
A number of studies in animal models demonstrated that the presence of neutralizing 
antibodies might limit the effectiveness of Ad-mediated gene transfer in vivo. This has 
posed major concern in the use of adenovector for cancer therapy since the majority of the 
population has been exposed to this virus during their lifetime. Most of the studies done 
have focused on administration of Ads into tissue such as liver or lung which being in 
direct contact with mucosal surfaces are more susceptible to anti-Ad antibodies. On the 
contrary solid tumors may be less susceptible to the penetration of anti-Ad antibodies. 
Bramson et al., investigated this issue and found that in animal pre-immunized with 
adenovirus the outcome of Ad-IL-12 delivery, in terms of transgene expression and 
effectiveness, was not different from that of non-immune mice (Bramson et al., 1997). 
Moreover they demonstrated that pre-existing immunity limits the spreading of the virus to 
distant organs such as liver without affecting transgene expression at tumor site.
Anti-tumor activity and induction of systemic immunity, in animal models, have been 
reported for adenoviruses expressing a variety of cytokines and chemokines, for example: 
IL-2, IL-12, TNF-a, GM-CSF, CXCL10, CCL20, XCL-1. In particular adenovirus gene 
transfer of IL-2, GM-CSF and IL-12 have been extensively studied and results have been 
promising enough to start clinical trials (Hitt and Gauldie, 2000).
3.2 Aims of the chapter
The aim of this part of the thesis was to construct an adenovector expressing CCL16 and to 
test CCL16 function as chemoattratant properties of T cells and DC as well as stimulator of 
CCL2 production by them.
To this aim:
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• AdCCL16 was rescued using a site specific recombination method
• The chemoattratant activity of viral produced and recombinant CCL16 was 
assessed on murine leukocyte subsets
• T cells and immature DC were stimulated with different amount of recombinant 
CCL16 and the amount of CCL2 released in the supernatants was evaluated.
3.3 Results
3.3.1 Construction of AdCCL16
To study whether delivery of CCL16 in prestablished tumors have antitumor activity an 
adenovirus encoding CCL16 was generated. AdCCL16 was generated by Cre-mediated 
homologous recombination in 293 cells (Ng P, 2000).
Two plasmids were used, one contains the entire Ad5 genome, except for key deletions 
and the Cre-recombinase gene followed by a lox P site. The second plasmid, called shuttle, 
contains an ITR junction, a packaging signal, a promoter, a polyadenilation signal and a 
lox P site.
The cDNA for CCL16 was cloned in the “shuttle” plasmid, PDC316, under the regulation 
of an exogenous promoter (CMV) and the simian virus (SV40) polyadenilation sequences 
(see material and methods section 2.2). The other plasmid is PBHGloxDEl,3 Cre that has a 
complete deletion of the El region and a 2653bp deletion in the E3 region of the viral 
genome. The combination of El and E3 deletions results in a cloning capacity of about 8 
kb (Ng P, 2000). Other essential features of this Ad genomic plasmid include an ITR 
junction, necessary for viral replication, a packaging signal, a target sequences for Cre- 
mediated recombination (lox P site) and a cassette for expression of the site specific
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recombinase (Cre gene). Cotransfection was performed in the E l complementing cell line 
293 cells as described in materials and methods (section 2.1.2). Recombination between 
the two plasmids results in excision of the Cre gene and integration of the transgene 
cassette into the Ad5 genomic plasmid (Fig 3.1). The recombinant Ad vector can replicate 
in 293 cells and be packed in infectious virions.
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Figure 3.1 Scheme of the method used to generate AdCCL16 adenovector.
Schematic map of the two plasmids that co-transfected into 293 cells recombine to 
generate AdCCL16. The Cre recombinase mediates the site-specific recombination 
between the two loxP site (circled in pink).
A number of plaques were obtained and were initially screened by restriction digestion of
the DNA from infected 293 cells. Figure 3.2 shows the map of AdCCL16 (panel A) and
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the restriction patterns obtained by digestion of four representative plaques (panel B). 
Subsequent analysis of supernatants from the same plaques by ELISA demonstrated 
correct expression of the CCL16 protein (Panel C).
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Figure 3.2 Analysis of rescued AdCCL16 viral plaques.
A) Schematic map of AdCCL16 DNA B) restriction enzyme digestion of viral DNA 
isolated from infected 293 cells, the band containing CCL16 DNA is indicated on the right 
of the agarose gel. C) CCL16 production by 293 cells infected cells.
As control, an empty adenoviral vector, Addl70-3, kindly provided by Dr. Frank Graham 
(Me Master University, Hamilton, Canada), was used.
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3.3.2 Characterization of chemotactic activity of recombinant and virus produced 
CCL16
CCL16 was described to be chemotactic for human monocytes and lymphocytes. To 
evaluate its function on mouse leukocytes, cell migration was assayed by the Boyden 
chamber methods.
CCL16 either from the supernatant of TSA tumor cells infected with AdCCL16 or the 
recombinant protein was used. To generate viral produced CCL16, TSA mammary 
carcinoma cells were infected as described in materials and methods (section 2.3) and the 
amount of CCL16 in the supernatant was carefully titrated in comparison to known amount 
of recombinant protein.
Figure 3.3 shows results obtained using splenocytes from BALB/c naive mice. The viral 
CCL16 showed a chemotactic activity comparable with the recombinant protein 
confirming that the protein produced by AdCCL16 is biologically active.
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Figure 3.3 Recombinant and virus produced CCL16 is chemotactic for murine 
splenocytes.
Splenocytes were tested for migration in response to supernatants containing different 
amounts of recombinant or virus-produced protein. After 3h cells attached to the bottom of 
the filter, separating the top and bottom of the Boyden chamber, were fixed and counted 
under a light microscope (40X objective). Assay was performed in triplicate (means of two 
independent experiments; mean ± SE). Specific migration (migration index) is expressed 
as number of cells migrated in the presence of recombinant or viral CCL 16/number of cells 
migrating in medium alone or in supernatant of control virus-infected TSA cells, 
respectively.
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Further analyses were performed on separated leukocytes subsets. For this purpose CD4+ 
and CD8+ T cells were purified from total splenocytes using magnetic beads and DC were 
generated from BM precursors and tested for their ability to migrate in response to both 
recombinant and viral produced CCL16 (Fig. 3.4 and 3.5).
Both naive CD4 and CD8 respond to CCL 16 in a dose dependent manner moreover the 
chemotactic response was abrogated by preincubation of cells with pertussin toxin, 
suggesting that CCL 16 mediates its chemotactic activity by G^-coupled receptors (Fig. 
3.4).
As a way to understand the potency of CCL16 in attracting DC, its chemotactic activity 
was compared to that of CCL20, which is perhaps the best-characterized chemokine 
known to attract immature DC both in vitro and in vivo (Dieu et al., 1998). As shown in 
Fig. 3.5 C, CCL16 and CCL20 recruited similar number of DC.
To characterize the ability of CCL16 to attract mature DC, BM derived DC were 
preincubated with LPS. As shown in Fig. 3.5 D, DC matured with LPS migrated 4-5 times 
less than immature DC in response to CCL 16 and to CCL20 as well.
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Figure 3.4 CD4, CD8 naive lymphocytes migrate in response to CCL16.
Purified CD8+ and CD4+ cells were tested for migration in response to supernatants 
containing different amounts of recombinant or virus-produced protein. After 3 h for CD4+ 
and CD8+ cells attached to the bottom of the filter, were counted. Preincubation with 
pertussin toxin (PTX) inhibited CCL16-induced migration. Assays were performed in 
triplicate (means of two independent experiments; mean ± SE). Specific migration 
(migration index) is expressed as number of cells migrated in the presence of recombinant 
or viral CCL16/number of cells migrating in medium alone or in supernatant of Addl70-3- 
infected TSA cells, respectively.
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Figure 3.5 DC migrate in response to CCL16.
Phenotypic characterization of immature (A) and mature BM-DC (B). (C) Immature cells 
were tested for migration in response to supernatants containing different amounts of 
recombinant hCCL16 or virus-produced hCCL16 or mCCL20. (D) In another sets of 
experiments immature and mature DC cells were tested for migration in response to 
recombinant CCL 16 and CCL20. Assays were performed in triplicate (means of triplicate; 
mean ± SD). Migration index is calculated as above described (Fig 3.4).
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3.3.3 CCL16 triggers CCL2 production from T lymphocytes and DC cells
Recombinant hCCL16 has been shown to induce the production of CCL2 in murine 
macrophages (Cappello et al., 2004). In this section it was evaluated whether CCL 16 has 
similar effects on murine DC and T lymphocytes. DC, CD4 and CD8 T cells were seeded 
in the presence of different amount of CCL 16 and the amount of CCL2 released was 
assessed 48 h later by ELISA (Fig. 3.6 A-B). Moreover the effect of CCL16 on activated 
CD4 and CD8 T cells was similarly evaluated (Fig. 3.6 A, right).
Naive Activated B
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□ 10 ng/ml
C04 Cos C04 COs 1000 ng/ml 100 ng/ml 10 ng/ml Only DC
Figure 3.6 CCL16 induces CCL2 expression in DC and T cells.
Purified CD4 and CD8 T cells (A, left) and BM-DC (B) were seeded at a concentration of 
lx l06/ml in 96 well plates with the indicated amount of rCCL16. To test CCL16 effects on 
activated T cells, CD4 and CD8 T cells were seeded in 96 well plates pre-coated with anti- 
CD3 Ab (A, right). Supernatants were collected 48 h later and the amount of CCL2 was 
evaluated by ELISA. Assays were performed in triplicate (mean ± SD).
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3.4 Discussion
The chapter aim was achieved throughout construction and characterization of an 
expression vector suitable for efficiently delivery of CCL 16 by infection of tumor cells in 
vivo. Adenovirus-mediated gene delivery was chosen because of its ability to infect tumor 
cells in vivo, to induce high levels of transgene expression and to provide a certain 
adjuvant activity in mounting an immune response.
The coding region of human CCL 16 was inserted into an adenoviral vector and the 
chemotactic activity of viral and recombinant protein was confirmed on murine leukocytes. 
Because CCL 16 exists in mice only as a pseudogene the knowledge of its biology is based 
on human studies (Shoudai et al., 1998; Youn et al., 1998). Youn et al, demonstrated that 
is chemotactic for human monocytes and naive lymphocytes, without studying whether 
difference might exist in lymphocytes subsets (Youn et al., 1998). Here it is shown that 
CCL 16 exerts chemotactic activity on murine lymphocytes both CD4 and CD8 T and that 
the viral produced CCL16 is as active as the recombinant protein (Fig. 3.4). The only 
previous study performed in mice that might have suggested an effect of human CCL 16 in 
mice was reported by Giovarelli et al (Giovarelli et al., 2000), showing that TSA 
carcinoma cells transfected with the human CCL 16 became heavily infiltrated by 
lymphocytes and DC when injected into syngenic mice.
Both human and murine chemokine receptors are coupled to Gt proteins and cells pre­
treatment with pertussin toxin blocks chemotaxis. CCL 16 follows this rule also in mice 
thus suggesting the same receptor might be involved (Fig. 3.4). In human it has been 
CCL16 is a functional ligand for CCR1, CCR2, CCR5 (Nomiyama et al., 2001) and CCR8 
(Howard et al., 2000), all G2 proteins coupled receptors.
Moreover, in this chapter, it is shown that CCL 16 exerts chemotactic activity on immature
BM-DC to a level comparable to that of CCL20, which is perhaps the best characterized
chemokine attracting immature DC. Upon maturation DC loose responsiveness to CCL 16
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(Fig. 3.5). These results are consistent with reports showing that, upon DC maturation, 
receptors for inflammatory chemokines as CCR1, CCR2, CCR5, CCR6 are down 
modulated while, receptor for chemokines expressed in lymphoid organs, CCR7, is 
upregulated (Sallusto et al., 1998) (Vecchi et al., 1999). A more detailed analysis showed 
that both human and mouse DC down regulate CCR6 expression upon maturation and 
become unable to migrate, in vitro, in response to rCCL20 (Dieu et al., 1998).
Capello et al, demonstrated that CCL 16 enhances the ability of murine peritoneal 
macrophages to release CCL2 (Cappello et al., 2004). The same cells, stimulated with as 
little as 100 ng/ml of CCL16, upregulated CD40, CD86 and CD80 costimulatory 
molecules. Accordingly to these results, it was found that rCCL16 induces release of high 
amount of CCL2 from mouse DC as well as CD4 and CD8 T cells, with no differences 
among naive and activated T cells (Fig. 3.6). Ten times more CCL2 was released by DC 
with respect to T cells, a value similar to that found in macrophages. However, differently 
for what reported in macrophages, DC stimulated with CCL 16 did not upregulate 
costimulatory molecules (not shown).
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CHAPTER 4: ABILITY OF AdCCL16 TO MODULATE TUMORIGENICITY
4.1 Introduction
In immunotherapy approaches, chemokines are most exploited for their ability to induce 
migration of dendritic cells (DC) (reviewed in Chapter 1 section 1.3 and (Homey et al., 
2002)).
DC recruitment has been described in prestablished B16 melanoma tumors treated with 
recombinant CCL19, although tumor rejection was incomplete (Kirk et al., 2001a; Kirk et 
al., 2001b). Other studies also reported DC recruitment to the tumor site, in mice injected 
intranodally with adenovirus carrying the human CCL20, a gene which , induced rejection 
in 60-80% of mice in two out of three tumor models tested, and in mice treated with 
adenovirus encoding CCL22, which was effective in 60% of mice (Guo et al., 2002). 
However most of investigations have not extensively investigated the actual role of DC in 
tumor rejection and no compelling animal models for prevention and cure of distant 
metastases, the critical issue in cancer therapy, has been tested before.
These points were addressed using human CCL 16, a chemokine poorly characterized at the 
functional level. To date only three reports analyzed the potential activity of CCL16 as 
antitumor agent.
The TSA mouse adenocarcinoma cell line was transfected with human CCL 16 cDNA and 
was shown to be rejected through a massive infiltration of leukocytes (Giovarelli et al., 
2000). Rejection of CCL 16 was associated with an impressive infiltrate of macrophages, 
dendritic cells, PMN and T cells and was abrogated by T cells and PMN depletion. This 
latter data suggests that both innate and adaptive response mediates the rejection of 
TSA/CCL16 tumors. Mice injected with CCL16-transfected TSA tumor cells were able to 
reject a contralateral challenge of the parental cells as early as 6 days later, indicating rapid
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development of systemic immunity. This latter result suggests that CCL 16 accelerate 
events that underline cross-talk between DC and T cells (Giovarelli et al., 2000).
In another study the antitumor activity of a fusion protein between CCL 16 and chTNT-3, a 
monoclonal antibody previously shown to target tumors by binding to DNA exposed in 
necrotic zones, was tested on prestablished tumors.
Immunohistochemical studies on CCL16/chTNT-3 treated tumors showed heavy 
infiltration of CD4+ and CD8+ T cells, PMNs and C D llc+CD llb+ myeloid dendritic cells. 
Despite the abundant leukocytes infiltration only 30-40% of treated tumors showed 
reduction of tumor growth and only 10% undergo complete regression (Li et al., 2003b). 
Authors hypothesized that infiltrated leukocytes might be suppressed by CD4+CD25+ 
regulatory T cells. Indeed in another study CCL16/chTNT-3 fusion protein combined with 
depletion of regulatory T cells results in a significant improvement in tumor rejection rate 
(70-90%). Number of CD8 T cells or DC at tumor site did not increase following 
regulatory T cell depletion, suggesting that infiltrate activation status more than its 
absolute number was affected following T regulatory depletion (Li et al., 2003a).
4.2 Aims of the chapter
The aims of this part of the project were to characterize the antitumor activity of CCL 16. 
This was done by:
• Infecting in vitro murine tumor cell lines with AdCCL16 and analyzing their 
growth in vivo;
• Studying the therapeutic effect of AdCCL16 on prestablished tumors;
• Investigating the immunological effector mechanisms responsible for the antitumor 
effect of AdCCL16 treatment;
• Studying the ability of AdCCL16 treatment to halt metastatic dissemination;
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4.3 Results
4.3.1 Infection of murine tumor cells with AdCCL16 and their in vivo 
tumorigenicity
To verify the ability of AdCCL16 to infect murine tumor cells, TSA (H2d mammary 
carcinoma) and C26 (H2d colon carcinoma) cells were infected at different MOI and the 
amount of CCL 16 in the supernatants was assayed by ELISA 24 and 48 h after the 
infection. 48 after infection C26 released 400 ±50 ng/ml at 100 MOI and 1200 ±180 at 200 
MOI (Fig 4.1 A). TSA infected cells produced similar amount of CCL16, 530 ±40 ng/ml at 
100 MOI and 1020 ±200 at 200 MOI (Fig 4.1 B).
Moreover the ability of AdCCL16 to modify the tumorigenicity of C26 and TSA cells was 
evaluated. For this purpose, cells were infected in vitro with 100 and 200 MOI of 
AdCCL16 or Addl70-3 (empty control vector) and after 24 hours, 5xl04 C26 cells or 1x10s 
TSA cells were injected subcutaneously into BALB/c syngenic animals. There was a 
significant inhibition of tumor growth of C26-AdCCL16-infected cells compared with 
cells infected with the control virus although no mice remained tumor free (Fig. 4.2 A-B). 
Differently, growth of TSA AdCCL16-infected cells was significantly inhibited with 60% 
of mice free of tumors 50 days after injection. The remaining 40% of the animals showed 
significant delay in tumor growth and significant prolongation of survival compared to the 
controls (Fig 4.2 C-D). Only two mouse out of 14 injected with TSA cells infected with 
control virus at the highest multiplicity of infection remained tumor free (Fig 4.2 C).
Mice that remained tumor free were challenged after sixty days with a second injection of 
1x10s TSA cells. No mice developed tumors suggesting the presence of immunological 
memory.
97
TSA 100 moi TSA 100 moi TSA 200 moi TSA 200 moi 
24hr 48hr 24hr 48hr
Figure 4.1 CCL16 production by AdCCL16-infected C26 and TSA tumor cells.
5x10s cells were seeded in 60 mm cell culture dishes in 5 ml of medium and infected 12 hr 
later with 100 or 200 MOL Supernatants, collected 24 and 48 h later, were analyzed for 
CCL16 secretion by ELISA. Data are given as mean±SE of three independent experiments.
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Figure 4.2 Tumorigenicity of AdCCL16-infected C26 and TSA cells.
3x106 C26 or TSA cells were seeded in 100 mm dishes and infected 12 h later with 100 or 
200 MOI of AdCCL16 or Addl70-3 empty virus. 24 later cells were collected and 1x105 
TSA cells or 5x104 C26 cells were inoculated each in 14 BALB/c mice. Tumor growth is 
expressed in A and C as number of tumor free mice and in B and D as tumor volumes. In 
B-D data are given as tumors volumes (mean ± SD).
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4.3.2 AdCCL16 inhibits tumor growth of prestablished tumors
Two tumor models were chosen to investigate the antitumor activity of AdCCL16 on pre- 
established tumors, TSA and MCA38 (H2Kb colon carcinoma). An unexpected toxicity of 
both AdCCL16 and the empty Addl70-3 virus inoculated into well-established C26 
nodules prevented the use of this tumor model in the studies described in chapter 4 and 5 
of the thesis.
At first, the ability of AdCCL16 to infect tumor cells in vivo was evaluated. To this aim, 
TSA and MCA38 nodules were injected with lxlO9 pfu of AdCCL16 or the empty vector 
Addl70-3 and collected after 48 h to assay the amount of CCL16 produced in vivo. 
Supernatants from four different nodules were analyzed separately by ELISA. CCL16 
production ranged from 120-150 ng/ml for TSA to 70-280 ng/ml for MCA38. No CCL16 
production was detected in tumors transduced with the empty vector (Fig. 4.3).
To evaluate the antitumor effect of AdCCL16, mice were injected subcutaneously with 
lxlO5 TSA or MCA38 cells, when tumors reached 2-4 mm of diameter (between day 7-11) 
lxlO9 pfu of AdCCL16 or Addl70-3 were injected into the tumors. The treatment was 
repeated four days later. Part of the animals bearing TSA nodules received only the first 
AdCCL16 treatment as a mean of comparing the effectiveness of one versus two 
injections. Tumor growth was significantly inhibited especially after two injections, 
whereas no inhibition was observed in the group treated with Addl70-3 virus and in the 
untreated group (Fig 4.4 A-B). Fifteen of 49 (31%) mice bearing TSA tumors and 7 of 21 
bearing MCA38 tumors (33%) were cured when treated with two injections of AdCCL16. 
No regressions were observed with control virus. Table 4.1 summarize data from 
independent experiments.
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Figure 4.3 Production of CCL16 following intratumoral injection of AdCCL16.
BALB/c and C57/BL6 mice were injected subcutaneously with 1x105 TSA cells or 
MCA38, respectively. When tumors reach 4 mm in diameter they were injected with 
AdCCL16 or Addl70-3. 48 hr later tumors were collected, treated with collagenase and 
plated at a density of 1x105 cells/ml. 18 hr later supernatants were tested by ELISA for the 
production of the protein. Four mice were used in each group. Data are given as mean 
±SD.
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Figure 4.4 Antitumor effects of AdCCL16 on pre-existing tumors.
A) BALB/c mice were injected subcutaneously on day 0 with lxlO5 TSA cells. When 
tumors became palpable, mice were left un- treated (♦) or treated with a single (□ ) or a 
double injection (■) of lx l09pfu of AdCCL16 or Addl70-3 (O). B) C57/BL6 mice were 
injected subcutaneously on day 0 with lxlO5 MCA38 cells. When tumors became palpable, 
mice were left un-treated (O ) or treated with a double injection (■) of lxlO9 pfu of 
AdCCL16 or Addl70-3 (♦). Data are given as tumors volumes (mean ± SD). *P<0.05 for 
(□ ) versus (♦,<>). ** P<0.01 for (■) versus (♦,<>). Seven mice were used in each group. 
Results are from 1 experiment of 7 for TSA and 3 for MCA38, performed with similar 
results.
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Table 4.1 Response following intratumoral injection ofAdCCL16
Treatmenta Complete regression % Rejection following secondary tumor challenge b%
TSA tumor
Addl-70-3 0/49 (0% )
AdCCLI 6 15/49 (31 %) p<0,001 15/15 (100%)
MCA38 tumor
Addl-70-3 0/21 (0%)
AdCCLI6 7/21 (33%) p<0,001 7/7(100% )
a Mice hosting s.c.tumor injected 7-10 earlier were injected intratumor with 109 pfu 
of AdCCLI 6 or the control virus at day 0 and 4.
b Mice that have undergone total regression were challenge 90 days later with 2x10s of live cells and 
monitored for tumor growth.
Data are pooled from independent experiments (7 with TSA and 3 with MCA38).
To evaluate whether mice that rejected TSA and MCA38 tumor following AdCCLI6 
treatment had developed immunological memory, the ability to reject a secondary 
challenge with live cells and the presence of memory CTL in their spleens was assessed. 
All mice rejected the challenge with TSA or MCA38 cells (Table 4.1). For CTL activity, 
spleens were collected 90 days after primary challenge, restimulated in vitro with 
irradiated tumor cells or with the specific peptides, corresponding to the known epitopes of 
the MuLV env protein presented in the context of class I MHC Ld (AH1) or class I MHC 
Lb (KSP). The env antigen, corresponding to the envelope protein of an endogenous 
leukemia virus (MuLV), is expressed by TSA and MCA38 tumor as an immunodominant 
antigen (Huang et al., 1994a). All mice tested, developed CTL activity although with 
different intensity among individual animals indicating that the rejection mediated by 
CCL16 treatment was associated with the development of memory lymphocytes that 
persisted for up to three months (Fig. 4.5 for TSA tumor model and 4.6. for MCA38 tumor 
model).
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Figure 4.5 Mice that reject TSA tumor following AdCCL16 treatment develop CTL 
memory response.
Spleen cells from three mice that have rejected TSA tumors were restimulated in vitro with 
irradiated TSA cells or with AH1 antigenic peptide of TSA. After five days lymphocytes 
were tested for cytotoxic activity against TSA cells and normal blasts (as negative 
controls). Data refers to single mice. In vitro stimulus is indicated in the legend. Effector: 
target ratio (E:T) is indicated.
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Figure 4.6 Mice that reject MCA38 tumor following AdCCL16 treatment develop 
CTL memory response.
Spleen cells from three mice that have rejected MCA38 tumor were restimulated in vitro 
with irradiated MCA38 cells or with KSP antigenic peptide of MCA38. After five days 
lymphocytes were tested for cytotoxic activity against MCA38 cells, B16 (a melanoma cell 
lines expressing the env antigen) and normal blasts (as negative controls). Data refers to 
single mice. In vitro stimulus is indicated in the legend. Effector: target ratio (E:T) is 
indicated.
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4.3.3 Morphologic analysis of TSA tumors after AdCCL16 treatment.
Immunohistology has been used to characterize the types of leukocytes infiltrating TSA 
treated tumors. Tumors were treated at day 0 and 4 with lxlO9 pfu of AdCCLI6 or 
Addl70-3 and collected for the analysis 1 day after last injection.
AdCCLI6 treated tumors showed the presences of reactive cell infiltration inside the tumor 
mass where small and multiple necrotic foci were also found (Fig. 4.7 A). A marked 
accumulation of reactive infiltrate with vast necrosis was found on the edge of the tumor 
and in its surrounding stroma (Fig. 4.7 B). Whereas Addl70-3-injected TSA tumors 
evidenced much less infiltration and barely detectable necrotic area (Fig. 4.7 C-D).
In-depth analysis of the leukocytes subsets infiltrating treated tumors revealed that 
although, consistent with the intrinsic immunogenicity of adenoviruses (Yang et al., 1994), 
in tumors injected with the empty vector leukocyte infiltration was greater than that in 
PBS-treated tumors, the infiltration induced by AdCCLI6 was significantly greater than 
that of Addl70-3-treated tumors (Table 4.2). All leukocyte subsets examined were more 
abundant in AdCCLI6-treated tumors with a predominance of C D llc+, CD4+ and 
especially CD8+ T cells (Table 4.2 and Fig. 4.8, A-B). The latter cells were the main source 
of tumor-associated IFN-y (Fig. 4.8 C-D), as confirmed by laser scanning confocal 
microscopy (Fig. 4.8 E-F).
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Figure 4.7 Histological analysis of TSA tumors after AdCCL16 or Addl70-3 
treatment.
TSA tumors of 3-4 mm were injected at day 0 and day 4 with AdCCLI6 or with Addl70-3 
and processed for immunoistochemistry analysis the following day. TSA tumors, formed 
by round to polygonal epithelial cells with frequent mitotic figures, when injected with 
A dCCLI6 evidenced small necrotic foci within the tumor mass (n) (A) and a marked 
inflammatory reaction particularly in the peripheral areas (B). Addl70-3-injected TSA 
tumors showed much less inflammatory reaction in both the inner part (C) and in the 
peripheral area (D) than AdCCLI6 treated tumors.
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Table 4.2 Reactive cell infiltration induced in TSA tumors after injection with PBS, 
Addl70-3 or AdCCL16
PBS Addl70-3 AdCCL16
Cells3
Macrophages 21 4 28 5b 32 6b
CD llc+ cells 14 ± 3 23 ± 3b 32 5C
CD8+ cells 15 ± 3 21 ± 3b 44 9°
CD4+ cells 12 ± 2 24 ± 4 b 34 ± 5C
Granulocytes 3 ± 1 7 ± 1 8 ± 2
NK cells 7 ± 2 10 ± 2 14 ± 3
3 Cell counts performed at x400 in a 0.180-mm2 field. At least 3 samples (1 sample/tumor growth area) 
and 10 randomly chosen fields/sample were evaluated. Results are expressed as mean ± SD of positive 
cells/field evaluated on cryostat sections by immunohistochemistry. 
b Values significantly different (p < 0.0051 from corresponding values of TSA tumors injected with 
PBS.
c Values significantly different (p <_0.005) from corresponding values of TSA tumor injected with Addl70-3.
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Figure 4.8 CD8+ T lymphocytes expressing IFN-y accumulate in AdCCL16 treated 
TSA tumors.
TSA tumors of 3-4 mm were injected at day 0 and day 4 with AdCCLI6 or with Addl70-3 
and processed for immunoistochemistry analysis the following day.
CD8+ lymphocytes and cells expressing IFN-y were among the most represented leukocyte 
population in AdCCLI6 treated tumors (A and B, respectively) than in tumor injected with 
Addl70-3 (C and D, respectively) (x400). Laser scanning confocal microscopy revealed 
frequent co-localization of IFN-y-producing cells (green staining in E) and CD8 cells (red 
in F), as shown in the yellow regions of the merged image (G) (x 1000)
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4.3.4 Kinetics of leukocyte infiltration in AdCCL16 treated tumors
Immunoistochemical analysis indicates that CCL16 promotes accumulation of DC and T 
cells at tumor site. To characterize the kinetic of leukocyte infiltration, single-cell 
suspension from TSA and MCA38 tumors were analyzed for the presence of CD4, CD8 
and DC at 2, 5 and 8 days after the initiation of AdCCLI6 treatment; for comparison 
tumors treated with Addl70-3 were also analyzed. The number of infiltrating leukocytes 
was determined by flow cytometry using antibodies for CD4, CD8 and DC cells. The total 
number of infiltrating cells was normalized to the tumor volume because tumor size varied 
between and within treatment groups (see materials and methods for details 2.9). In both 
tumors models, TSA and MCA38, significant influx of CD4, CD8 and DC into tumors was 
seen 2 and 5 days after AdCCLI6 but not control Addl70-3 treatment. Four days after last 
AdCCLI6 treatment, number of infiltrating lymphocytes return to the levels seen in 
Addl70-3 controls animals (Fig. 4.9).
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Figure 4.9 Kinetics of leukocytes infiltration following AdCCL16 treatment.
TSA and MCA38 tumors of 3-5 mm were injected at day 0 and day 4 with A dCCLI6 or 
with Addl70-3. Tumors were collected at day 2, 5 and 8 after the first injection and 
processed according to materials and methods. Number of cells/mm3 were calculated as 
follows: percentage of positive cells x total number of infiltrating leukocytes x 100/tumor 
volume. 5 tumors mice were analyzed for time point. Data are given as mean ± SD. Results 
are representative of 3 independent experiments.
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4.3.5 AdCCL16 induces inflammation of draining lymph nodes
One of the most evident consequences of AdCCLI6 treatment was the swelling of lymph 
nodes draining the tumors. To evaluate this phenomenon, inguinal and axillary lymph 
nodes draining treated tumors were isolated at day 2, 5, 8, 12 and 18 after the first 
treatment and total number of cell counted. The number of cells was significantly 
increased in AdCCLI6 compared with Addl70-3 treated group, in both TSA and MCA38 
tumor models (Fig. 4.10). FACS analysis of lymph nodes cells revealed a dramatic
increase in the number of CD4+, CD8+ lymphocytes and C D llc+ DC in lymph nodes
draining AdCCLI6-treated tumors as compared to Addl70-3-treated tumors at all points 
except day 18 when cell count returned to normal. Figures 4.11 and 4.12 shows cell counts 
of the specific subsets for TSA and MCA38, respectively. No significant differences 
between Addl70-3-treated and untreated mice were observed.
112
4 0  -
.  3 5 -  
o
*  3 0  - 
a>
£  2 5  - o
a>
|  20 - 
l i s io
h  1 0 -  
5 -
0
TSA
I DAY 2  □  DAY 5 □  DAY 8  □  DAY 1 2  ID DAY 1 8
K T * *
i  * n
n iW i ifkn
AdCCLI 6  AdCCLI 6  A d d l7 0 -3  A d d l7 0 -3
Inguinal Axillary Inguinal Axillary
MCA38
60 -I
50 -
I DAY 2 □  DAY 5 □  DAY 8 EB DAY 12 □  D A Y 18
I**
11
**
IIIt L  11
A dC C L 16
Inguinal
Ad C C L 16  
Axillary
A d d !70-3
Inguinal
A d d l70-3
Axillary
Figure 4.10 Enlargement of draining lymph nodes following AdCCL16 treatment.
TSA or MCA38 tumors of 3-4 mm were injected at day 0 and day 4 with A dCCLI6 or 
with Addl70-3 and inguinal and axillary draining lymph nodes were harvested 2, 5, 8, 12 
and 18 days after the first treatment and processed as described in Materials and Methods. 
Lymph node enlargement was due to increased numbers of cell per lymph node. Three 
mice were examined at each time point. Data are given as mean ± SD of number of cells. 
Results are representative of 2 independent experiments with similar results. Statistical 
difference is indicated and compares the numbers of cells collected from LN draining 
AdCCLI6 or Addl70-3 injected tumors, *P<0.05; ** P<0.01.
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Figure 4.11 Increase number of CD4, CD8 and DC in LN draining TSA treated 
tumors.
TSA tumors of 3-4 mm were injected at day 0 and day 4 with AdCCL16 or with Addl70-3 
and lymph nodes were harvested and analyzed as described in materials and methods. The
numbers of CD4+ and CD8+ lymphocytes as well as of CD1 lc DC were greatly increased.
Three mice were examined at each time point. Data are given as mean ± SD of number of 
cells. Results are representative of 2 independent experiments with similar results. 
Statistical difference is given for each time point and compares the numbers of cells 
collected from LN draining AdCCLI6 or Addl70-3 injected tumors, *P<0.05; ** PcO.Ol
114
CD4
□ DAY 2 ■ DAY 5 □ DAY 8 CD DAY 12 01 DAY 8
CD8
□  DAY 2 ■  DAY 5 □  DAY 8 SB DAY 12 ED DAY 8
9
8
7
6
5
4
3
2
1
0
AdCCLI6 Ad CCL16 Addl70-3 Addl70-3
r f e i i f i  ~ w 5 ? i
Inguinal Axillary Inguinal Axillary
AdC C LI 6  A d C C L I 6  A d d l70-3  
Inguinal Axillary Inguinal
A d d l70 -3
Axillary
DC
□  DAY 2 ■  DAY 5 El DAY 8 □  DAY 12 □  DAY 8
o
x  1 4 ‘ 
O 1 2 -  
Q  1 0 -  o
rLTfifii
AdCCLI6 AdCCLI6 Addl70-3 Addl70-3 
Inguinal Axillary Inguinal Axillary
Figure 4.12 Increase number of CD4, CD8 and DC in LN draining MCA38 treated 
tumors.
MCA38 tumors of 3-4 mm were injected at day 0 and day 4 with A dC CLI6 or with 
Addl70-3 and lymph nodes were harvested and analyzed as described in materials and
methods. The numbers of CD4+ and CD8+ lymphocytes as well as of CD1 lc DC were
greatly increased. Three mice were examined at each time point. Data are given as means ± 
SD of number of cells. Results are representative of 2 independent experiments with 
similar results. Statistical difference is given for each time point and compares the numbers 
of cells collected from LN draining AdCCLI6 or Addl70-3 injected tumors, *P<0.05; ** 
P<0.01
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In addition, immunohistochemical analysis of inguinal lymph nodes collected at day 5 
showed that CDllc+ cells were more represented in the paracortical T cell areas of the
lymph nodes draining AdCCLI6-injected TSA tumors than in those draining Addl70-3- 
injected tumors (Fig. 4.13 A-B). In the paracortical areas, and sometimes in the medullary 
cords of lymph nodes draining AdCCLI 6-injected tumors, IL-12 expression was detected 
in cells with DC morphology (Fig. 4.13 C-D).
To test the loco-regional activation of T lymphocytes from the draining lymph nodes, IFN- 
Y was measured by ELISA of total lymphocytes while the percentage of IFN-y producing
cells was evaluated by FACS analysis of CD4+ and CD8+ subsets. To this extent lymph
node cells collected 5 and 8 days after first treatment were restimulated in vitro with plate- 
bound anti-CD3 Ab and IFN-y was meseaured by both ELISA and FACS analysis. Cells 
from AdCCLI6-treated mice produced significantly higher amounts of IFN-y than cells
from mice treated with control virus (Fig. 4.14 A) and the majority of both CD4+ and 
CD8+ cells actively produced the cytokine (Fig. 4.14 B).
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Figure 4.13 Immunohistochemical analysis of inguinal lymph nodes draining TSA 
tumors on day 5 after treatments.
C D llc+  cells were more represented in the paracortical T cell areas of the lymph node 
draining AdCCLI 6-injected tumors (B ) as composed with those draining Addl70-3- 
injected tumors (A). In addition, lymph node draining AdCCLI 6-injected TSA tumors 
revealed distinct expression of IL-12 in cells with cytoplasmatic projections identifiable as 
DC (the insert shows the detail indicated by the arrow at xlOOO magnification) inside the 
paracortical areas and sometimes in the medullary cords (D). By contrast, the IL-12 
expression was barely detected in the lymph node draining Addl70-3-injected tumor (C) 
(x400).
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Figure 4.14 Production of IFN-y by lymph nodes draining treated tumors.
TSA tumors were injected at day 0 and day 4 with AdCCLI6 or with Addl70-3 and lymph 
node cells were isolated on day 5 and 8 after the first adenoviral injection. IFN-y 
production was evaluated by ELISA (A) and by mouse IFN-y secretion assay (.B) as 
described in Materials and Methods. Three mice were analyzed for each time point. Data 
in (A) are given as mean +SD. IFN-y level (p<0,05). Flow cytometry plots in B show the 
expression of IFN-y among gated CD4+ or CD8+ cells; the percentage of positive cells is 
indicated in the top right comer of the plot. Results are representative of 2 independent 
experiments.
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4.3.6 DC in lymph nodes draining AdCCL16-treated tumors are loaded with TAA 
and stimulate TAA- specific T lymphocytes
Since DC proliferation in lymph nodes is unlikely (Flores-Romo, 2001), their 
accumulation in these nodes following AdCCLI6 treatment suggests their migration from 
the tumor. To address this point, CD llc+ DC from lymph nodes draining AdCCL16- 
treated tumors were purified using magnetic beads and used to stimulate IFN-y production 
by the T cell clone E/88 , as an indication of TAA capture by DC. The CD8 T cells clone, 
E/88 , specifically recognizes the AH1 epitope (Rodolfo et al., 1991) (scheme of the 
experiment is given below in Fig. 4.15).
W Cells from  LN draining  
P  trea ted  tu m ors
C D IIc  - fraction
C D IIc  .+ fraction
CTL activ ity
E /8 8  stim ulation
Figure 4.15 Scheme of the experiment presented in Fig. 4.16
119
As shown in Fig. 4.16 A, E/88 cells produced IFN-y when cocultured with DC from lymph 
nodes of treated mice, whereas no IFN-y production was observed by DC alone, E88 alone
or by the CD 11c- fraction of the magnetic DC separation containing lymphoid cells. TSA
tumor cells were used as positive controls. The low yield of DC from lymph nodes 
draining tumors treated with Addl70-3 precluded their use as controls in this assay.
The CD 11c- fraction of the magnetic separation, containing lymphoid cells, was
restimulated for five days in the presence of irradiated tumor cells or the specific AH1
peptide and then used to test CTL activity. Lymphocytes from the CD l ie -  fraction from
AdCCL16 but not Addl70-3-treated tumors elicited specific CTLs against TSA cells, AH1- 
pulsed blasts cells and C26 colon carcinoma cells which share the same TAA with TSA 
(Fig. 4.16 B).
Together, these results suggest that DC infiltrating the lymph nodes took up and processed 
the TAA for presentation to CTL clones as well as for priming of naive T cells in the 
draining lymph nodes.
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Figure 4.16 Functional characterization of DC from lymph nodes draining treated 
tumors.
Tumors were treated with AdCCLI6 or Addl70-3 at day 10 and 14 from challenge. Two 
days after the last treatment, draining lymph nodes were isolated and DC were separated 
by magnetic beads. Two lymph nodes pools, each from three mice, were processed 
independently. (A) E88 (1x10s) cells were incubated with stimulating cells at a ratio of 1:1 
for TSA cells and 1:2 for purified DC for 18 h. DC, E88 or CD1 lc negative fractions were 
incubated alone as negative controls. IFN-y in the medium was tested by ELISA (mean± 
SD relative to the two independent groups). (B) Lymphocytes from the CD 11c negative 
fraction were restimulated in vitro with TSA cells or AH1 peptide and tested 5 days later 
for CTL activity. Results are representative of 2 independent experiments.
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4.3.7 Antitumor effects is abrogated in mice lacking T cells or in IFNy-KO mice
To evaluate the role of specific effector cells in AdCCLI6 antitumor activity CD4+ or
CD8+ cells were depleted in tumor bearing animals by means of specific antibodies. In
both CD4 and CD8 depleted animals the effect of AdCCL16 was abrogated (Fig. 4.17, A- 
B). The increase production of IFN-y in LN of mice treated with AdCCLI6 (Fig. 4.14) 
suggests that this cytokine may play a key role in the antitumor activity mediated by 
CCL16. To test this hypothesis IFN-y KO (GKO) mice implanted with TSA tumors were 
treated with AdCCL16 or control virus. In these mice AdCCLI6 treatment of tumors was 
no longer inhibitory (Fig. 4.17 C).
These results indicate that AdCCLI6 antitumor activity depends on the presence of both 
CD8+ and CD4+ T cells and involves IFN-y.
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Figure 4.17 Contribution of CD4+, CD8+ cells and IFN-yto AdCCL16 anti-tumor 
effect.
Tumor growth was monitored in mice depleted of CD4+ cells (A), CD8+ cells, (B ) and 
IFN-y-knout-out mice (GKO) (C) treated with AdCCLI 6 or Addl70-3. Number of mice is 
indicated in each panel. Data are given as mean + SD of tumor volumes.
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4.3.8 AdCCL16 treatment of metastatic disease
Despite the strong pro-inflammatory activity and the initiation of an effective immune 
response, intralesional administration of AdCCLI6 lead to tumor rejection in only 31% of 
mice. While addition of costimuli and/or cytokines might have increased the cure rate, it 
was preferred to focus on the potential usefulness of AdCCLI6 in preventing metastatic 
spread. Perhaps the most compelling model for studying spontaneous metastases, at least 
on a BALB/c background, is the 4T1 mammary carcinoma (Pulaski and Ostrand- 
Rosenberg, 1998), since metastases spread immediately after tumor injection and the 
process is not impaired by removal of primary tumor (Pulaski et al., 2000).
As in TSA model, treatment of the 4T1 established tumors with AdCCLI6 significantly 
inhibited primary tumor growth, but tumors eventually regrew and no complete rejection 
was observed (Fig. 4.18).
Addl-70-3 AdCCLI61200
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Figure 4.18 Antitumor effects of AdCCL16 on 4T1 pre-existing tumors.
BALB/c mice were injected s.c. on day 0 with 7000 4T1 cells and 10 days later, lxlO9 pfu 
of AdCCLI6 or Addl70-3 was injected intratumorally. The treatment was repeated 4 days 
later. Twelve mice were used in each group. Data are given as means +SD of tumor 
volume. ** P<0,01 for (■) versus (♦).
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To determine whether AdCCL16 treatment of the primary 4T1 tumor might affect 
metastatic dissemination and whether surgical removal of the primary tumor after 
treatment might synergize increasing survival, tumor-bearing mice were inoculated with 
AdCCL16 or the control virus at day 10 and day 14; in one group of mice, the primary 
tumor was surgically removed at day 19. At this time tumors size ranged between 3 and 6 
mm in diameters and it is well known that mice with tumors of 2 mm have already 
disseminated metastases (Pulaski and Ostrand-Rosenberg, 1998). Part of the mice were 
followed for survival or sacrificed at day 29 and the number of lung metastasis scored by 
clonogenic assay.
Figure 4.19 schematizes the experimental protocol.
Day 0 s.c. injection 
of 4T1 cells 7000/mice
Day 10 and Day 14 
intratumor injection 
of AdCCL16or Addl70-3 
(lxlO9 pfii)
Day 19 surgical 
excision of primary 
tumor or no excision
Day 29 clonogenic 
assay of lungs (Fig.4.20A-B) 
part of the mice were not 
sacrificed and followed for survival (Fig. 4.20 C).
Figure 4.19 Scheme of the experiments presented in Fig 4.20
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AdCCL16 reduced the number of lung metastases relative to the group that received the 
control virus (range 0-40 vs 50-5000; p<0.001), and when CCL16 treatment was combined 
with surgical removal of the primary tumor, 11 of 14 mice where metastases free and the 
remaining 3 mice had less than 10 metastases (range 0-8 versus 90-4000 in mice receiving 
Addl70-3 plus surgery; p<0,001) (Fig.4.20 A).
The abrogation of lung metastases obtained by combining CCL16 treatment with surgery 
was mainly T cell mediated since experiment performed in nu/nu mice showed a full 
metastatic capacity of 4T1 cells (Fig 4.20 B).
Moreover of a total of 30 mice that received AdCCL16 and surgery in three independent 
experiments, 19 were cured (63%; p<0.001), while all 24 mice treated with Addl70-3 and 
surgery succumbed (Fig 4.20 C). Challenge of surviving mice with 104 live 4T1 cells 90 
days after primary tumor injection revealed protection in 12 of 19 mice (63%) indicating a 
long term immunity.
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Figure 4.20 Effects of AdCCL16 treatment on metastatic spread of 4T1 tumors.
Experiments were performed as schematized in Figure 4.19. (A) Number of metastasis. 
Results are from two independent experiments (B) Role of T cells in the synergy between 
AdCCL16 treatment and surgical excision of primary tumor. Number of metastasis in 
nu/nu mice compared with wt BALB/c mice. For both A and B dot represents metastases 
from individual mice. Total number of treated mice is indicated on the top of each panels. 
Horizontal lines represent median. (C) Survival curve following AdCCL16 treatment and 
surgical excision of the primary tumor. Cumulative results of three independent 
experiments, (a total of 30 mice treated in the AdCCL16 treatment group and 24 in the 
Addl70-3 control group).
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4.4 Discussion
Most experimental data obtained with transplantable tumors show that the best vaccine 
formulations effectively preimmunize mice against even a poorly or apparently non- 
immunogenic tumor challenge (Colombo and Fomi, 1997) but that their efficacy declines 
if administered when the tumor overcomes a critical threshold and becomes clinically 
evident (Bocchia et al., 2000). Generally, only a minority of mice bearing established 
tumors has been cured, and only when the vaccine was administered in the first few days 
after tumor cell challenge (Cavallo et al., 1997). Similarly only few patient with 
established tumors display objective response, which in any event are only temporary 
(Parmiani et al., 2002).
Those results are not altogether surprising, considering that most of those patients have 
already been treated in various ways and no longer respond to conventional therapy. These 
considerations underline the need to investigate the use of molecules involved in the 
immune response in the context of existing tumors and moreover after removal of primary 
tumor (Bocchia et al., 2000).
CCL16 is remarkable in vivo with respect to rapid induction of systemic immunity and 
tumor rejection. Both features are important when dealing with transplantable murine 
carcinomas, since tumors can double or triple in size during the time required for 
vaccination to “instruct” the immune system. When transfected into TSA cells, CCL16 
rendered these cells unable to form tumors in vivo due to rapid rejection by locally
recruited monocytes, DC and CD8+ T cells. Most likely, CCL16 induces chemokines and
cytokines by nearby leukocytes that provide the appropriate signal for massive 
inflammatory infiltration. In this context, it was found that a) CCL16 induces direct
migration in vitro of CD4+ and CD8+ lymphocytes other than DC, at concentration of
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1000-10 ng/ml, and (Chapter 3 Fig. 3.4 and 3.5) b) CCL16 induces potent CCL2/MCP-1 
production by macrophages {Cappello, 2003 #95}, DC and T cells, (Chapter 3 Fig. 3.6). 
The experimental setting of treatment established 3-4 mm tumors instead of injection of 
CCL16 transfected cell suspension necessitated delivery of CCL16 via an adenoviral 
vector. This size of TSA or MCA38 tumors exceeds that of any previous therapeutic 
attempt using immunological strategies (Cavallo et al., 1999). It was previously shown that 
TSA forms large highly invasive tumors of 2-3 mm in 7 days. At this time the tumor mass 
is well vascularized by self-induced vessel (Di Carlo et al., 1998).
In vivo, CCL16 production upon adenoviral delivery was quite similar to that of in vitro 
transduced TSA cells and the extent of ensuing tumor leukocyte infiltration was also 
similar. On the other hands use of stable in vitro-transfected cells (Giovarelli et al., 2000) 
or in vitro-AdCCL16 infected TSA cells (Fig 4.2) led to 75-85% tumor rejection versus 
30% complete rejection when AdCCL16 was inoculated to established tumors (Fig 4.4). 
This observation is consistent with the difficulties for the immune response in eradicating 
large tumors, as underlined by the ability to reject normal tissue but not tumors expressing 
the same target antigen (Singh et al., 1992), and by the numerous mechanisms used by 
tumors to escape immune attack (Marincola et al., 2003). Indeed, mice bearing 1 day TSA 
established tumors are cured almost completely by repeated local administration of r-IL12. 
However the efficacy of this treatment disappear on 7 days tumors suggesting that at that 
time the tumor had grown to a point at which is no longer effectively controlled by the 
host’s immune response (Cavallo et al., 1999).
In this chapter it was studied the mechanisms underling the rapid systemic immune 
response starting from the observed swelling of lymph nodes draining the AdCCL16 but 
not control Addl70-3-injected tumors. Node enlargement reflected the increased numbers
of CD4+, CD8+ T lymphocytes and DC. Such DC stimulated a T cell clone specific for the
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TSA TAA (Gri et al., 2002; Huang et al., 1996) (Fig. 4.16 A), suggesting the tumor origin 
of these cells.
Consistent with this finding, the lymphoid fraction, remaining after CD1 lc magnetic beads 
sorting, induced CTL activity against TSA and its TAA immunodominant epitope AH1 
(Fig. 4.16 B).
T lymphocytes from LN draining AdCCL16 but not control TSA-treated tumors produced 
IFN-y (Fig. 4.14), an effect that is not a direct consequence of CCL16 expression since
CD4+ and CD8+ purified T cells in vitro did not produce IFN-y when co incubated for 24 
or 48h with recombinant CCL16.
The finding that AdCCL16 treatment performed in animal depleted of T cells as well as in 
IFN-y KO mice loose its effectiveness suggest a role for T cells and the IFN-y produced 
upon their activation in mediating AdCCL16 antitumor effect (Fig. 4.17).
IFN-y plays an important role in immune-mediated tumor destruction. Its antitumor effects 
are mediated by: 1) the ability to stimulate cell mediated immune responses; 2 ) the 
induction of DC activities necessary to support Thl development and cell mediated 
immune responses; 3) the inhibition of tumor neoangiogenesis. Moreover, IFN-y 
production at tumor site stimulates the expression of gene products that when induced in 
tumor cells themselves or in leukocytes infiltrating treated tumors may be responsible for a 
direct anti-tumor activity. These include the expression of enzyme systems that generate 
reactive oxygen and nitrogen products by a variety of myeloid cell types. Indeed, IFN-y, 
can stimulate endothelial cells, epithelial cells, T cells and macrophages to synthesize 
iNOS and to produce NO, which induces tumor cytotoxicity [reviewed in ref. 
(Tannenbaum and Hamilton, 2000)]. To this extent IFN-y production was found to be 
produced by CD8 T cell lymphocytes infiltrating TSA treated with AdCCL16 (Fig. 4.8) 
and in T cells from LN draining the same treated tumors (Fig. 4.14).
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The robust and specific immune response against the tumors was therapeutic for only 
-30% of mice. An effort to improve this rate refuted to increase to number of AdCCL16 
injection because of the vector immunogenicity, rather it focused on application of 
AdCCL16 in a more clinically relevant context that generally requires surgical removal of 
primary tumor since the tumor lethality usually stems from the relatively small number of 
cells that remain after surgical excision, radiotherapy and chemotherapy.
Although the TSA carcinoma has metastatic capacity, this model is cumbersome (Cavallo 
et al., 1999). Perhaps the most compelling model for studying spontaneous metastases, at 
least on a BALB/c background, is the 4T1 mammary carcinoma (Pulaski and Ostrand- 
Rosenberg, 1998), since metastases spread immediately after subcutaneous tumor injection 
and the process is not impaired by removal of primary tumor (Pulaski et al., 2000).
The 4T1 tumor model has been used extensively by Ostrand-Rosenberg and colleagues to 
study the therapeutic potential of cellular vaccines composed of various 
immunomodulatory molecules on metastatic spread (Ostrand-Rosenberg et al., 1998; 
Pulaski and Ostrand-Rosenberg, 1998; Pulaski et al., 2000).
Vaccination with tumor cell transfected with MHC class II and B7.1 without removal of 
the primary tumor reduced the number of metastases but had no impact on survival 
(Pulaski and Ostrand-Rosenberg, 1998). Also, a treatment with an immunostimulator as 
mB7-2 Ig fusion protein combined with the angiogenesis inhibitor SU668 , started as earlier 
as 3 days after tumor injection significantly reduced tumor growth and number of lung 
metastases but did not achieved any cure (Huang et al., 2002b).
A critical issue is the size of the tumor at the time of vaccination, since tumors exceeding 4 
mm in diameter already have a large metastatic load precluding successful treatment 
(Pulaski et al., 2000). Surgical removal of the primary tumor as the first line of treatment in 
the 4T1 model was not sufficient to arrest metastases-induced death, but did change the 
setting in which a vaccine is called to act against residual disease (numerous small
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metastases). In 4T1 tumor-bearing mice, removal of primary tumors followed by repeated 
vaccination with MHCII- and B7-1-co-transfected cells plus cells transfected with SEB 
superantigen encoding gene, significantly extended survival time but did not cured the 
mice (Pulaski et al., 2000).
A more effective strategy might involve the treatment of primary tumors before surgery, an 
approach that might reduce the time for priming the host against its tumor. In fact, 
AdCCL16 injected into tumor nodules twice at days 10 and 14, followed by surgical 
removal at day 19, cured 19 of 30 mice (63%) and reduced the number of lung metastases 
in mice sacrificed for clonogenic assay (3 mice with less than 10 metastases and 11 free of 
metastases) (Fig.4.20 A-B). A similar approach using a combination of adenoviruses 
encoding thymidine kinase (TK), IL-2 and GM-CSF reduced the number of lung 
metastases and prolonged survival of 6 mice of 20 in a follow-up of only 35 days 
(Majumdar et al., 2000). A rough comparison of those data and the ones presented in this 
chapter suggests that CCL16 is more effective than such multiple combinations.
Better results (cure rate of 90%) has been obtained only in one study through a more 
intensive treatment protocol such as surgery followed by vaccination with syngeneic tumor 
cells mixed with bystander cells, and finally donor lymphocyte infusion of mice 
transplanted with allogeneic stem cells under non myeloablative conditions (Luznik et al., 
2003).
A curative rate of 60% was also obtained by surgical excision of primary 4T1 tumor 
injected into STAT6-/- mice (Ostrand-Rosenberg et al., 2002; Ostrand-Rosenberg et al., 
2000). While the lack of STAT6 signaling protects these mice from IL-13- mediated 
immunosuppression (Jensen et al., 2003; Ostrand-Rosenberg et al., 2002) a possibility is 
the recognition of tumor- associated STAT6 as a foreign antigen (Jensen et al., 2003).
It is unclear why the effectiveness of this AdCCL16 treatment on primary TSA and 4T1 
tumor regression is limited to a small number of mice. In the 4T1 model, the lack of
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STAT6 has been shown to impair development of metastases but was not sufficient to 
induce primary tumor rejection (Ostrand-Rosenberg et al., 2002). In addition to NKT cell 
produced IL-13 immunosuppression of an unknown target cell (Terabe et al., 2000), other 
immunosuppressive cytokines such as IL-10, PGE2 and TGF-p produced by tumors or 
infiltrating leukocytes impair function and survival of tumor-associated APC (Vicari AP, 
2002). In this context strategies aimed neutralizing IL-10 in the TSA model (Vicari et al., 
2002) or TGF-p in the 4T1 model have led to the functional restoration of tumor- 
infiltrating APC (Kobie et al., 2003).
Together, the results obtained from this area of the study with CCL16 given alone suggest 
that the therapeutic potential of this chemokine might be augmented by strategies aimed to 
further improve antigen-presenting functions of DC recruited at the tumor site.
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CHAPTER 5: AdCCL16 POTENTLY SYNERGYZES WITH A MICROBIAL 
STIMULI (CpG-ODN) AND BLOCK OF THE IL10 RECEPTOR
5.1 Introduction
Although tumors are capable of autonomous growth, their progression is highly influenced 
by their stromal component (Coussens and Werb, 2002). Thus, the tendency of novel 
therapeutic approaches is to target both the tumor cells and their embedding stroma. The 
extracellular matrix, the blood vessel fibroblasts and tumor infiltrating leukocytes such as 
macrophage, in addition to their structural role, may exert either inhibiting or promoting 
effects on tumor growth (Gordon, 2003; Mantovani et al., 2002). Two distinct activation 
states of macrophages, which are among the most abundant leukocytes infiltrating mouse 
and human tumors, have been described: conventionally activated Ml macrophages 
produce high levels of inducible nitric oxide synthase (iNOS), IL-12 and TNF-a whereas 
the alternatively activated M2 macrophages produce arginase, IL-10, TGF-P and PGE2. 
Ml macrophages are extremely potent effector cells that kill tumor via nitric oxide (NO) 
and TNF-a (Klimp et al., 2002), while M2 macrophages promote angiogenesis, tissue 
remodeling and limit Thl immune responses (Mantovani et al., 2002). Macrophages with 
M2 phenotype have been isolated from mouse and human tumors and shown to suppress T 
cell activation and proliferation through IL-10 and TGF-p (Balkwill and Mantovani, 2001). 
Thus, although tumor-infiltrating macrophages are potentially able to induce an anti-tumor 
innate response, their activation state is modulated in the tumor micro-environment and 
they may be redirected to exert a tumor growth promoting effect. Similarly to 
macrophages, TIDC have been shown to be defective in their ability to produce pro- 
inflammatory cytokines such as IL-12 and to induce innate IFN-y production or adaptive 
Th-1 responses.
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In order to initiate and maintain an effective anti-tumor response after TAA uptake, DC 
should migrate to draining lymph nodes and prime T cells. This process is triggered by an 
activation-driven maturation process of DC characterized by up-regulation of 
costimulatory molecules (CD40, CD80, CD86), a switch in the chemokine receptor 
repertoire, and production of immunomodulatory cytokines (IL-12, IFN-a) necessary for 
the generation of cytotoxic T cells (CTL) (Chiodoni et al., 1999). However, 
immunosuppressive cytokines such as IL10, TGF-P, PGE2 and VEGF interfere with DC 
maturation and migration, hampering the anti-tumor response.
A possible immunotherapeutic approach would be to target the tumor escape mechanisms 
that paralyze the macrophage/DC tumor infiltrate and prevent both innate and adaptive 
anti-tumor responses. Indeed, repeated treatments with a combination of a microbial 
stimulus (a TLR9 ligand, CpG oligonucleotide) and an antibody blocking the IL10R were 
able to revert the functional paralysis of tumor-infiltrating DC and to re-establish their 
ability to produce IL-12 (Vicari et al., 2002).
In chapter 4 it was found that the delivery via adenoviral vector of the chemokine CCL16 
in established TSA mammary carcinomas induced a specific systemic anti-tumor response 
and a massive accumulation of leukocytes (T cells, macrophages and DC) at the tumor site. 
However, a complete tumor rejection was not accomplished, possibly due to the lack of 
proper activation of the TIDC.
In this chapter it was investigated whether the leukocyte infiltrate promoted at the tumor 
site by CCL16 expression was paralyzed by the tumor microenvironment. Moreover it was 
investigated whether combination with a microbial stimuli CpG and block of the 
immunosuppressive cytokine, IL-10, could revert such paralysis synergizing with CCL16 
in inducing rejection of large primary tumors.
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5.2 Aims of the chapter
In this chapter the issues introduced above were investigated by:
• evaluating the phenotype of macrophages and DC accumulating in AdCCL16 
treated tumors;
• analyzing whether CCL16 synergizes with local CpG treatment and systemic block 
of the IL-10 receptor in promoting rejection of TSA, MCA38 and 4T1 primary 
tumors;
• characterizing the innate response that follows the treatment;
• evaluating the relative contribution of the innate and adaptive responses in tumor 
rejection.
5.3 Results
5.3.1 CCL16 potently synergizes with CpG and anti-ILlOR to reject large tumors
It was tested whether adenoviral vector delivery of CCL16 into large established tumors in 
combination with a single injection of CpG and anti-IL-lOR synergized to reject larger 
primary tumors. The same three tumor model, TSA, 4T1 and MCA38 used in chapter 4 to 
test antitumor effect of AdCCL16 given alone were used to investigate the combinational 
regime. Tumors of 5 mm or larger were injected with AdCCL16 and 36 h later with CpG 
while anti-ILlOR was given systemically. When mice were treated with CCL16 in 
combination with either anti-ILlOR or CpG less than 20% of mice rejected the tumor. 
Similarly, control virus Addl70-3 combined with CpG and anti-ILlOR showed little 
therapeutic effect (20 to 30% tumor rejection). In contrast, when CCL16 was combined 
with CpG and anti-ILlOR, up to 90% of the mice rejected established TSA tumors and 
74% the MCA38 tumors and 60% the 4T1 tumors (Fig 5.1 A-C) (all p<0,001 vs Addl70- 
3+CpG+anti-IL10R control groups). Mice rendered tumor-free after a single treatment
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with CCL16, CpG, and anti-ILlOR acquired long-term immunity and rejected a challenge 
with live tumor cells 100 days later.
In chapter 4 (Fig. 4) it was confirmed the metastatic potential of 4T1 cells that disseminate 
to several distant organs as soon as the primary tumor reach 2 mm in diameter (Pulaski and 
Ostrand-Rosenberg, 1998).
In order to determine whether the combination treatment affected the metastatic 
dissemination of 4T1 mammary carcinoma, 4T1 nodules were treated with AdCCL16 
alone or combined with CpG plus anti-ILlOR. Mice were sacrificed at day 32 after tumor 
inoculation and scored for lung metastases by a clonogenic assay. While treatment with 
AdCCL16 significantly reduced the number of lung metastases (range 12000-160000 vs. 
1000-23600 of Addl70-3 vs AdCCL16; p=0,02), the additional treatment with CpG plus 
anti-ILlOR completely prevented metastases in 7 mice out of 14 and reduced the number 
to less than 10 in the remaining 7 mice (Fig 5.1 D) (range 1000-2000 vs 0-12 between 
AdCCL16 or Addl70-3 combined with CpG+antilLlOR; p<0,001).
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Figure 5.1 Combination of CCL16, CpG and anti-ILlOR induces rejection of pre­
existing tumors.
Mice bearing TSA (A), MCA38 (B), or 4T1 (C) tumors were injected intratumorally with 
1x109 pfu of AdCCLI6 or control Addl70-3 and 36 h later left untreated or treated with 
anti-ILlOR (200 jxg) intraperitoneally and CpG intratumorally (5 pg). D) Effects of the 
combinatory treatment on the metastatic spread of 4T1 tumors. Mice bearing 4T1 tumors 
were intratumorally injected with lxlO9 pfu of AdCCLI6 or Addl70-3 and 36 h later mice 
were left untreated or treated with CpG plus anti-ILlOR. Metastases were evaluated in the 
lung 32 days after tumor inoculation and results expressed per individual mice. Cumulative 
results of two independent experiments each performed with 7-8 mice are shown.
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5.3.2 The early anti-tumor effect of CCL16, CpG, and anti-ILlOR combination is 
the result of a rapid innate inflammatory response
Tumor-bearing mice treated with Addl70-3 or AdCCLI6 combined or not with CpG and 
anti-ILlOR were sacrificed for macroscopic evaluation of the tumor area 6 and 16 h post­
treatment. Although CpG plus anti-ILlOR combined with control Addl70-3 showed partial 
necrosis, only the combination with AdCCLI6 induced tumor shrinkage associated with a 
massive necrosis that was mostly colliquative as indicated by blood extravasion already 
present 6 h post-treatment (Fig 5.2).
Microscopically, tumors from the animals treated with Addl70-3 and CpG plus anti-ILlOR 
showed discrete areas of necrosis, while in the nodules treated with AdCCLI6 and the 
same combination the necrotic area extended to almost the entire tumor mass (Fig 5.3).
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Figure 5.2 Macroscopic evaluation of treated tumors.
Mice bearing TSA tumors were injected intratumorally with AdCCLI6 or control Addl70- 
3 and 36 h later treated with CpG plus anti-ILlOR or PBS as control. 6 and 16 h later skin 
was opened and tumors photographed unfixed to show size, gross vascularization and 
necrosis. While injection of control Addl70-3 allowed progressive growth of well- 
vascularized tumors, the addition of CpG and anti-ILlOR provoked necrosis in part of the 
tumor while other grow normally. Injection of AdCCLI6 induced small hemorrhagic area 
at 16 h while its combination with CpG and anti-ILlOR lead to impressive induction of 
necrosis coupled with large hemorrhagic area already at 6 h after treatment. Ten hours 
later, most of the tumor area is flat, the nodule almost dissolved and the hemorrhagic area 
already partially reabsorbed.
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iFigure 5.3 Histological evaluation of treated TSA tumors.
Representative sections of treated TSA tumors were stained with Masson’s trichrome. Pre- 
established TSA tumors were treated with Addl70-3 (A-B) or A dCCLI6 (C-D) together 
with CpG and anti-ILlOR. Mice were sacrificed 16 h later. Tumors treated with A dCCLI6, 
CpG and anti-ILlOR demonstrated massive necrosis in both tumors (n) and stroma (sn), 
consistent with hemorrhagic necrosis. On the contrary, Addl70-3 combined with CpG and 
anti-ILlOR showed extended areas of necrosis alternated with large areas of live tumor 
tissue (t) (x40). B and D are enlargement of boxed area (xlOO).
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To gain insight on the mechanism of the synergistic effect of CCL16 and CpG plus anti- 
IL10R, the cellular infiltrate recruited by CCL16 expression at the tumor site was analyzed 
36 h after AdCCL16 treatment.
Alteration of the function of tumor infiltrating macrophages has been described and 
includes production of IL-10, defective production of reactive nitrogen, down modulation 
of inflammatory cytokines such as TNF-a and IL-12 and impaired tumor cytoxicity. 
Indeed, TSA tumors treated with a single injection of AdCCLI6 showed a significantly 
higher number of F480+ macrophages and CDllc+ DC than tumors treated with control 
adenovector or PBS (Fig. 5.4 A). However, macrophages infiltrating CCL16-treated 
tumors produced IL-10 as suggested by staining co-localization, but not detectable level of 
TNF-a or IL-12, consistent with an M2 phenotype (Mantovani et al., 2002) (Fig. 5.5 A-B). 
In tumors treated with the control adenovector, macrophages, although less numerous (Fig. 
5.4), also expressed IL-10 (Fig. 5.5 C-D), indicating that, although CCL16 is able to 
promote macrophages infiltration, it is unable to prevented their alternative activation into 
a M2 phenotype once they have been recruited into the tumor microenvironment.
In agreement with this conclusion the observation that despite the abundant infiltrate only 
minimal necrotic foci were found in CCL16 treated tumors strongly indicating an inability 
of the macrophage infiltrate to initiate massive tumor destruction.
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Figure 5.4 Immunohistochemical analysis of TSA tumors after AdCCL16 or Addl70- 
3 treatment.
TSA tumors were injected with AdCCL16 or with Addl70-3 or with PBS and processed 
for immunohistochemistry analysis 36 h later. Cryostat sections were stained for the 
macrophage marker F4/80, the dendritic cell marker C D llc  and for IL-10 expression. 
Cumulative data are presented as bars (mean ± SD of positive cells counted in 10 randomly 
chosen field from three tumors in each group). A significantly higher number of F4/80, 
C D llc  and IL-10 positive cells were detected in AdCCLI6 treated tumors as compared 
with tumors treated with the empty vector Addl70-3 or PBS. *** P= 0,001, ** P=0,01.
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Figure 5.5 Macrophages infiltrating TSA tumors produce IL-10.
TSA tumors were injected with AdCCLI6 (A-B) or with Addl70-3 (C-D) and processed 
for immunohistochemistry analysis 36 h later. Serials cryostat sections were stained for the 
macrophage marker F4/80 and for IL-10 expression. M acrophages (F4/80) (A-C) 
colocalize with IL-10 (B-D) (xlOO) (the insert show magnification of the boxed area, 
x400).
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PMN leukocytes have been shown to participate in immunosurveillance against tumors 
where they have been found responsible for the hemorrhages and thrombosis associated 
with tumor necrosis. PMN produce several cytotoxic mediators including hypochlorous 
acid (HOC1), which is a membrane-perforating agent, TNF-a, IL-1 (3 and IFNs (Di Carlo et 
al., 2001). To understand whether PMN could be responsible of the potent necrotic 
reaction exerted by combination treatment, serial tissue sections of TSA treated-tumors 
where stained with GR-1 and F480 Abs to identify PMN and macrophages, respectively. 
As shown in Fig. 5.6 the abundant macrophagic infiltrate localized at the edge and in the 
inner part of the tumor inside the area of necrosis while PMN, present in a much lower 
number, were found predominantly at the edge of the tumor. This result suggests that 
macrophages are the main subsets of leukocytes responsible for the necrosis associated 
with the early inflammatory response.
The addition of CpG plus anti-ILlOR to the CCL16 treatment drastically changed the 
activity of tumor-associated macrophages that became able to produce TNF-a and IL-12 
(Fig. 5.7 A-D).
One of the most potent cytostatic molecules released by activated macrophages is nitric 
oxide (NO) (Klimp et al., 2002). AdCCL16 induced three times more NO than Addl70-3 
when combined with CpG plus antilLlOR (Fig. 5.7 E). Together these results indicated a 
role of CCL16 in recruiting macrophages and of CpG plus antilLlOR in restoring their 
ability to exert an anti-tumor activity throughout mechanisms of the innate response.
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Figure 5.6 Localization of macrophages and PMN in treated tumors.
Pre-established TSA tumors were treated with A dCCLI6 together with CpG and anti- 
ILlOR. Mice were sacrificed 16 h later. Serials cryostat sections were stained for the 
macrophage marker F4/80 (A) and for the PMN marker GR-1 (B).
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Figure 5.7 Macrophages infiltrating treated tumors express TNF-a, IL-12 and Nitric 
Oxide.
TSA tumors were injected with A dCCLI6 and 36 h later with CpG and anti-ILlOR. 
Tumors were collected for immunohistochemical analysis 6 h later. Macrophages (F4/80) 
(A, C) co-localized in serial sections with TNF-a (B) and IL-12 (D) (x400). Arrows 
indicate co-localization of stained cells in serial sections E) Production o f nitric oxide in 
response to the indicated treatments. Tumors were collected for analysis 4 h after treatment 
(mean ±SD from five tumors per group; one of two independent experiments is shown).
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5.3.3 Induction of tumor specific adaptive response by combination treatment.
To confirm the primary finding that specific antitumor immunity was induced after 
combination treatment, CTL activity in tumor bearing mice after treatment was evaluated. 
As shown in Fig. 5.8 TSA tumor-bearing treated with AdCCLI6, CpG and anti-ILlOR 
developed tumor specific systemic CTL activity as early as 7 days post-treatment.
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Figure 5.8 Induction of CTL in treated mice.
TSA tumors were injected with A dCCLI6 and 36 h later with CpG and anti-ILlOR. 
Splenocytes collected 7 days after treatment were in vitro restimulated with the AH1 
antigenic peptide of TSA and cytotoxicity measured against TSA tumor cells or blast cells 
loaded or not with the AH1 peptide. Results are representative of two independent 
experiments, each performed with three mice.
Evidences that the in vitro specific cytolysis was relevant in vivo came from Winn Assay 
experiments. Lymphocytes freshly isolated from LNs and spleens of mice treated with 
AdCCL16 or Addl70-3 combined with CpG plus anti-ILlOR were mixed to a 50:1 ratio 
with live TSA cells and injected in naive mice. Based on the percentage of mice free of 
tumors it appears that AdCCLI6 combined with CpG plus anti-ILlOR leads to a better 
priming of T lymphocytes (Fig 5.9).
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Two TSA tum or-bearing anim als were treated  
with AdCCL16 or Addl70-3 and 36 h later with 
CpG plus Anti-ILlOR. Two mice were left untreated  
’ as control.
Draining lymph nodes and sp leens  
were collected and used in Winn Assay.
days later
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Figure 5.9 Winn assay for protection of TSA tumor bearing mice by lymphocytes 
from treated mice.
A) Scheme of the experiment. TSA tumor bearing mice (n=2) were treated with AdCCLI 6 
or Addl70-3 combined with CpG plus anti-ILlOR or left untreated. Four days later, 
draining lymph nodes and spleens were collected and lymphocytes mixed with live TSA 
cells to a ratio of 50:1 (T cells: tumor cells) and injected s.c. in BALB/c mice. B) 
Lymphocytes from each DLN and spleen were transferred to 4 mice for a total of 8 mice 
per group. The percentage of mice free of tumor is given at day 90.
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5.3.4 Innate and adaptive responses participate in the eradication of established 
large tumors.
Next it was tested whether innate resistance was sufficient or adaptive immunity was also 
required for complete tumor rejection. When TSA tumor-bearing Rag-KO mice, which are 
deficient of T and B cells, were treated with AdCCL16, CpG plus anti-ILlOR, only 28% of 
them completely rejected the tumors (Fig. 5.10 A).
Antibody-mediated depletion of either CD4 or CD8 T cells starting one week before tumor 
challenge also reduced to 50% the number of BALB/c mice rejecting TSA tumors (Fig. 
5.10 A).
To better dissect the role of CD4 and CD8 T cells in the effector phase of the rejection 
process, they were depleted by antibody treatment of the mice 5 days post AdCCL16 and 
CpG plus anti-ILlOR treatment. Late CD8 T cell depletion still reduced the rejection rate 
to 37% compared to 85% in the non-depleted group. Unlike CD8 T cells, late CD4 T cell 
depletion did not affect the rejection rate, suggesting that CD4 T cells had a role during the 
priming rather than the effector phase whereas CD8 T cells were required in both phases 
(Fig. 5.10 B).
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Figure 5.10 Role of CD4 and CD8 T cells in CCL16, CpG and anti-ILlOR-induced 
tumor rejection.
TSA tumors were injected with AdCCL16 and 36 h later with CpG and anti-ILlOR. A) 
Tumor rejection was monitored in mice depleted of CD4 or CD8 T cells prior to treatment 
as well as in RAG-KO mice. B) Tumor rejection was monitored in mice in which CD4 and 
CD8 T cells were depleted starting five days after treatment. The number of mice treated is 
indicated in the figure.
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Together, the above results unambiguously indicated that complete eradication of the 
tumors required the participation of T cells and suggested that both innate and adaptive 
responses were involved in tumor eradication. However, both conventional T cells as well 
as non-conventional T cell subsets such as NKT and Ty/6 cells can be recruited in a non­
antigen specific fashion in amplifying the innate response, for example by producing 
tumor-inhibiting cytokines such as IFN-y. Thus, it was important to test whether mice in 
which T cells were present but were unable to mount a tumor-specific adaptive response 
were able to eradicate the tumors when treated with the combination protocol. This was 
accomplished by using bone-marrow (BM) chimeric mice in which only the adaptive 
response was impaired because of H-2 mismatch. Irradiated CB6F1 mice reconstituted 
with BM cells from either B6 or BALB/c were injected with TSA tumor cells (H-2d). 
CTL were able to recognize H-2d-presented TSA antigens in BALB/c>CB6 but not in 
B6>CB6 chimera. Whereas 92% of AdCCL16, CpG plus anti-ILlOR treated 
BALB/c>CB6 mice rejected the TSA tumors, only 26% of B6>CB6 did so (Fig. 5.11 A). 
The innate response measured as NO production was comparable in the two groups of 
treated mice (Fig. 5.1 IB).
These results strongly indicate that in mice in which the innate response failed to 
completely eradicate the primary tumor, adaptive T cell responses, in particular CD8 T 
cells, were essential to control local recurrence.
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Figure 5.11 Role of tumor specific CTL in antitumor response.
A) BALB/c>CB6 and B6>CB6 chimeras were inoculated with 2x l05 TSA cells. 12 days 
later, tumors were treated with AdCCL16, CpG and anti-ILlOR. Cumulative data from two 
independent experiments, each performed with 8 mice, are shown. B) In a separate 
experiment, AdCCL 16-treated tumors (n=5/group) were collected 4 h after CpG plus anti- 
IL10R treatment and processed to measure NO production (results expressed as mean ± 
SD).
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5.3.5 CD40 KO and IL-12 KO mice fails to reject tumors in response to CCL16, 
CpG plus anti-ILlOR treatment
To test whether the requirement for CD4 T cell subsets reflects the need for interaction 
between DC and CD4 T cells (since TSA tumor is MHC class-II negative), antitumor 
effects of the combination treatment was evaluated in mice lacking CD40 a key molecule 
for the interaction between DC and CD4 T cells during CTL induction (Schoenberger et 
al., 1998). Moreover since CD40 cross-linking on DC by CD40L expressed by CD4 cells 
has been shown to induce IL-12 that is the primary cytokine bridging innate and adaptive 
immune responses (Trinchieri, 2003), we also tested the efficacy of the combined 
treatment in IL12p35-KO mice. As shown in Fig. 5.12A both CD40- and IL-12p35-KO 
mouse strains failed to reject TSA tumors in response to the combination protocol.
To determine whether lack of tumor rejection in CD40 and IL-12 KO mice might rest in 
defective T cell activation the ability of mice treated with the combined treatment to 
generate CTL in absence of CD40 or IL-12 molecules was compared to wt mice. As shown 
in Fig. 5.12 B both mouse strains failed to generate CTL.
154
A
1 0 0 i
75
50-
O 25-
10 20 30 40
Days
50 60
BALB/C
CD40KO
IL 12K O
70
B
TARGET BLAST+AH1
■BALB/C
50
45
40
35
.2 30
25
15
10
5
0
12:1100:1 50:1 25:1
n 30 1
Z 25
TARGET BLAST
-BALB/C
-IL12KO
-CD40KO
100:1 50:1 25:1
E:T ra tio
Figure 5.12 CCL16, CpG and anti-ILlOR induced tumor rejection is abolished in 
mice deficient for CD40 or IL-12.
A) Tumor rejection was monitored in wt, CD40-KO and IL-12p35-KO mice (n=8). B) 
CTL activity was monitored 30 days after treatment, upon in vitro restimulation with the 
AH1 antigenic peptide of TSA, against blast cells loaded or not with the AH1 peptide. 
(mean+ SD from three mice per group).
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5.3.6 The combination of CCL16, CpG and antilLlOR restores tumor infiltrating 
DC functions and bridges innate and adaptive immunity.
In addition to macrophages, AdCCL16 treatment recruited DC in TSA tumors (Fig. 4A). 
The functions of these TIDC, however, can be impaired by the tumor milieu. The 
generation of CD8 tumor antigen-specific T cell response in the treated mice and their 
requirement for tumor eradication suggested that the combined treatment restored DC 
functions.
Therefore the phenotype and functions of TIDC from treated vs non-treated animals was 
evaluated. DC infiltrating AdCCL16-treated tumors showed an immature phenotype 
similar to the Addl70-3 control treated group, suggesting that the majority of DC recruited 
by CCL16 at tumor site are impaired in their antigen presentation functions.
AdCCL16 combined with CpG and anti-ILlOR induced up-regulation of CD40, CD80 and 
CD86 in CD1 lc+ DC whereas the omission of anti-ILlOR abrogated this effect (Fig. 5.13). 
Consistent with the activated phenotype, TIDC from the treated mice produced high levels 
of IL-12 and TNF-a (Fig. 5.14 C-D) and vigorously stimulated allogeneic naive T cells to 
proliferate and produce IFN-y (Fig. 5.14 A-B).
156
A d d l70-3
AdCCL16
CD40
 ^ 35%
10u 101 10* 10-* 10
25%
AdCCL16 
CpG+Ctrl-Ab • U f c v
40%
10u 10' 10 10J 10^
AdCCL16
C pG +alL-lO R
100%
CD86
L L A I  W v  I
95%
kfl 4
CD80
m10° 10' 10* 10° 10
26%
m.
C lass II
65%
—- 8 - 36%
| S
i 3° 101 102 103 10- FL1-H
8 27%
",
4 1 0 101 102 103 10- FL1-H
8 - 34%
r 1 "1
M s .
104 1 °S' 10s Vo3 VoFL1-H
8- 70%
1 j » -  
„  ::JtCl-10v 10' 10* 10v 10n 10u 10' 10* 10 10s
Figure 5.13 Phenotypic characterization of tumor infiltrating DC.
TSA tumor were treated with AdCCL16 or Addl70-3 and 36 h later treated with PBS or 
with CpG alone or combined with anti-ILlOR Ab. TIDC were purified from treated tumors 
10 h later last treatment and analyzed by FACS analysis for the activation markers CD40, 
CD80, CD86 and MHC-II.
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Figure 5.14 Functional characterization of tumor infiltrating DC.
TSA tumor were treated with AdCCLI6 or Addl70-3 and 36 h later treated with PBS or 
with CpG alone or combined with anti-ILlOR Ab. TIDC were purified from treated tumors 
10 h later last treatment an analyzed for their ability to: stimulate proliferation (A) and 
IFN-y production of allogeneic T cells in an MLR assay (B) and for IL-12 and T N F -a  
production by ELISA, C and D, respectively. Data from one representative experiments 
out of three with similar results (mean± SD of the triplicates).
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In order to prime the anti-tumor CTL response observed in treated mice, either TIDC 
migrated to the DLN before the fast and massive necrosis of the tumor mass affected their 
viability or DC other than TIDC were involved in the onset of the adaptive response, for 
example by uptaking tumor-antigens released into lymphoid sites following tumor 
necrosis. To investigate these possibilities, DLN were collected 6 and 16 h after the 
different types of treatments from mice in which FITC-labeled beads were injected as 
tracer in the tumor mass. CCL16 treatment combined or not with CpG plus anti-ILlOR 
induced the highest number of FITC-labeled DC detected in DLN collected 6 h after 
treatment, a number that did not significantly differ from that of DC collected after 16 h 
(Fig. 5.15A). This observation suggested that the majority of TIDC migrated to the DLN 
during the first 6 h post-treatment. Indeed, mice in which the injection of FITC-beads was 
delayed 6 h post-treatment showed a significant lower number of FITC-labeled DC in 
DLN than the mice receiving the beads together with the treatment (Fig. 5.15B).
Finally, the functional requirement of DC migration for tumor eradication was tested using 
CCR7-KO mice, whose DC cannot respond to CCL19 and CCL21. No more than 25% of 
TSA tumor bearing CCR7-KO eradicated the tumor in response to the combined treatment 
(Fig. 5.16).
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Figure 5.15 CCL16, CpG and anti-ILlOR substantially increase the number of 
CDllc+ DC migrating to DLN.
A) TSA tumors were treated with AdCCLI6 or Addl70-3 and 36 h later with CpG together 
with fluorescent latex beads and anti-ILlOR or control Ab given systemically. 6 h or 16 h 
later, DLNs were analyzed for the presence of C D llc+  cells carrying FITC+ beads 
(representative plots on the left). Total number of migrated DC is reported (right). B) 
Tumors were treated with AdCCLI6 and 36 h later antilL-lOR was given systemically and 
fluorescent beads were injected together with CpG or 6 h later. DLN were collected 16 h 
after beads injection (representative plots are shown on the left and cumulative data of 
migrated DC on the right). Each dot in cumulative graphs refers to a single DLN collected 
from an individual treated mouse.
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Figure 5.16 CCL16, CpG and anti-ILlOR induced tumor rejection is abolished in 
mice deficient for CCR7.
Tumor rejection was monitored in wt and CCR7 KO (n=8).
5.3.7 Mice lacking TNF-a in their BM compartment are unable to develop 
hemorrhagic necrosis and to reject large tumors.
The results presented above showed that the combination treatment results in an early 
inflammatory response accountable for the initial tumor debulking and for the induction of 
the adaptive response, which it was demonstrated necessary to completely reject tumors. 
However in none of the above experiments it was demonstrated what was the impact of the 
innate response in the tumor rejection process. This was investigated creating chimeras 
mice bearing BM from TNF-KO, which lack a key factor responsible of the innate 
response. Chimeras were generated by transferring BM from TNF-KO mice into congenic
161
B6.SJL mice. The donor and recipient strains differed for the CD45 allele that allowed to 
follow the engraftment of TNF-KO BM after transplantation.
Moreover since TNF-a gene deletion spans nearby MHC sequence, donor cells were 
tolerized to host MHC, avoiding tumors rejection because of subtle MHC disparity. 
Injection of MCA38 in these mice produces large tumors that if treated with the combined 
treatment were not rejected (Fig. 5.18A). Macroscopical examination of treated-tumors 
revealed that in absence of TN F-a the hemorrhagic necrosis was strongly defective (Fig. 
5.17 A-B). Histological analysis showed absence of necrosis area in mice lacking TNF-a if 
compared with wt animals confirming the above observations (Fig. 5.17 C-D). Lack of the 
innate response impact the ability of TIDC to migrate to DLN as demonstrated by a strong 
decrease in the number of TIDC that reached DLN after treatment (Fig. 5.18 B). These 
results suggest that the early inflammatory response is instrumental for both tumor 
destruction and migration of DC to DLN.
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Figure 5.17 Role of TNF-a in hemorrhagic necrosis.
TNFKO> B6.SJL chimeras, differing in the CD45 allele, were used to test the role of 
leukocytes produced TNF-a. B .SJL (A-C) and chimeras (B-D) were injected with 
MCA38 carcinoma cells and were treated, when palpable, with A dCCLI6 combined with 
CpG plus antilLlOR. Macroscopic evaluation (A-B) tricromic staining (C-D) of tumor 
sections collected 16 h after treatment. Necrotic area (n) and intact tumor area (t) are 
indicated in the figure.
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Figure 5.18 Role of the inflammatory response in tumor rejection and TIDC 
migration.
TNFKO> B6.SJL chimeras, defective for inflammatory response (Fig 5.17) were used to 
test the role of the early inflammatory response in tumor rejection and TIDC migration. A) 
Tumor rejection was monitored in B6.SJL wt mice and TNFKO> B6.SJL chimeras (n=8).
B) MCA38 tumors were treated with A dCCLI6 36 h later with CpG together with 
fluorescent latex beads and anti-ILlOR given systemically. lOh later, DLNs were analyzed 
for the presence of CD11 C +  cells carrying FITC+ beads. Total number of migrated DC is 
reported TIDC migration.
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5.4 Discussion
Many studies have definitively shown that both in experimental animals and in humans, 
mechanisms of immune surveillance are able to control the appearance of new tumors or 
affect the progression of existing tumors (Dunn et al., 2004). Within the mechanisms 
responsible for immune surveillance, the processes of inflammation and innate resistance 
as well as tumor antigen specific adaptive immunity have been implicated.
Many protocols of cancer immunotherapy have been designed to induce tumor-specific 
CTL that are thought to be the most efficient effector cells to destroy existing tumors 
(Blattman and Greenberg, 2004). In patients involved in clinical trials using antigen loaded 
DC, CTL were often generated that were not associated with complete tumor regression 
probably due to a low CTL precursor frequency, tumor size and an adverse tumor 
microenvironment (Dunn et al., 2004; Marincola et al., 2003).
Treatment with chemokines in the attempt to recruit DC directly at the tumor site without
need of in vitro manipulation has been experimentally tested in many laboratories in order
to facilitate the in vivo encounter of DC with tumor antigens. As reviewed in introduction
(chapter 1 section 1.3), inflammatory chemokines act on a heterogeneous population of
circulating monocytes and DC that, after entering tumors, may differentiate not only into
TIDC but also into tumor-associated macrophages (TAM). TAM remain in the invaded
tissue while DC maintain the ability to migrate into the DLN (Imhof and Aurrand-Lions,
2004). TIDC and TAM are components of the tumor stroma and the functions of the cells
recruited through chemokine manipulation are likely to be modulated by the tumor
microenvironment (see chapter 1 section 1.5 and (Coussens and Werb, 2002)).
TAM are the main source of intratumor IL-10, a potent immunomodulating molecule able
to turn down both innate and immune responses by affecting DC functions and acting in an
autocrine fashion by maintaining the infiltrating macrophages in an M2 state (Moore et al.,
2001). In such a hostile tumor environment and in the absence of proper inflammation,
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recruited DC may present antigen in an inappropriate T cell context, generating tolerance 
to TAA instead of immunity (Steinman et al., 2003). Strategies able to overcome such 
tumor escape mechanisms are the key to effective immunotherapy. Although various 
soluble and cellular factors have been implicated in tumor-induced immune suppression, it 
was previously demonstrated that IL-10 has a sufficient and essential role in determining 
the anergic state of TIDC. Indeed, DC infiltrating a number of different mouse tumors 
were shown to be refractory to maturation stimuli, unable to produce IL-12, and to 
stimulate T lymphocytes, unless the inhibitory effect of IL-10 was blocked using repeated 
treatments with an anti-IL-lOR antibody (Vicari et al., 2002).
In this part of the study, we tested whether the treatment of tumor bearing mice with a 
chemokine able to enhance the tumor infiltration by macrophages and DC as well as to 
synergize with a treatment that simultaneously fights DC paralysis and subverts the 
macrophages phenotype from M2 to Ml. In chapter 4 it was demonstrated that treatment 
with an adenoviral vector carrying CCL16 reduced tumor growth but induced complete 
tumor eradication only in a small proportion of animals. In this part of the study it was 
demonstrated that macrophages recruited by CCL16 produced IL-10 but not IL-12 or TNF- 
a , consistent with a M2 phenotype that also characterizes the resident TAM (Fig. 5.5 and 
5.6). This contrasts with in vitro results showing that recombinant CCL16 effectively 
induced peritoneal macrophages to produce pro-inflammatory cytokines such as CCL2, IL- 
12 and TNF-a and to kill TSA tumor cells (Cappello et al., 2004). The in vivo results 
presented here indicate that CCL16-recruited macrophages became functionally inhibited 
by the tumor unless CpG and anti-ILlOR are added to the treatment. Mice treated with this 
combination protocol successfully rejected established TSA, MCA38 and 4T1 tumor 
nodules (Fig. 5.1). When combined with CpG plus anti-ILlOR, not only 60% of CCL16- 
treated animals rejected the 4T1 primary tumors but they were also cleared of distant 
metastases, whereas, as reported in chapter 4, AdCCL16 given alone, although unable to
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unable to eradicate the transplanted 4T1 tumors, was effective in curing their distant 
metastases only when associated with the surgical excision of primary nodules, consistent 
with the hypothesis that that the tumor is the source of both local and systemic 
immunosuppression.
The TLR9 agonist CpG has been widely used as adjuvant of tumor-specific antigen 
vaccines, or given intratumorally in a therapeutic setting (Klinman, 2004). Peritumoral 
injection of CpG as single agent induced tumor regression in some tumor models 
(Heckelsmiller et al., 2002; Kawarada et al., 2001) while has proven ineffective in others 
(Furumoto et al., 2004; Garbi et al., 2004). In all these reports, CpG was given repeatedly 
at high dose (50-100 pg/dose) to animals bearing small tumors.
In combination with CCL16 and an antibody blocking IL10R, a single CpG administration 
of 5 pg is sufficient to eradicate large vascularized tumors (Fig. 5.1). Considering that CpG 
is entering clinical trials for different applications including cancer immunotherapy and 
that repetitive high dose have been recently described to be toxic and to induce 
immunosuppression (Heikenwalder et al., 2004; Klinman, 2004) the findings reported here 
provide proof of concept that combination protocol can reduce both amount and frequency 
of CpG administrations while maintaining effectiveness. In comparison to the previous 
work with CpG and anti-ILlOR alone (Vicari et al., 2002), the addition of CCL16 allowed 
to successfully treat tumors at least twice in size than those previously tested using a single 
rather than three injections.
One of the most impressive observations in the present study was the rapid triggering of 
events leading to tumor necrosis and systemic immunity. The massive hemorrhagic tumor 
necrosis was comparable to a localized Shwartzman reaction (Brozna, 1990), completed in 
16 h, and accompanied by the release of nitric oxide (Fig. 5.3 and 5.7). Macrophages 
recruited by CCL16 produced IL-12 and TNF-a as soon as 6 h after CpG plus anti-ILlOR 
treatment (Fig. 5.7) and were likely the major inflammatory cell type responsible for the
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induction of tumor necrosis. Indeed, polymorphnuclear leukocytes, although frequently 
described to take part in necrosis and capable of tumor toxicity via production of the 
oxidant HOC1 (Di Carlo et al., 2001), were observed to be localized at the edge of tumors 
treated with the combinatory regimen (Fig. 5.6), thus they are unlikely to take part in the 
process of tumor destruction.
The extensive hemorrhagic necrosis observed points to a central role of TNF-a and other 
pro-inflammatory cytokines and the participation of innate resistance mechanisms in tumor 
destruction. Indeed in tumor-bearing chimeric mice reconstituted with BM from TNF-KO 
mice, the combination treatment failed to induce hemorrhagic necrosis and to provoke 
tumor debulking (Fig. 5.17 and 5.18).
These results demonstrate that subversion of M2 phenotype requires that the inflammatory 
stimulus be combined with block of the IL-10 pathway. This is the first report showing in 
vivo such a rapid switch from M2 to Ml phenotype.
Tumors treated with CCL16 were also enriched in TIDC that showed the typical immature 
myeloid phenotype of the resident TIDC in the absence of added chemokines ((Vicari et 
al., 2002)) that is characterized by low lymphocyte stimulatory activity and low ability to 
produce inflammatory cytokines like TNF-a and IL-12 (Fig. 5.13 and 5.14). The refractory 
state of TIDC, together with the observed M2 phenotype of infiltrating macrophages, 
correlates with the poor rejection of tumors in animals treated with AdCCLI6 alone 
(Chapter 4 Table 4.1). Along with macrophages, DC also shifted phenotypically and 
functionally in response to the combinatory treatment. TIDC up-regulated costimulatory 
molecules, produced IL-12 and TNF-a and stimulated T lymphocytes proliferation and 
IFN-y secretion (Fig. 5.13 and 5.14). However, the rapid hemorrhagic necrosis induced by 
the treatment was so massive that it should have been expected to destroy infiltrating 
leukocytes along with tumor cells, questioning whether TIDC could reach the DLN before 
their viability was affected. In vivo experiments with fluorescent beads demonstrated that
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TIDC massively migrated within the first 6 h post-treatment (Fig. 5.15). This latter result, 
together with the fact that significantly more DC were recovered from the DLN of mice 
treated with CpG and anti-IL-lOR in combination with AdCCLI6 than with Addl70-3, 
indicates that the FITC-labeled DC observed in the DLN had captured latex beads within 
the tumor, and not within the lymph node (Fig. 5.15).
The impact of the inflammatory response on DC mobilization from the tumor was 
confirmed in chimeric mice reconstituted with BM from TNF-KO mice that showed both 
reduced inflammation and DC migration to the DLN (Fig. 5.17 and 5.18).
The more likely hypothesis is that the rapid migration from the tumor to the DLN of 
mature DC, at least some of which loaded with TAA, is instrumental to activate systemic 
immune responses and generation of CTL, before the progressive necrosis destroys 
intratumoral DC or prevent their ability to migrate to the DLN. This hypothesis is 
supported by the data of experiments shown in this chapter that analyzed separately innate 
and systemic response and showed that the innate response, while responsible for the early 
tumor necrosis, is in most mice insufficient for tumor eradication. Most of tumor-bearing 
CCR7-deficient mice failed to completely reject tumors when treated with CCL16 and 
CpG plus anti-ILlOR (Fig. 5.16). CCR7, a chemokine receptor critically required for DC 
entering the lymphatic vessels and migration into the DLN, is upregulated in mature DC 
(Forster et al., 1999; Gunn et al., 1999). In addition, CCR7-KO mice have also altered 
homing of naive T cells and recirculation of effectors T cells (Forster et al., 1999). Only 
25% of treated CCR7-KO mice rejected tumors, a fraction similar to that of observed with 
other mice deprived of adaptive response, such as RAG-KO mice or mice depleted of T 
cells by antibody treatment (Fig. 5.10). None of the treated CCR7-KO that have eradicated 
the primary tumor had the ability to reject a challenge with live tumor cells, demonstrating 
that in these mice only the innate response was operative.
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Accordingly, in B6>CXB6 chimera mice in which B6-induced CTL cannot recognize TSA 
(H-2d) tumors, the observed low tumor rejection rate was due to the innate response (Fig. 
5.11). A more detailed analysis of the role of CD4 and CD8 T cells indicated that, while 
depletion of CD8 T lymphocytes either during the priming or the effector phase reduce 
anti-tumor efficacy, CD4 T cells are needed for efficient priming (Fig.5.10). CD4 T cell 
help for the induction of effector CD8 T cells is mediated by CD40/CD40L interaction 
with DC (Mackey et al., 1998a). Accordingly, lack of tumor rejection and defective CTL 
induction was observed in mice lacking CD40 indicating the need of a correct DC-T cell 
cross-talk (Fig. 5.12).
IL-12 bridges innate and adaptive immunity by promoting CTL induction, NK function 
and Thl differentiation of CD4 helper T cells (Trinchieri, 2003). Impaired anti-tumor 
response in the absence of CD40/CD40L interaction might result from a defective IL-12 
production (Mackey et al., 1998b). Indeed abrogation of both tumor rejection and CTL 
generation was observed in mice lacking IL-12 (Fig. 5.12). Although alternative pathways 
of CTL induction independent from CD40 and IL-12 have been described, they were 
mainly effective against non-tolerized antigens and/or in the presence of high number of 
specific T cells precursors (Lu et al., 2000; Wan et al., 2001) and thus unlikely to be 
effective in an anti-tumor response. Indeed, in this chapter it was demonstrated that to 
induce adaptive immunity to TAA the presence of high inflammatory stimuli cannot 
compensate for the lack of CD40/CD40L co-stimulation that is probably required for full 
maturation and activation of DC in the lymph nodes, including optimal production of IL- 
12 following T cell encounter (Schulz et al., 2000).
Taken together, the results presented in this chapter strongly support that the manipulation 
of macrophages and DC recruitment within tumors together with their activation and relief 
of tumor immunosuppression may represent a potentially effective anti-tumor therapy.
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CHAPTER 6: SUMMARY AND FUTURE PLANS
6.1 Summary
Aim of the first part of this thesis was to characterize the antitumor activity of the 
neglected human chemokine, CCL16. Delivery of CCL16 by an adenoviral vector into 
prestablished murine recruited T cells, macrophages and DC at the tumor site and led to 
rapid swelling of draining lymph nodes with accumulation of DC in the T cell area. 
However, despite the local accumulation of reactive cell infiltrate and the induction of a 
systemic immune response, large primary tumors were not completely rejected. While the 
result might have been expected considering the difficulties of rejecting well-established, 
vascularized tumors, it pointed to the utility of intralesional injection before surgery, for 
prevention of metastases in the presence of bad prognostic factors. Experimentally, this 
was investigated using the spontaneously metastatic 4T1 mammary carcinoma, which 
spread to several distant organs when priming tumors were surgically excised at the size of 
2mm. Injection of AdCCLI6 5 days before surgery results in mice either free or with less 
than 10 metastases in the lung whereas all mice, treated with empty adenovector or 
untreated, have hundreds of metastases.
In the second part of the project the tumor escape mechanisms responsible for the paralysis 
of CCL16 induced leukocytes infiltration were characterized. Macrophages infiltrating 
CCL16-treated as well as untreated tumors showed an M2 phenotype characterized by 
secretion of IL-10 but not of IL-12 or TNF-a production and by lack of cytoxicity against 
the tumor. Similarly, TIDC purified from CCL16-treated tumors, showed an immature 
phenotype suggesting that their migration to DLN might not only result in an inefficient T 
cell priming, rather in induction of tolerance to TAA. These findings are in line with what 
found by many groups reporting that macrophages and DC, spontaneously infiltrating 
human and murine tumors, are functionally paralyzed or working in favour of tumor
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progression. This suggests a cautionary note for those clinical approaches involving 
enrichment of immune cells at the tumor site since they might be rendered ineffective by 
the strong tumor escape mechanisms that co-opt recruited cells to act pro-tumorally.
The combination of CCL16 and CpG given locally together with the systemic 
administration of a mAb to IL10R induced, within a few hours, a shift of resident and 
recruited tumor-infiltrating macrophages from the M2 to Ml type and cured the majority 
of mice bearing large tumors. In addition, TIDC rapidly up-regulated costimulatory 
molecules and secreted inflammatory cytokines such as IL-12 and TNF-a. This potent 
inflammatory response not only induced massive hemorrhagic necrosis and tumor 
shrinkage but also a fast DC migration to DLN preceding tumor necrosis and allowing the 
generation of tumor-specific CTL response able to clear any tumor remnant.
Innate and adaptive responses work in concert to reject large tumors. Different 
experimental approaches confirmed that the innate response is responsible of initial tumor 
debulking while capable to reject completely the tumors in a fraction of 30% of treated 
mice. The importance of the early inflammatory response was underscored by experiments 
showing that in absence of TNF-a, tumors were not rejected and TIDC remained subjected 
to tumor induced suppression.
In conclusion the work presented here revealed the mechanisms by which large numbers of 
tumor-infiltrating macrophages and dendritic cells can be redirected to become potent 
effectors and activators of the innate and adaptive immunity. Overcoming the strong local 
immunosuppression was shown to be the key to reject successfully large tumors and 
suggest a new strategy for clinical interventions.
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6.1.1 Future plans
The following points provide a framework for future studies.
6.1.2 Role of CCL2 in AdCCL16 antitumor activity.
In this thesis it was shown that CCL16 treated tumors are infiltrated by macrophages and 
DC. These subsets of cells become activated after CpG plus antilLlOR treatment to 
become potent effectors of the innate response. CCL16 potently enhance the release of 
CCL2 from macrophages (Cappello et al., 2004), DC and T cells (Chapter 3). CCL2 is one 
of the most active chemokine attracting mononuclear cells. This property has led to the 
suggestion that CCL2 could have antitumor properties in vivo. Experiments in animal 
models demonstrated that high level of CCL2 expression of at the tumor site can suppress 
tumor growth by recruiting macrophages and DC in high number (Conti and Rollins, 
2004). Therefore, it is possible that parts of the antitumor properties exerted by local 
delivery of CCL16 are mediated through CCL2. To this extent AdCCLI6 treatment alone 
could be performed in CCL2 KO mice to evaluate number of infiltrating mononuclear cells 
and their M2 phenotype.
6.1.3 Dissecting the role of IL-12 in tumor rejection mediated by AdCCL16 and 
CpG plus antilLlOR treatment.
IL-12 is a cytokine playing essential role both innate and adaptive immunity. IL-12 
enhances the generation of cytotoxic T lymphocytes and augments their cytotoxic activity 
through upregulation of perforin and granzyme. IL-12 secretion by DC following cognate 
interaction with Th cells is dependent from CD40/CD40L interaction (Colombo and 
Trinchieri, 2002; Trinchieri, 2003).
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In chapter 5 it has been demonstrated that mice deficient of CD40 or IL-12 were unable to 
reject TSA tumors treated with AdCCLI6, CpG and anti-ILlOR, as well as to generate 
tumor specific CTL. Together with its role in modulating T cell response IL-12 has also 
been implicated in sustaining the innate response. Products from microrganism such as 
double strand RNA, bacterial DNA and CpG containing sequences are strong inducers of 
IL-12 production by macrophages and DC. Indeed, both TIDC and macrophages recruited 
by CCL16 at tumor site produce IL-12 after CpG administration and block of IL10R. 
Macrophages from the IL-12KO mice, could not properly respond to CpG triggering, and 
might provide an insufficient inflammatory response with consequences on both the innate 
and adaptive responses. This hypothesis could be tested as follows:
• TSA tumors grown in wt and IL-12KO mice treated with the AdCCLI6, CpG and 
anti-ILlOR could be evaluated for local innate response. Histological analysis could 
be used to evaluate the extension of necrotic destruction and production of TNF-a 
and nitric oxide. Moreover tumor-infiltrating macrophages collected after the 
treatments performed in IL-12KO and wt animals could be evaluated in vitro for 
their ability to lyse TSA tumor cells.
6.1.4 Alternative TLR for the activation of the tumor infiltrate
In the present studies in mice, it was used human CCL16 to promote macrophage and DC 
recruitment within mouse tumors, since its mouse homologue exists only as a pseudogene 
(Shoudai et al., 1998; Youn et al., 1998), thus facilitating the possibility of translation of 
the therapeutic protocol into the clinical setting. However, the fact that different subsets of 
cells respond to CpG in humans and mice raises the question of whether CpG would 
induce similar response in human tumors. In humans, plasmacytoid DC (pDC) are the
main cells triggered by CpG that, in the mouse, activates indistinctly myeloid DC, 
monocytes/macrophages and pDC.
Human blood pDC can differentiate into fully competent DC following microbial stimuli 
such as CpG (Kadowaki et al., 2001) and abundant pDC infiltration was observed in 
human ovarian carcinoma and melanoma (Salio et al., 2003; Vermi et al., 2003; Zou et al., 
2001). Although the exact role of pDC infiltrating human tumors is yet to be determined, 
the observation of their immature phenotype and their inability to release IFN-a suggest 
that infiltrating pDC are negatively regulated by the tumor microenvironment. Indeed, in 
vitro, blocking of IL10R re-established the ability of pDC extracted from tumors to 
stimulate T lymphocytes (Zou et al., 2001).
Although injection of CpG in human tumors would not directly activate macrophages or 
myeloid DC, through induction of IFN-a by pDC CpG could indirectly activate them 
leading to a cascade of events similar to what has been described here for the mouse 
system.
Alternatively, other ligand of Toll-like receptors that activate both macrophages and DC in 
humans could replace CpG for the treatment of human cancer.
Bacillus Calmette-Guerin cell-wall skeleton (BCG-CWS), which has been used as a potent 
adjuvant therapy in patients with cancer, has been identified to signal through TLR2 and 
TLR4 in human (Tsuji et al., 2000). Indeed, the costimulatory molecules 
CD80/CD83/CD86 and inflammatory cytokines TNF-a and IL-12 are up-regulated in 
human DCs after stimulation with BCG-CWS in a TLR2/4 dependent manner (Tsuji et al., 
2000). A clinical trial where more then 600 patients were treated following postoperative 
surgery of bladder cancer brought good prognosis for more than 60% of the treated 
patients (Hayashi, 1998). One of the notable phenomena after BCG bladder instillation in 
human patients is a transient secretion of several inflammatory cytokines such as INF-g, 
IL-12 and IL-2 in BCG-CWS responders. On the contrary patients that fails to respond to
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BCG-CWS therapy showed high levels of IL-10 (Elsasser-Beile et al., 2000; O'Donnell, 
1996). Similarly, in mouse models IFN-y and IL-12 but not IL-10 and IL-4 have been 
suggested to be required for the antitumor activity against an orthotopic model of bladder 
cancer (Riemensberger et al., 2002).
Waiting for recombinant molecules triggering TLR2 and TLR4 BCG-CWS, although 
contaminated of bacterial product, can be tested to substitute CpG to activate both human 
DC and macrophages infiltrating tumors. To test this hypothesis the following assays could 
be performed.
• test the antitumor activity of CCL16 combined with intratumoral injection of BGC 
and systemic block of IL10R on prestablished TSA tumors.
• characterize the innate response by immunoistochemistry.
• characterize the activation status of TIDC and TAM following BCG treatment.
• characterize the migratory capacity of TIDC activated by BCG treatment.
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